Drug coated balloon catheter for body cavity
By applying water-soluble additives and anti-proliferative therapeutic agents on the balloon catheter, combined with speculum assisted technology, the problem of low drug delivery and dilation efficiency in body cavity stenosis treatment is solved, and effective treatment and recurrence rate of body cavity stenosis is achieved reduce.
Patent Information
- Application Number
- CN202410880698.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2017-05-05
- Filing Date
- 2018-05-04
- Publication Date
- 2024-11-15
AI Technical Summary
The prior art is difficult to effectively treat body cavity stenosis, such as benign prostate hyperplasia, urethral stenosis and asthma, especially in drug delivery and tissue expansion, with problems of low efficiency and high recurrence rates.
Using drug-coated balloon catheter, the balloon catheter is gradually expanded by adding water-soluble additives and anti-proliferative therapeutic agents, such as paclitaxel, paclitaxel and rapamycin, combined with the help of spectral lenses. Dilate the site of stenosis and release the drug to reduce stenosis and prevent recurrence.
Effective expansion and drug delivery of stenosis in the body cavity are achieved, which significantly improves the therapeutic effect, reduces the recurrence rate of stenosis, and rapidly absorbs drugs in a short period of time, improving treatment efficiency.
Smart Images

Figure CN118949148A_ABST
Abstract
Description
[0001] This application is a divisional application of the Chinese patent application with application number 202210624650.8, and the Chinese patent application is a divisional application of the Chinese patent application with application number 201880002506.2 (a patent application entering the Chinese national stage of the PCT international application with international application number PCT / US2018 / 031083). The contents of the above-mentioned Chinese patent application are incorporated herein by reference in their entirety. Technical Field
[0002] The present application relates to a drug-coated balloon catheter for use in a body cavity and an application thereof.
[0003] CROSS-REFERENCE TO RELATED APPLICATIONS
[0004] This application claims the benefit of priority to U.S. Provisional Patent Application Serial No. 62 / 502,212, filed on May 5, 2017, the disclosure of which is incorporated herein by reference in its entirety. Background Art
[0005] Benign prostatic hyperplasia is a noncancerous enlargement of the prostate that affects more than 50% of men over the age of 60. The prostate is the size and shape of a walnut early in life and weighs about 20 grams. Prostate enlargement appears to be a normal process. With age, the prostate gradually increases in size to twice or more times its normal size. As the prostate grows, it presses on the urethra and narrows it, causing prostatic urethral compression and urinary tract obstruction, making it difficult or impossible to urinate.
[0006] Urethral stricture disease occurs in men in up to 0.6% of cases in some populations. Urethral stricture disease appears to be more common in older adults. Patients with strictures experience moderate to severe complications such as lower urinary tract voiding symptoms or urinary retention, recurrent urinary tract infections, and the need for repeated urethral surgeries such as dilation, urethrotomy, or urethroplasty.
[0007] Ureteral strictures of the upper urinary tract can be congenital or acquired. Congenital ureteral strictures are most often located at the ureteropelvic junction. Most ureteral strictures are acquired and are usually iatrogenic. The most common cause of ureteral strictures is injury during endoscopic, open, or laparoscopic surgery.
[0008] Digestive body cavity or gastrointestinal strictures include esophageal strictures, achalasia strictures, bile duct strictures, gastric strictures, small intestinal strictures, duodenal strictures, jejunal strictures, ileal strictures, colonic strictures, rectal strictures, and large intestinal strictures. The type of disease classifies strictures as benign or malignant.
[0009] Bile duct strictures, also called biliary strictures, occur when the bile ducts become smaller or narrower. The bile ducts are the tubes that carry bile from the liver to the small intestine. When the bile ducts become narrowed, food becomes harder to digest. Bile duct strictures can be caused by any injury to the bile ducts, swelling, pancreatitis, intestinal injury, and bile duct or pancreatic cancer. Symptoms of bile duct strictures include pain, chills and fever, itching, and nausea or vomiting.
[0010] Esophageal strictures are a common problem in gastroenterology and can be caused by malignant or benign lesions. Dysphagia is a symptom experienced by all patients. Most of these patients require palliative care to relieve dysphagia.
[0011] Gastrointestinal strictures are narrowings of a portion of the intestine that cause problems by slowing or blocking the movement of food through that area. These strictures are caused by recurrent inflammation, cancer, Crohn's disease, and ulcerative colitis. These strictures include esophageal strictures, achalasia strictures, stent strictures, bile duct strictures, stomach strictures, small intestinal strictures, duodenal strictures, jejunal strictures, ileal strictures, colonic strictures, rectal strictures, and large intestinal strictures.
[0012] Chronic obstructive pulmonary disease (COPD) is a term used to classify two major airflow obstruction diseases: chronic bronchitis and emphysema. About 16 million Americans have COPD, and 80% to 90% of them have been smokers for most of their lives. COPD is the leading cause of death in the United States. Chronic bronchitis is an inflammation of the bronchial airways. The bronchial airways connect the trachea to the lungs. When inflamed, the bronchi secrete mucus, which causes a chronic cough. Emphysema is an overinflation of the alveoli, or air sacs, in the lungs. This condition can cause shortness of breath.
[0013] Asthma is a chronic respiratory disease characterized by inflammation of the airways, excess mucus production, and over-reactivity of the airways, a condition in which the airways are too narrow or too reactive to irritation. Asthma attacks, or episodes, can cause the airways to narrow, which can make breathing difficult. Asthma attacks can have a significant impact on a person's life, limiting participation in many activities. In severe cases, asthma attacks can be life-threatening. Currently, there is no cure for asthma.
[0014] Chronic sinusitis is an inflammation of the membrane lining of one or more paranasal sinuses. Chronic sinusitis lasts for more than 3 weeks and often lasts for months. In cases of chronic sinusitis, there is usually tissue damage. According to the Centers for Disease Control (CDC), 37 million cases of chronic sinusitis are reported each year. Summary of the invention
[0015] In various embodiments, the present invention provides a drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body cavity stenosis. Body cavity stenosis may include benign prostatic hyperplasia (BPH), urethral stenosis, ureteral stenosis, prostate cancer, esophageal stenosis, achalasia stenosis, stent stenosis, bile duct stenosis, stomach stenosis, small intestinal stenosis, duodenal stenosis, jejunal stenosis, ileal stenosis, colonic stenosis, rectal stenosis and large intestinal stenosis, asthma and chronic obstructive pulmonary disease (COPD). The balloon catheter includes an elongated balloon with a major diameter. The balloon catheter also includes a coating covering the outer surface of the balloon, wherein the coating includes one or more water-soluble additives and an initial drug loading therapeutic agent.
[0016] In various embodiments, the present invention provides a method for treating body cavity stenosis. The method includes inserting a balloon catheter into a target site of a body cavity. The method optionally includes flushing the body cavity with water, saline solution, or an aqueous solution containing at least one water-soluble additive before, during, or after inserting the balloon into the target site. The balloon catheter also includes a coating covering the outer surface of the balloon. The coating includes one or more water-soluble additives and an initial drug loading of a therapeutic agent. The method includes inflating the balloon until the coating contacts the wall of the body cavity at the target site and the balloon reaches an inflated balloon diameter for an inflation period. Presenting features (a), or (b), or (c), or (a) and (b), or (a) and (c), or (b) and (c), or (a) and (b) and (c): (a) the ratio of the inflated balloon diameter to the standard body cavity diameter at the target site is about 1.0 to about 20; or (b) the inflation includes inflating the balloon to a pressure equal to or greater than the nominal pressure of the balloon catheter, and the stretch ratio of the nominal diameter of the balloon catheter to the standard body cavity diameter at the target site is about 1.0 to about 20; or (c) the inflation includes inflating to a pressure greater than the nominal pressure of the balloon catheter, and the nominal diameter of the balloon catheter is less than the inflated balloon diameter; or (d) a combination of (a), (b) and (c). The method includes deflation of the balloon after the inflation period. The method also includes removing the balloon catheter from the body cavity.
[0017] In various embodiments, the present invention provides a method for treating body cavity stenosis. The method includes inserting a scope such as a cystoscope into the body cavity. The method includes inserting a balloon catheter with a drug coating into the body cavity. The method includes inflating the balloon catheter to an initial pressure between 0.5atm and 1.5atm, and maintaining the initial pressure until the pressure no longer decreases. The method includes inflating to a next higher pressure that is at least 0.5atm to 1.5atm higher than the initial pressure, and maintaining the next higher pressure until the pressure in the balloon no longer decreases, and repeating this step until the inner cavity expands to the desired diameter. The method includes keeping the balloon inflated for 1 minute to 7 days, 1 minute to 1 day, or 1-10 minutes to release the drug into the tissue and prevent bleeding. The method includes shrinking the balloon catheter. The method also includes removing the scope and balloon catheter from the body cavity.
[0018] Various embodiments of the present invention provide a method for treating body cavity stenosis. The method includes inserting a flexible endoscope into a body cavity stenosis. The method includes inserting a balloon catheter and an endoscope side by side into a body cavity stenosis. The method includes slowly inflating the balloon catheter to prevent the balloon from moving, such as by optionally inflating to an initial pressure between 0.5atm and 1.5atm, and maintaining the initial pressure until the pressure no longer decreases, and inflating to a higher pressure of 0.5atm to 1.5atm higher than the initial pressure, and maintaining the higher pressure until the pressure no longer decreases, and repeatedly inflating to a higher pressure, and maintaining until the pressure no longer decreases, until the tissue of the body cavity yields. The method includes keeping the balloon inflated for 1 minute to 7 days, 1 minute to 1 day, or 1-10 minutes to release the drug into the tissue and prevent bleeding. The method includes shrinking the balloon catheter. The method also includes removing the endoscope and balloon catheter assembly from the body cavity.
[0019] Various embodiments of the present invention provide a method for increasing Q maxThe method includes inserting a balloon catheter into a target site of a urinary tract stricture. The balloon catheter includes an elongated balloon and a coating covering the outer surface of the balloon. The coating includes one or more water-soluble additives and an initial drug loading amount of a therapeutic agent. The method includes inflating the balloon until the coating contacts the wall of the urinary tract stricture for an inflation period. Presenting features (a), or (b), or (c), or (a) and (b), or (a) and (c), or (b) and (c), or (a) and (b) and (c): (a) the ratio of the inflated balloon diameter to the standard body cavity diameter at the target site is about 1.0 to about 20; or (b) the inflation includes inflating the balloon to a pressure equal to or greater than the nominal pressure of the balloon catheter, and the stretch ratio of the nominal diameter of the balloon catheter to the standard body cavity diameter at the target site is about 1.0 to about 20; or (c) the inflation includes inflating to a pressure greater than the nominal pressure of the balloon catheter, and the nominal diameter of the balloon catheter is smaller than the inflated balloon diameter; or (d) a combination of (a), (b) and (c). The method includes deflation of the balloon after the inflation period. The method includes removing the balloon catheter from the urinary tract stricture. The method removes Q max Increase to a minimum of 15 mL / s.
[0020] Various embodiments of the present invention provide a method for reducing the International Prostate Symptom Score (IPSS). The method includes inserting a balloon catheter into a target site of urinary tract stenosis. The balloon catheter includes an elongated balloon and a coating covering the outer surface of the balloon. The coating includes one or more water-soluble additives and an initial drug loading of a therapeutic agent. The method includes inflating the balloon until the coating contacts the wall of the urinary tract stenosis for a period of inflation. Presenting features (a), or (b), or (c), or (a) and (b), or (a) and (c), or (b) and (c), or (a) and (b) and (c): (a) the ratio of the inflated balloon diameter to the standard body cavity diameter at the target site is about 1.0 to about 20; or (b) the inflation includes inflating the balloon to a pressure equal to or greater than the nominal pressure of the balloon catheter, and the stretch ratio of the nominal diameter of the balloon catheter to the standard body cavity diameter at the target site is about 1.0 to about 20; or (c) the inflation includes inflating to a pressure greater than the nominal pressure of the balloon catheter, and the nominal diameter of the balloon catheter is less than the inflated balloon diameter; or (d) a combination of (a), (b) and (c). The method includes deflation of the balloon after the inflation period. The method includes removing the balloon catheter from the urinary tract. The method reduces IPSS to 14 or less.
[0021] Various embodiments of the present invention provide a method of forming a balloon. The method includes placing a tube containing balloon material in a balloon mold, wherein the balloon mold has a shape including a proximal cone, at least one main body portion, at least one neck portion having a diameter smaller than the at least one main body portion, another at least one main body portion, and a distal cone. The method includes applying pressure to the interior of the tube of balloon material. The method also includes expanding the tube of balloon material into contact with the interior of the mold.
[0022] Various embodiments of the present invention provide a method for separating an enlarged prostate or creating a commissure incision to treat benign prostatic hyperplasia. The method includes inserting a drug-coated balloon catheter sheath assembly and a scope. The method includes placing the scope and balloon catheter side by side near the external sphincter. The method optionally includes flushing the body cavity with water, saline solution or an aqueous solution containing at least one water-soluble additive before, during or after inserting the balloon into the target site. The method includes removing the sheath from above the balloon and slowly inflating until the pressure drops, the prostate tissue yields, and creating a commissure incision. The method includes further increasing the pressure upward to the rated burst pressure to expand the prostate more. The method includes keeping the balloon inflated for 1 minute to 7 days, 1 minute to 1 day, or 1-10 minutes to release the drug into the tissue and prevent bleeding. The method includes shrinking the balloon catheter and covering the balloon with a sheath. The method also includes removing the scope and balloon catheter assembly from the body cavity. Presenting features (a), or (b), or (c), or (a) and (b), or (a) and (c), or (b) and (c), or (a) and (b) and (c): (a) the ratio of the inflated balloon diameter to the standard body cavity diameter at the target site is about 1.0 to about 20; or (b) the inflation includes inflating the balloon to a pressure equal to or greater than the nominal pressure of the balloon catheter, and the stretch ratio of the nominal diameter of the balloon catheter to the standard body cavity diameter at the target site is about 1.0 to about 20; or (c) the inflation includes inflating to a pressure greater than the nominal pressure of the balloon catheter, and the nominal diameter of the balloon catheter is smaller than the inflated balloon diameter; or (d) a combination of (a), (b) and (c).
[0023] Various embodiments of the present invention provide a method for separating an enlarged prostate or creating a commissure incision to treat benign prostatic hyperplasia. The method includes inserting an uncoated balloon catheter sheath assembly and a speculum. The method includes placing the speculum and balloon catheter side by side near the external sphincter. The method includes removing the sheath from above the balloon and slowly inflating until the pressure drops, the prostate tissue yields, and creating a commissure incision. The method includes further increasing the pressure to the rated burst pressure to expand the prostate more. The method includes keeping the balloon inflated for 1 minute to 7 days, 1 minute to 1 day, or 1-10 minutes to prevent bleeding. The method includes shrinking the uncoated balloon catheter and covering the balloon with a sheath. The method includes removing the speculum and the uncoated balloon catheter assembly from the body cavity. The method includes inserting a drug-coated balloon catheter sheath assembly and a speculum. The method includes placing the speculum and the drug-coated balloon catheter side by side near the external sphincter. The method includes removing the sheath from over the drug-coated balloon and slowly inflating it to a rated burst pressure to expand the prostate more. The method includes keeping the balloon inflated for 1 minute to 7 days, 1 minute to 1 day, or 1-10 minutes to release the drug into the tissue and prevent bleeding. Presenting features (a), or (b), or (c), or (a) and (b), or (a) and (c), or (b) and (c), or (a) and (b) and (c): (a) the ratio of the inflated balloon diameter to the standard body cavity diameter at the target site is about 1.0 to about 20; or (b) the inflation includes inflating the balloon to a pressure equal to or greater than the nominal pressure of the balloon catheter, and the stretch ratio of the nominal diameter of the balloon catheter to the standard body cavity diameter at the target site is about 1.0 to about 20; or (c) the inflation includes inflating to a pressure greater than the nominal pressure of the balloon catheter, and the nominal diameter of the balloon catheter is smaller than the inflated balloon diameter; or (d) a combination of (a), (b) and (c).
[0024] Various embodiments of the present invention provide a method for treating benign prostatic hyperplasia. The method includes inserting a balloon catheter into a target site of the prostate. The balloon catheter includes a coating covering the outer surface of the balloon. The coating includes one or more water-soluble additives and an initial drug loading amount of a therapeutic agent. The method includes inflating the balloon until the coating contacts the wall of the body cavity at the target site and the balloon reaches an inflated balloon diameter for an inflation period. Presenting features (a), or (b), or (c), or (a) and (b), or (a) and (c), or (b) and (c), or (a) and (b) and (c): (a) the ratio of the inflated balloon diameter to the standard body cavity diameter at the target site is about 1.0 to about 20; or (b) the inflation includes inflating the balloon to a pressure equal to or greater than the nominal pressure of the balloon catheter, and the stretch ratio of the nominal diameter of the balloon catheter to the standard body cavity diameter at the target site is about 1.0 to about 20; or (c) the inflation includes inflating to a pressure greater than the nominal pressure of the balloon catheter, and the nominal diameter of the balloon catheter is less than the inflated balloon diameter; or (d) a combination of (a), (b) and (c). The method includes deflation of the balloon after the inflation period. The method includes removing the balloon catheter from the body cavity. The method separates the prostatic urethra from the prostate, achieves a urinary prostatic urethra diameter of at least 12 mm, and achieves an inflated diameter of the balloon catheter of at least 20 mm or at least 25 mm.
[0025] Various embodiments of the present invention provide a method for treating urethral stricture. The method includes inserting a balloon catheter into a target site of the urethra. The balloon catheter includes a coating covering the outer surface of the balloon. The coating includes one or more water-soluble additives and an initial drug loading amount of a therapeutic agent; wherein the therapeutic agent is paclitaxel, docetaxel, taxol, their analogs, rapamycin, sirolimus, everolimus, tacrolimus, MTOR inhibitors, their analogs, and combinations thereof, and the water-soluble additive is at least one of the following: N-acetylglucosamine, N-octyl-D-glucosamine, N-nonanoyl-N-methylglucosamine, N-octanoyl- N-methylglutamine, C6-ceramide, dihydro-C6-ceramide, cerebrosides, sphingomyelin, galactocerebrosides, lactocerebrosides, N-acetyl-D-sphingosine, N-hexanoyl-D-sphingosine, N-capryl-D-sphingosine, N-lauroyl-D-sphingosine, N-palmitoyl-D-sphingosine, N-oleoyl-D-sphingosine, PEG caprylic / capric diglyceride, PEG8 caprylic / capric glyceride, PEG caprylate , PEG8 caprylate, PEG caprate, PEG caproate, glyceryl monocaprylate, glyceryl monocaprate, glyceryl monohexanoate, monolaurin, monocapric glyceryl, monocaprylic glyceryl, monomyristic glyceryl, monopalmitoleic glyceryl, monooleic glyceryl, sarcosine, creatinine, agmatine, citrulline, guanidine, sucralose, aspartame, hypoxanthine, theobromine, theophylline, adenine, uracil, uridine, guanine, thymine, Thymidine, xanthine, xanthine riboside, xanthine riboside monophosphate, caffeine, allantoin, (2-hydroxyethyl) urea, N,N'-bis(hydroxymethyl) urea, pentaerythritol ethoxylate, pentaerythritol propoxylate, pentaerythritol propoxylate / ethoxylate, glycerol ethoxylate, glycerol propoxylate, ethoxylated trimethylolpropane, pentaerythritol, dipentaerythritol, crown ethers, 18-crown-6, 15-crown-5, 12-crown-4, and combinations thereof. The method optionally includes flushing the body cavity with water, saline solution, or an aqueous solution comprising at least one water-soluble additive before, during, or after inserting the balloon into the target site. The method includes inflating the balloon until the coating contacts the wall of the body cavity at the target site and the balloon reaches an inflated balloon diameter for an inflation period.Presenting feature (a), or (b), or (c), or (a) and (b), or (a) and (c), or (b) and (c), or (a) and (b) and (c): (a) the ratio of the inflated balloon diameter to the standard body cavity diameter at the target site is about 1.0 to about 20; or (b) the inflation includes inflating the balloon to a pressure equal to or greater than the nominal pressure of the balloon catheter, and the stretch ratio of the nominal diameter of the balloon catheter to the standard body cavity diameter at the target site is about 1.0 to about 20; or (c) the inflation includes inflating to a pressure greater than the nominal pressure of the balloon catheter, and the nominal diameter of the balloon catheter is less than the inflated balloon diameter; or (d) a combination of (a), (b) and (c). The method includes deflation of the balloon after the inflation period. The method includes removing the balloon catheter from the body cavity. The method achieves a urethral diameter of at least 6.7 mm after expansion, and the inflated diameter of the balloon catheter is at least 7 mm.
[0026] Various embodiments of the present invention provide a balloon catheter for treating urethral stricture. The balloon catheter includes a coating covering the outer surface of the balloon. The coating comprises one or more water-soluble additives and an initial drug loading amount of a therapeutic agent; wherein the therapeutic agent is paclitaxel, docetaxel, taxol, their analogs, rapamycin, sirolimus, everolimus, tacrolimus, MTOR inhibitors, their analogs, and combinations thereof, and the water-soluble additive is at least one of the following: N-acetylglucosamine, N-octyl-D-glucosamide, N-nonanoyl-N-methylglucosamine, N-octanoyl-N-methylglucosamine, -Methylglutamine, C6-ceramide, dihydro-C6-ceramide, cerebroside, sphingomyelin, galactocerebroside, lactocerebroside, N-acetyl-D-sphingosine, N-hexanoyl-D-sphingosine, N-capryl-D-sphingosine, N-lauroyl-D-sphingosine, N-palmitoyl-D-sphingosine, N-oleoyl-D-sphingosine, PEG caprylic / capric diglyceride, PEG8 caprylic / capric glyceride, PEG caprylate, PEG8 caprylate, PEG caprate, PEG caproate, glyceryl monocaprylate, glyceryl monocaprate, glyceryl monohexanoate, glyceryl monolaurate, glyceryl monocaprate, glyceryl monocaprylate, glyceryl monomyristate, glyceryl monopalmitoleate, glyceryl monooleate, sarcosine, creatinine, agmatine, citrulline, guanidine, sucralose, aspartame, hypoxanthine, theobromine, theophylline, adenine, uracil, uridine, guanine, thymine, Thymidine, xanthine, xanthine riboside, xanthine riboside monophosphate, caffeine, allantoin, (2-hydroxyethyl) urea, N,N'-bis(hydroxymethyl) urea, pentaerythritol ethoxylate, pentaerythritol propoxylate, pentaerythritol propoxylate / ethoxylate, glycerol ethoxylate, glycerol propoxylate, ethoxylated trimethylolpropane, pentaerythritol, dipentaerythritol, crown ethers, 18-crown-6, 15-crown-5, 12-crown-4, and combinations thereof. Presenting features (a), or (b), or (c), or (a) and (b), or (a) and (c), or (b) and (c), or (a) and (b) and (c): (a) the ratio of the inflated balloon diameter to the standard body cavity diameter at the target site is about 1.0 to about 20; or (b) the inflation includes inflating the balloon to a pressure equal to or greater than the nominal pressure of the balloon catheter, and the stretch ratio of the nominal diameter of the balloon catheter to the standard body cavity diameter at the target site is about 1.0 to about 20; or (c) the inflation includes inflating to a pressure greater than the nominal pressure of the balloon catheter, and the nominal diameter of the balloon catheter is smaller than the inflated balloon diameter; or (d) a combination of (a), (b) and (c). After treatment, Q max The urethral diameter after dilation is at least 6.7 mm. The inflated diameter of the balloon catheter is at least 7 mm. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] The following figures illustrate various embodiments of the invention generally by way of example, and not by way of limitation.
[0028] Figure 1A A balloon catheter having a neck portion is shown according to various embodiments.
[0029] Figure 1B A balloon catheter having two neck portions is shown according to various embodiments.
[0030] Figure 1C A balloon catheter having three neck portions is shown according to various embodiments.
[0031] Figure 2 A two-neck drug-coated balloon catheter according to various embodiments is shown, which includes a catheter shaft, a catheter tip, and a Tuohy Borst adapter (the balloon catheter includes a fixed-line, cross-line, and rapid-exchange balloon catheter, Figure 2 Details not shown).
[0032] Figure 3 is a perspective view of an embodiment of a balloon catheter according to the present invention (the balloon catheter includes fixed-line, cross-line and rapid exchange balloon catheters, Figure 3 Details not shown).
[0033] Figures 4A-4C yes Figure 3 Cross-sectional views of various embodiments of the distal portion of a balloon catheter taken along line AA showing exemplary coatings. DETAILED DESCRIPTION
[0034] Reference will now be made in detail to certain embodiments of the disclosed subject matter, examples of which are partially illustrated in the accompanying drawings.While the disclosed subject matter will be described in conjunction with the enumerated claims, it will be understood that the exemplary subject matter is not intended to limit the claims to the disclosed subject matter.
[0035] In this document, values expressed in range format should be interpreted in a flexible manner to include not only the values explicitly listed as the range limits, but also all individual values or sub-ranges contained in the range, as if each value and sub-range were explicitly listed. For example, a range of "about 0.1% to about 5%" or "about 0.1% to 5%" should be interpreted as including not only about 0.1% to about 5%, but also the individual values (e.g., 1%, 2%, 3% and 4%) and sub-ranges (e.g., 0.1% to 0.5%, 1.1% to 2.2%, 3.3% to 4.4%) within the range shown. Unless otherwise specified, the expression "about X to Y" has the same meaning as "about X to about Y". Similarly, unless otherwise specified, the expression "about X, Y or about Z" has the same meaning as "about X, about Y or about Z".
[0036] In this document, unless the context clearly indicates otherwise, the terms "a, an" or "the" are used to include one or more than one. Unless otherwise specified, the term "or" is used to refer to a non-exclusive "or". The description "at least one of A and B" has the same meaning as "A, B, or A and B". In addition, it should be understood that the words or terms used herein and not otherwise defined are for description only and not for limitation. Any section headings are used to assist in reading the document and are not to be interpreted as limitations; information related to the section heading may appear within or outside that particular section.
[0037] In the methods described herein, unless a time or sequence of operations is explicitly stated, the actions may be performed in any order without departing from the principles of the invention. In addition, unless the explicit claim language states that specific actions are performed separately, they may be performed simultaneously. For example, a claimed action to implement X and a claimed action to implement Y may be performed simultaneously in a single operation, and the resulting method will fall within the literal scope of the claimed method.
[0038] As used herein, the term "about" may allow a certain degree of variability in a value or range, for example, within 10%, within 5% or within 1% of the stated value or limit of the stated range, and include the exactly stated value or range.
[0039] As used herein, the term "substantially" refers to a majority or majority, such as at least about 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, 99.99%, or at least about 99.999% or more, or 100%.
[0040] One aspect of various embodiments of the present invention is to deliver therapeutic agents such as paclitaxel, taxol, docetaxel, rapamycin, sirolimus, tacrolimus, everolimus, mTOR inhibitors or their analogs to the wall of a body cavity to treat narrowing or stenosis. These drugs can be considered anti-inflammatory drugs or antiproliferative drugs. The stenosis can be in a vascular cavity (e.g., coronary artery or peripheral arterial vascular stenosis) or the stenosis can be in a non-vascular cavity. The drug can be a water-insoluble drug.
[0041] The antimicrobial properties of various fatty acids and monoglycerides of C8-C12 fatty acids have been studied for many years. These studies have confirmed that both fatty acids and monoglycerides can inhibit the growth of a variety of bacteria and viruses. The coating formulations of the present invention include various fatty acids and monoglycerides of C8-C12 fatty acids, such as caprylic acid, monocaprilin, capric acid, monocaprin, lauric acid and monolaurin, as an additive for treating various diseases.
[0042] Causes of non-vascular body lumen stenosis and related non-vascular diseases (such as benign prostatic hyperplasia (BPH), urethral stenosis, ureteral stenosis, prostate cancer, esophageal stenosis, achalasia stenosis, stent stenosis, biliary tract stenosis, gastric stenosis, small intestinal stenosis, duodenal stenosis, jejunal stenosis, ileal stenosis, colonic stenosis, rectal stenosis and large intestinal stenosis, asthma and chronic obstructive pulmonary disease (COPD)) may include cancer and infection and inflammation caused by pathogens such as bacteria and viruses. Various embodiments of the present invention provide for delivering a coating formulation to a stenosis, the coating formulation comprising drugs and additives having properties of killing and inhibiting bacteria and viruses.
[0043] The present invention provides new methods for treating body lumen stenosis to have long-term and lasting effects. These new methods open the lumen and prevent, reduce or minimize the re-narrowing and recurrence of stenosis. These methods involve delivering therapeutic agents such as anti-inflammatory drugs and anti-proliferative drugs (e.g., paclitaxel, taxol, docetaxel, rapamycin, sirolimus, tacrolimus, everolimus, mTOR inhibitors, or their analogs) and one or more water-soluble additives to target tissues.
[0044] Embodiments of the present invention provide a medical device coating formulation comprising a drug for treating non-vascular body lumen stenosis and an additive that enhances the absorption of the drug into body lumen tissue. These additives may have antibacterial and antiviral properties. A balloon catheter includes a coating covering the outer surface of the balloon, wherein the coating includes one or more water-soluble additives and an initial drug loading of an antiproliferative therapeutic agent.
[0045] By coating the outer surface of the balloon catheter with a layer containing, for example, a therapeutic agent and an additive, the problems associated with the coating can be effectively solved. For example, the additive may have a hydrophilic portion and a pro-drug portion. The pro-drug portion may be a hydrophobic portion and / or may have affinity for the therapeutic agent through hydrogen bonding and / or van der Waals interactions. Surprisingly, the additive containing a hydrophilic portion and a pro-drug portion according to an embodiment of the present invention is combined with an anti-proliferative therapeutic agent to form an effective drug delivery coating on a medical device without the use of oil and lipids, thereby avoiding the lipolysis dependence and other disadvantages of conventional oil-based coating preparations. In addition, the additive according to an embodiment of the present invention contributes to rapid elution of the drug and efficient penetration of the drug into the lesion site of the tissue. Therefore, the coating according to an embodiment of the present invention provides an anti-proliferative therapeutic agent to be absorbed into non-vascular lesion tissue or non-vascular body cavity at a high rate and / or degree. In an embodiment of the present invention, the coated device delivers the anti-proliferative therapeutic agent to non-vascular tissue in an extremely short deployment time of less than 10 minutes and less than 2 minutes, and reduces the re-narrowing and reoccurrence of non-vascular body cavity stenosis.
[0046] Various embodiments of the present invention relate to a medical device for delivering a therapeutic agent to a vascular or non-vascular body lumen stenosis, the device comprising a layer covering the outer surface of the medical device. The device comprises one of the following: a balloon catheter, a fixed-line balloon catheter, a cross-line balloon catheter, a rapid exchange balloon catheter, a perfusion balloon catheter, a separate double balloon (spaced double balloon), a cutting balloon catheter, a scored balloon catheter or an infusion catheter (e.g., a distal perforated drug infusion tube, a perforated balloon, a separate double balloon, a porous balloon or a weeping balloon). The balloon catheter comprises an elongated balloon having a narrow diameter middle portion. The balloon of the balloon catheter comprises at least one neck portion, which comprises a diameter less than the main diameter, and the at least one neck portion divides the balloon into at least two main parts, each having a diameter equal to or different from the main diameter. In addition, non-vascular cavities or non-vascular stenosis include one of the following: esophagus, airway, sinus, trachea, colon, bile duct, stomach, small intestine, duodenum, jejunum, ileum, rectum, large intestine, urinary tract, prostate, urethra, ureter and other non-vascular cavities. Vascular cavities include arteries, veins or any cavity with blood. Non-vascular cavities include those without blood. The balloon catheter shaft and balloon material can be composed of polyether-amide block copolymers, polyamides, nylons or blends thereof.
[0047] In some embodiments, the additive is at least one of a surfactant and a chemical compound. The coating covering the exterior of the medical device may include one or more water-soluble additives. The coating covering the exterior of the medical device may include one or more water-soluble additives (e.g., a water-soluble first additive, a water-soluble second additive, and a water-soluble third additive).
[0048] The medical device may further include a dimethyl sulfoxide solvent layer, wherein the dimethyl sulfoxide solvent layer covers an outer surface of the medical device.
[0049] The device is capable of releasing the therapeutic agent and additives and delivering the therapeutic agent to the tissue within about 0.1 to 10 minutes. The concentration of the therapeutic agent in the layer can be 1 to 20 μg / mm 2 , which is measured when the balloon is inflated to its nominal diameter. The concentration of the therapeutic agent in the layer may be 2 to 10 μg / mm 2 .
[0050] In some embodiments, the additive can enhance the release of the therapeutic agent from the balloon. The additive can enhance the penetration and absorption of the therapeutic agent into the tissue. The additive can have a water solubility and an ethanol solubility of at least 1 mg / ml, and the therapeutic agent can be water insoluble.
[0051] The layer covering the outer surface of the medical device may include a therapeutic agent and at least two additives, wherein each additive includes a hydrophilic portion and a drug-loving portion, wherein the drug-loving portion is at least one of a hydrophobic portion, a portion having affinity for the therapeutic agent through hydrogen bonding, and a portion having affinity for the therapeutic agent through van der Waals interactions, and wherein each additive is soluble in a polar organic solvent and soluble in water. In one aspect of this embodiment, the polar organic solvent is selected from methanol, ethanol, isopropanol, acetone, dimethylformamide, tetrahydrofuran, methyl ethyl ketone, dimethyl sulfoxide, acetonitrile, ethyl acetate and chloroform and mixtures of these polar organic solvents with water. In another aspect of this embodiment, the device also includes a top layer covering the surface of the layer covering the outer surface of the medical device to reduce drug loss during transport through the body to the target tissue.
[0052] In some embodiments, the additive reduces the crystal size and particle number of the therapeutic agent, and wherein the additive is water-soluble, and the therapeutic agent is not water-soluble. The additive may have a fatty chain of an acid, ester, ether, or alcohol, wherein the fatty chain may be directly inserted into the lipid membrane structure of the tissue. The additive may penetrate into the lipid membrane structure of the tissue and rearrange it. The additive may have one or more functional groups with affinity for the drug through hydrogen bonding and / or van der Waals interactions. In some embodiments, the additive may be at least one of a surfactant and a chemical compound, and wherein the chemical compound has a molecular weight of 50 to 750 g / mol. The chemical compound may have more than four hydroxyl groups. In some embodiments, the chemical compound with more than four hydroxyl groups has a melting point of 120° C. or less, and the chemical compound is an alcohol or ester. In some embodiments, the therapeutic agent is not water-soluble.
[0053] The medical device coating for drug delivery to non-vascular tissue or non-vascular stenosis can be prepared by a mixture. The coating can be prepared by a mixture comprising the following items: an organic phase containing drug particles dispersed therein and an aqueous phase containing a water-soluble additive. The water-soluble additive can be selected from polyethylene glycol, polyvinyl alcohol, polyvinyl pyrrolidone, polypeptide, water-soluble surfactant, water-soluble vitamins and protein. The preparation mixture can be included in high shear conditions and optionally homogenized under pressure.
[0054] The coating covering the outer surface of the medical device may consist essentially of a therapeutic agent and an additive. The coating covering the outer surface of the medical device may consist essentially of a therapeutic agent, a water-soluble first additive, and a water-soluble second additive. The coating covering the outer surface of the medical device may consist essentially of a therapeutic agent and one or more water-soluble additives (e.g., a water-soluble first additive, a water-soluble second additive, and a water-soluble third additive).
[0055] In some embodiments, a method for treating a non-vascular body lumen stenosis comprises inserting a balloon catheter comprising a coating into a body stenosis, wherein the stenosis is one of: urethral stenosis, benign prostatic hyperplasia (BPH) stenosis, ureteral stenosis, esophageal stenosis, achalasia stenosis, bile duct stenosis, gastric stenosis, small intestinal stenosis, duodenal stenosis, jejunal stenosis, ileal stenosis, colonic stenosis, rectal stenosis, stent stenosis, large intestinal stenosis, and antral stenosis, wherein the coating comprises a drug and an additive; inflating the balloon catheter and releasing the drug to the wall of the stenosis, deflated the balloon; and removing the balloon catheter, wherein the residual drug on the balloon catheter can be about 1% to 70% of the total drug load. In one aspect of this embodiment, the additive enhances absorption of the drug into tissues of the non-vascular body lumen.
[0056] Some drugs used in various embodiments that are considered particularly suitable for the airways, sinuses, and other nasal cavities are corticosteroids such as budesonide, flunisolide, triamcinolone, beclomethasone, fluticasone, mometasone, mometasone furoate, dexamethasone, hydrocortisone, methylprednisolone, prednisone, cotisone, betamethasone, triamcinolone acetonide, and the like.
[0057] Various embodiments relate to a method for treating a non-vascular body lumen stenosis, and may include flushing the lumen with water, saline solution, or an aqueous solution of an additive described herein; inserting a balloon catheter comprising a coating into the body lumen, wherein the coating comprises a drug and an additive; inflating the balloon catheter and releasing the drug to the wall of the body lumen; deflation of the balloon; and removal of the balloon catheter. A method for treating a non-vascular body lumen stenosis may include infusing water, saline solution, or an aqueous solution comprising at least one of the additives described herein; inserting a balloon catheter comprising a coating into a stenosis in a non-vascular body lumen, wherein the non-vascular body lumen stenosis is one of the following: urethral stenosis, ureteral stenosis, esophageal stenosis, achalasia stenosis, stent stenosis, antral stenosis, gastric stenosis, small intestinal stenosis, duodenal stenosis, jejunal stenosis, ileal stenosis, rectal stenosis, and large intestinal stenosis and biliary stenosis, wherein the coating comprises a drug and an additive; inflating the balloon catheter and releasing the drug to the wall of the stenosis in the non-vascular body lumen; deflation of the balloon; and removal of the balloon catheter. In one aspect of this embodiment, the additive enhances absorption of the drug into tissues of non-vascular body cavities. In another aspect of this embodiment, the additive comprises a hydrophilic portion and a drug-loving portion, wherein the drug-loving portion is at least one of a hydrophobic portion, a portion having affinity for the therapeutic agent by hydrogen bonding, and a portion having affinity for the therapeutic agent by van der Waals interactions. In another aspect of this embodiment, the drug is selected from paclitaxel, docetaxel, taxol, and analogs thereof, and rapamycin, sirolimus, everolimus, tacrolimus, and analogs thereof. In another aspect of this embodiment, the additive is selected from PEG-fatty acids and PEG-fatty acid monoesters and diesters, polyethylene glycol glyceride fatty acid esters, alcohol-oil transesterification products, polyglycerol fatty acids, propylene glycol fatty acid esters, sterols and derivatives thereof, polyethylene glycol sorbitan fatty acid esters, polyethylene glycol alkyl ethers, sugars and derivatives thereof, polyethylene glycol alkylphenols, polyoxyethylene-polyoxypropylene block copolymers, sorbitan fatty acid esters, fat-soluble vitamins and salts thereof, water-soluble vitamins and amphiphilic derivatives thereof, amino acids and salts thereof, oligopeptides, peptides and proteins, and organic acids and esters and anhydrides thereof. In another aspect of this embodiment, the drug may be released to the airway wall before, during or after an asthma attack. In another aspect of this embodiment, the drug may be released to the esophageal wall. In another aspect of this embodiment, the drug may be released to the sinus wall. In another aspect of this embodiment, the drug may be released to the bile duct wall. In another aspect of this embodiment, the drug may be released to the wall of the urinary tract, prostate, urethra and ureteral cavity. In another aspect of this embodiment, the drug can be released to the wall of the stomach, small intestine, duodenum, jejunum, ileum, colon, rectum or large intestine. In another aspect of this embodiment, the drug can be released to the wall of the non-vascular stenosis in the stent.
[0058] In various embodiments, the present invention provides a method of treating a body cavity comprising inserting a balloon catheter (such as any of the balloon catheters described herein) into a target site in the body cavity. The method comprises inserting Figure 1A , Figure 1B , Figure 1C , Figure 2 or Figure 3 The method may include inserting a balloon catheter and a scope into a target part of a body cavity side by side, or the balloon catheter is in the lumen of the scope. The scope may be an endoscope, an enteroscope, a colonoscope, a sigmoidoscope, a rectoscope, an anoscope, a nasal mirror, a bronchoscope or a cystoscope. The scope may be used to ensure that the balloon catheter is correctly positioned in the target lumen. The method may include flushing the body cavity with water, a saline solution or an aqueous solution containing at least one water-soluble additive before, during or after inserting the balloon into the target part. The method includes inflating the balloon until the coating contacts the wall of the stenosis of the body cavity at the target part and the balloon reaches the inflated balloon diameter for one inflation period. Presenting features (a), or (b), or (c), or (a) and (b), or (a) and (c), or (b) and (c), or (a) and (b) and (c): (a) the ratio of the inflated balloon diameter to the standard body cavity diameter at the target site is about 1.0 to about 20; or (b) the inflation includes inflating the balloon to a pressure equal to or greater than the nominal pressure of the balloon catheter, and the stretch ratio of the nominal diameter of the balloon catheter to the standard body cavity diameter at the target site is about 1.0 to about 20; or (c) the inflation includes inflating to a pressure greater than the nominal pressure of the balloon catheter, and the nominal diameter of the balloon catheter is less than the inflated balloon diameter; or (d) a combination of (a), (b) and (c). The method includes deflation of the balloon after the inflation period. The method also includes removing the balloon catheter from the stenosis in the body cavity.
[0059] In some embodiments, the balloon is inflated until the coating contacts the wall of the stenosis, and the stenosis is expanded while the drug is transferred to the stenosis. In some embodiments, the balloon is inflated until the coating contacts the wall of the stenosis, and the inflation expands the stenosis to increase its diameter so that contact with the stenosis can provide full circumference transfer of the drug to the wall of the stenosis. In some embodiments, the portion of the balloon containing the drug (e.g., in embodiments including less than 100% of the surface area coated with the drug) can contact the stenosis uniformly. In other embodiments, various portions of the balloon surface are not in uniform contact with the stenosis.
[0060] The inflated diameter of the balloon can be any suitable diameter reached during the inflation period or throughout the inflation period, so as to achieve a desired ratio of the inflated balloon diameter to the standard diameter of the body cavity. The inflated diameter of the balloon can correspond to the pressure used to inflate the balloon during the inflation period. The inflation pressure can be in the range of the nominal inflation pressure to the rated burst pressure. The nominal pressure is the pressure at the nominal diameter of the inflated balloon catheter. The nominal diameter is the diameter at the nominal pressure of the balloon catheter and is clearly stated on the product label. In some embodiments, the inflation pressure can be the nominal pressure of the balloon, and the inflated diameter of the balloon can be approximately equal to the nominal diameter of the balloon, or can be smaller than the nominal diameter of the balloon due to the constraint of the stenosis. In some embodiments, the inflation pressure of the balloon during the inflation period can be higher or lower than the nominal pressure, and the inflated diameter of the balloon can be correspondingly larger or smaller than the nominal diameter of the balloon.
[0061] In various embodiments, the present invention provides a method for treating a body cavity. The method includes 1) loading a balloon catheter into a scope (e.g., a cystoscope) from behind. The method includes 2) inserting a scope-balloon catheter assembly into a body cavity. The method includes 3) inflating the balloon to an initial pressure (e.g., 0.5atm, 1atm, or 1.5atm), and maintaining the initial pressure until the pressure no longer decreases, for 1-2 minutes. The method includes 4) inflating to the next higher pressure, increasing 0.5, 1, or 1.5atm from the previous pressure, and maintaining the higher pressure until the pressure no longer decreases, for 1-2 minutes. The method includes 5) repeating the steps of 4) until the lumen tissue (such as prostate tissue) yields. The method includes 6) keeping the balloon inflated for 1 minute to 7 days, or 1 minute to 1 day, or 1-10 minutes, to release the drug into the tissue, and to prevent bleeding. The method includes 7) shrinking the balloon catheter. The method includes 8) removing the scope-balloon catheter assembly from the body cavity. In this embodiment, a speculum may be used to ensure proper positioning of the balloon catheter prior to and / or during inflation.
[0062] In various embodiments, the present invention provides a method for treating a body cavity. The method includes 1) inserting a flexible endoscope and a balloon catheter in a sheath side by side into a body cavity. The method includes 2) removing the sheath from above the balloon, and inflating to an initial pressure (e.g., 0.5atm, 1atm, or 1.5atm), and maintaining the initial pressure until the pressure no longer decreases, for 1-2 minutes. The method includes 3) inflating to the next higher pressure, increasing 0.5, 1, or 1.5atm from the previous pressure, and maintaining the higher pressure until the pressure no longer decreases, for 1-2 minutes. The method includes 4) repeating the steps of 3) until the body cavity tissue yields. The method includes 5) keeping the balloon inflated for 1 minute to 7 days, 1 minute to 1 day, or 1-10 minutes to release the drug into the tissue and prevent bleeding. The method includes 6) shrinking the balloon catheter. The method includes 7) pulling the balloon catheter back into the sheath. The method includes 8) removing the endoscope and balloon catheter / sheath from the body cavity. In this embodiment, a speculum may be used to ensure proper positioning of the balloon prior to and / or during inflation.
[0063] In various embodiments, the present invention provides a method for treating a body cavity. The method includes 1) inserting a flexible scope into a body cavity. The method also includes 2) inserting a balloon catheter and a scope side by side into the body cavity. The method includes 3) inflating to an initial pressure (e.g., 0.5atm, 1atm, or 1.5atm), and maintaining the initial pressure until the pressure no longer decreases, for 1-2 minutes. The method includes 4) inflating to the next higher pressure, increasing 0.5, 1, or 1.5atm from the previous pressure, and maintaining the higher pressure until the pressure no longer decreases, for 1-2 minutes. The method includes 5) repeating the steps of 4) until the body cavity tissue yields. The method includes 6) keeping the balloon inflated for 1 minute to 7 days, 1 minute to 1 day, or 1-10 minutes to release the drug into the tissue and prevent bleeding. The method includes 7) shrinking the balloon catheter. The method includes 8) removing the scope and balloon catheter assembly from the body cavity. In this embodiment, a scope can be used to ensure that the balloon catheter is correctly positioned before and / or during inflation.
[0064] In various embodiments, the present invention provides a method for treating benign prostatic hyperplasia. The method includes 1) inserting a balloon catheter sheath assembly and a scope (e.g., a cystoscope). The method includes 2) placing the scope and balloon catheter side by side near the external sphincter. The method includes 3) removing the sheath from above the balloon, and inflating to an initial pressure (e.g., 0.5atm, 1atm, or 1.5atm), and maintaining the initial pressure until the pressure no longer decreases, for 1-2 minutes. The method includes 4) inflating to the next higher pressure, increasing 0.5, 1, or 1.5atm from the previous pressure, and maintaining the higher pressure until the pressure no longer decreases, for 1-2 minutes. The method includes 5) repeating the steps of 4) until the prostate tissue yields, and forming a commissure incision. The method includes 6) keeping the balloon inflated for 1 minute to 7 days, 1 minute to 1 day, or 1-10 minutes, to release the drug into the tissue, and to prevent bleeding. The method includes 7) shrinking the balloon catheter. The method includes 8) taking out the scope and balloon catheter assembly from the body cavity. Presenting features (a), or (b), or (c), or (a) and (b), or (a) and (c), or (b) and (c), or (a) and (b) and (c): (a) the ratio of the inflated balloon diameter to the standard body cavity diameter at the target site is about 1.0 to about 20; or (b) the inflation includes inflating the balloon to a pressure equal to or greater than the nominal pressure of the balloon catheter, and the stretch ratio of the nominal diameter of the balloon catheter to the standard body cavity diameter at the target site is about 1.0 to about 20; or (c) the inflation includes inflating to a pressure greater than the nominal pressure of the balloon catheter, and the nominal diameter of the balloon catheter is smaller than the inflated balloon diameter; or (d) a combination of (a), (b) and (c).
[0065] Various embodiments of the present invention relate to treating body cavity stenosis by delivering an effective amount of a therapeutic agent, such as an anti-inflammatory and antiproliferative drug (e.g., rapamycin, sirolimus, everolimus, tacrolimus, paclitaxel, taxol, docetaxel, or their analogs) to a target tissue. Body cavity stenosis includes vascular stenosis, non-vascular stenosis, urethral stenosis, ureteral stenosis, esophageal stenosis, achalasia stenosis, stent stenosis, sinus stenosis, bile duct stenosis, gastric stenosis, small intestinal stenosis, duodenal stenosis, jejunal stenosis, ileal stenosis, colonic stenosis, rectal stenosis, and large intestinal stenosis. Embodiments of the present invention relate to methods for treating at least one of the following: vascular and non-vascular cavity stenosis, benign prostatic hyperplasia (BPH), urethral narrowing, prostate cancer, asthma, and chronic obstructive pulmonary disease (COPD). Treatment is intended for a variety of animals, such as premature newborns to adults.
[0066] The drug on the balloon catheter coating can be released into the target body cavity. The multi-part balloon with a neck portion having a smaller diameter mechanically anchors the balloon in the body cavity, thereby preventing the balloon from sliding in the body cavity. If the balloon slides or leaves the target lesion site, the target site may be missed and the healthy lumen may be injured.
[0067] In various embodiments, the present invention has advantages, at least some of which are unexpected. For example, coating the outer surface of a balloon catheter with a layer comprising a therapeutic agent and an additive having a hydrophilic portion and a pro-drug portion can be used to treat diseases disclosed herein. The pro-drug portion is a hydrophobic portion and / or has affinity for the therapeutic agent through hydrogen bonding and / or van der Waals interactions. Surprisingly, the additive comprising a hydrophilic portion and a pro-drug portion according to an embodiment of the present invention forms an effective drug delivery coating on a medical device together with the therapeutic agent. In addition, the additive according to an embodiment of the present invention can help the drug to elute quickly and the drug to penetrate efficiently into the lesion site of the tissue. Therefore, the coating according to an embodiment of the present invention can provide a therapeutic agent for absorption into the diseased tissue or body cavity at a high rate and / or degree. In an embodiment of the present invention, the coated device can deliver the therapeutic agent to the tissue in an extremely short deployment time of less than 10 minutes (e.g., less than 2 minutes), and can reduce the narrowing of the body cavity and reoccurrence such as compared with other balloon catheters lacking such a neck portion or a configuration of the neck portion.
[0068] In various embodiments, the balloon catheter of the present invention is compatible with a flexible or rigid scope that allows viewing of the treatment area, thereby allowing more precise and efficient placement than other balloon catheters. The scope can be an endoscope, an enteroscope, a colonoscope, a sigmoidoscope, a proctoscope, an anoscope, a rhinoscope, a bronchoscope, or a cystoscope. In various embodiments, the balloon catheter of the present invention is self-seeking, wherein even if the balloon catheter is slightly out of position at the beginning of inflation, the neck portion of the balloon catheter guides the balloon catheter to the appropriate position during inflation (e.g., the neck portion of the balloon catheter (the distal-most neck portion) is in the bladder neck).
[0069] Balloon catheter and method of using the same
[0070] In various embodiments, the present invention provides a balloon catheter for delivering a therapeutic agent to a target site of a body cavity. The balloon catheter may include an elongated balloon having a plurality of main or main parts and at least one neck part having a diameter smaller than the main part. The balloon catheter may include an elongated balloon having a main diameter, such as a plurality of main parts having a main diameter or having an average diameter equal to the main diameter. The multi-part balloon with a neck part having a smaller diameter is mechanically anchored in the body cavity; therefore, it can prevent the balloon from sliding in the body cavity. If the balloon slides off the target lesion site, it may miss, and the healthy lumen site may be injured. The balloon catheter may include at least one neck part on the balloon, and the at least one neck part includes a diameter smaller than the main diameter. The balloon catheter may also include a coating covering the outer surface of the balloon. The coating may include one or more water-soluble additives and an initial drug loading of a therapeutic agent (e.g., paclitaxel, taxol, docetaxel, their analogs, rapamycin, sirolimus, everolimus, tacrolimus, their analogs, and combinations thereof). In a method of using a balloon catheter, feature (a), or (b), or (c), or (a) and (b), or (a) and (c), or (b) and (c), or (a) and (b) and (c): (a) the ratio of the inflated balloon diameter to the standard body cavity diameter at the target site is about 1.0 to about 20; or (b) the inflation includes inflating the balloon to a pressure equal to or greater than the nominal pressure of the balloon catheter, and the stretch ratio of the nominal diameter of the balloon catheter to the standard body cavity diameter at the target site is about 1.0 to about 20; or (c) the inflation includes inflating to a pressure greater than the nominal pressure of the balloon catheter, and the nominal diameter of the balloon catheter is smaller than the inflated balloon diameter; or (d) a combination of (a), (b) and (c).
[0071] The major diameter of the balloon can be the diameter of the main portion of the balloon when inflated. In some embodiments, the inflation pressure used to determine the major diameter can be any pressure that eliminates any folded or wrinkled areas of the balloon and achieves toughness of the balloon. The inflation pressure used to determine the major diameter can be a pressure that causes the inflated balloon to have a shape and size corresponding to the desired shape and size of the balloon during the intended treatment of the body cavity. The inflation pressure used to determine the major diameter can be the nominal pressure of the balloon, so that the nominal diameter of the balloon catheter is equal to the major diameter of the balloon.
[0072] In one embodiment, the drug-coated balloon includes two main parts at both ends with the same diameter, a neck part with a smaller diameter between the two main parts, and two cones at the proximal and distal balloon bodies. The drug-coated balloon may include three main parts with the same diameter, two neck parts with a smaller diameter, wherein the three main parts and the two neck parts are arranged alternately, and the neck parts are adjacent to the main parts with a larger diameter, and the two cones are at the proximal and distal balloon bodies. The drug-coated balloon may include four main parts with a larger diameter, three neck parts with a smaller diameter, wherein the four main parts with a larger diameter and the three neck parts are arranged alternately, and the neck parts are adjacent to the main parts with a larger diameter, and the two cones are at the proximal and distal balloon bodies. The drug-coated balloon may include five main parts with a larger diameter, four neck parts with a smaller diameter, wherein the five main parts with a larger diameter and the four neck parts are arranged alternately, and the neck parts are adjacent to the main parts with a larger diameter, and the two cones are at the proximal and distal balloon bodies. The balloon catheter includes at least one neck portion on the balloon, which includes a smaller diameter than the balloon diameter of the main portion. The balloon catheter may include an elongated (e.g., cylindrical) balloon having multiple portions of various diameters. The balloon catheter presents features (a), or (b), or (c), or (a) and (b), or (a) and (c), or (b) and (c), or (a) and (b) and (c): (a) the ratio of the inflated balloon diameter to the standard body cavity diameter at the target site is about 1.0 to about 20; or (b) the inflation includes inflating the balloon to a pressure equal to or greater than the nominal pressure of the balloon catheter, and the stretch ratio of the nominal diameter of the balloon catheter to the standard body cavity diameter at the target site is about 1.0 to about 20; or (c) the inflation includes inflating to a pressure greater than the nominal pressure of the balloon catheter, and the nominal diameter of the balloon catheter is less than the inflated balloon diameter; or (d) a combination of (a), (b), and (c). The multi-part balloon with a smaller neck increases the friction between the balloon and the body cavity; thus, it prevents the balloon from sliding in the body cavity.
[0073] Drug coated balloon catheter can be a medical device for treating benign prostatic hyperplasia (BPH). Balloon catheter can expand the prostatic urethra, and can include a catheter shaft for inserting the urethra and a compliance, semi-compliant or non-compliant balloon for inflation in the prostatic urethra. The balloon can be coated with a therapeutic agent, which is delivered to prostatic tissue and the prostatic urethra when the balloon is inflated. Any suitable method can be used to position the balloon in the prostate, such as by an independent positioning balloon in the bladder, a positioning balloon in the bulbous urethra, or a catheter shaft can be compatible with a speculum-(e.g., a cystoscope-), allowing placement by direct observation, or a catheter can be side by side with a speculum. For example, several possible catheter designs allow direct observation of the balloon during positioning and inflation. A design is compatible with a cystoscope, in which the catheter is loaded from behind by a working channel. Once by a cystoscope, a TouhyBorst adapter and a one-way cock can be attached to the catheter shaft to allow balloon inflation. Another design may include a multi-lumen catheter with one lumen in the center of the shaft to allow the optics of a rigid cystoscope to be inserted and positioned near the proximal edge of the balloon.
[0074] In some embodiments, when treating the prostate, the size of the balloon catheter should be designed so that one or more main parts of the catheter are between the bladder neck sphincter (at the bladder outlet) and the external sphincter. In other embodiments, one or more main parts of the catheter are above the external sphincter, passing through the prostate, and one or more body parts pass through the bladder neck sphincter and are located in the bladder. In these embodiments, preferably, the neck area of the balloon catheter is aligned with the bladder neck. As discussed herein, a scope with visualization conditions can be used to appropriately determine the size of the balloon catheter and place the balloon catheter. In embodiments where the balloon catheter includes a soft tip, a Coude tip, etc., the tip can be inserted into the internal urethral sphincter (e.g., the bladder neck sphincter) to help place the balloon catheter in the desired position.
[0075] Balloon catheters can relieve lower urinary tract symptoms (LUTS) caused by BPH by directly dilating prostate tissue. Prostate dilation with a balloon having a ratio of 1.0 to 20 of the inflated balloon diameter to the standard body cavity diameter at the target site or a balloon having a stretch ratio of 1.0 to 20 of the nominal balloon diameter to the standard body cavity diameter at the target site can produce a commissure incision in the natural plane, separating the cross-section in the transition zone of the prostate. At the same time, drugs can be released from the coating into the prostate tissue, which can, for example, prevent the prostate from enlarging and the newly formed opening from narrowing again.
[0076] In various embodiments, during inflation of the balloon in a body lumen (e.g., during performance of the methods of the invention), the nominal balloon diameter of the catheter (e.g., the diameter typically achieved at nominal pressure) can be such that the ratio of the nominal balloon diameter to the standard diameter of the body lumen treatment location is any suitable ratio, such as about 1.01 to about 20, or about 1.01 to about 15, or about 1.2 to about 10, or about 1.31 to about 8, or less than, equal to, or greater than about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.8, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, or about 20 or more. In some embodiments, the inflated diameter of the balloon at the target site during inflation to the nominal pressure is equal to the nominal diameter; however, during actual use, some stenosis may prevent the nominal diameter from being achieved, or may restrict the inflation of the balloon, forming a "dog bone" shape. For different diameters of the balloons used for various diseases, the nominal balloon diameter under a predetermined pressure (e.g., 2atm, 3atm, 6atm, or 9atm) can be different. For example, for 6mm, 8mm, 10mm, 12mm, and 14mm balloon catheters, the nominal diameter of the urethral stricture balloon when inflated at 6atm can be 6mm, 8mm, 10mm, 12mm, and 14mm. Under the nominal pressure when inflated at 2atm, 3atm, 4atm, 6atm, or 9atm, the nominal diameter of the BPH stenosis balloon can be 25mm, 30mm, 35mm, 40mm, and 45mm, and the balloon length is 20mm, 25mm, 30mm, 35mm, 40mm, 45mm, 50mm, 55mm, and 60mm balloon catheters. Table 1 shows examples of the nominal balloon sizes, nominal pressures, and ratios of the minimum balloon diameter to the standard lumen diameter for treating the stenosis of various diseases. The nominal pressure is the pressure required to inflate a balloon to its labeled nominal diameter in an unconstrained pressure ramp test. The nominal diameter is the expected diameter that the product is labeled to have. All physicians purchase balloons and select balloons based on the nominal diameter. The rated burst pressure is the maximum pressure that a balloon can be inflated to with a high degree of certainty that it will not burst, a labeling requirement for balloon catheters, and is calculated from a statistical analysis of the pressures observed when balloons burst in an unconstrained pressure ramp test.
[0077] Table 1. Examples of nominal balloon sizes, nominal pressures, and ratios of minimum balloon diameter to standard lumen diameter for treating stenoses in various diseases.
[0078]
[0079]
[0080] In various embodiments, the balloon catheter can be sufficient so that at a predetermined pressure (e.g., a nominal pressure), the balloon can have any suitable ratio of the inflated balloon catheter diameter to the standard diameter of the body lumen at the treatment location; for example, at a pressure of about 1 atm (304 kPa) to about 30 atm (3040 kPa) (e.g., about 1 atm or less, or less than, equal to, or greater than about 4 atm, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 24, 26, 28, or about 30 atm or greater).
[0081] Unless otherwise specified, the stretch ratio is defined herein as the ratio of the nominal diameter of the balloon to the standard diameter of the area treated by the balloon catheter in the body cavity. The nominal diameter of the balloon is the diameter of the balloon when it reaches the nominal pressure in an unrestricted environment. The standard lumen diameter is the average diameter of the healthy lumen near the stricture (stricture, stenosis) or lesion (i.e., the proximal and distal ends of the lumen stricture or lesion). For the urinary tract, for example, in the urethra and prostatic urethra, the standard lumen diameter will be the average diameter of the urinary urethra at the proximal and distal ends of the obstacle of the healthy lumen. For all lumens, if the average diameter of the proximal and distal ends of healthy tissue cannot be obtained, the standard lumen diameter will be the diameter when the lumen is healthy and there is biological material flowing through. The inflated balloon diameter can be the actual diameter after the balloon is inflated, which in some embodiments can be equal to, less than or greater than the nominal diameter of the balloon. In various embodiments, the stretch ratio of the balloon catheter of the present invention makes it more effectively treat non-vascular cavities than other catheters. In performing the methods of the present invention, the stretch ratio may be selected to be any suitable ratio that achieves a desired ratio of actual inflated balloon diameter to standard lumen diameter over the pressure range used during the method. In various embodiments, the stretch ratio of the balloon can be about 1.01 to about 20, 1.31 to 20, or about 1.01 to about 15, or about 1.1 to about 10, 1.2 to 10, 1.3 to 10, 1.31 to 10, 1.4 to 10, 1.5 to 10, 1.6 to 10, 1.7 to 10, 1.8 to 10, 2 to 10, 2.2 to 10, 2.5 to 10, or less than, equal to, or greater than about 1.1, 1.2, 1.3, 1.31, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, or about 20 or more; such stretch ratios can be produced at the pressures used during the inflation period. The ratio of the desired inflated balloon diameter to the standard lumen diameter can be the same, similar or different than the stretch ratio, such as about 1.01 to about 20, 1.31 to 20, or about 1.01 to about 15, or about 1.1 to about 10, 1.2 to 10, 1.3 to 10, 1.31 to 10, 1.4 to 10, 1.5 to 10, 1.6 to 10, 1.7 to 10, 1.8 to 10, 2 to 10, 2.2 to 10, 2.5 to 10, or less than, equal to or greater than about 1.1, 1.2, 1.3, 1.31, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18 or about 20 or more.
[0082] In various embodiments, the method includes measuring the body cavity stenosis to be treated. The distal and proximal healthy tissue diameters and the length of the stenosis can be evaluated to select the drug-coated balloon to be used. The doctor will select the balloon based on the standard diameter of the body cavity stenosis and the stretch ratio of the balloon nominal diameter to the standard diameter of the body cavity stenosis of 1.0-20 or 1.1-15 or 1.2-10 or 1.31-8. The doctor can then inflate the balloon to at least the nominal pressure, and in some cases, the balloon can be inflated to exceed the nominal pressure or until the rated burst pressure of the balloon. The pressure range used during the inflation period can be referred to as the working pressure range of the drug-coated balloon. In some cases, the method may include exceeding the rated burst pressure of the balloon. Because the nominal diameter of the balloon is determined without any tightening, the inflated diameter of the balloon in the stenosis during treatment will be approximately equal to or less than or greater than the nominal diameter. At or above the burst pressure, the inflated diameter of the balloon can be less than the nominal diameter, equal to the nominal diameter, or can exceed the nominal diameter. For example, a body lumen stenosis may be measured to have a standard diameter of 10 mm. The physician may select a 14 mm nominal diameter drug coated balloon with a nominal pressure of 6 atm and a rated burst pressure of 10 atm. The stretch ratio is 1.4. The physician will inflate the balloon to at least 6 atm, and in some cases to 10 atm, and in some cases to more than 10 atm during treatment to achieve the desired inflated balloon diameter.
[0083] In various embodiments, the balloon catheter has one or more neck portions that separate one or more main portions, and the configuration of at least one neck portion or one or more neck portions of the balloon catheter of the present invention allows the balloon catheter to stay in place more consistently and effectively during treatment to dilate the stenosis and deliver the drug, compared to other balloon catheters lacking such neck portions or neck portion configurations.
[0084] In various embodiments, the balloon catheter may be equipped with a sheath. The catheter assembly and a scope (e.g., a cystoscope) are inserted into the prostatic urethra through the urethra and positioned side by side near the external sphincter. The external sphincter may be positioned using real-time video transmission from the scope. The balloon may be positioned near the external sphincter and within the prostatic urethra. Balloon expansion, drug release, and balloon contraction may be seen through the scope.
[0085] In various embodiments, the balloon catheter can be assembled with the cystoscope by loading the shaft from behind through the working channel and attaching the Tuohy Borst and one-way stopcock at the proximal end. The cystoscope-catheter assembly is inserted into the prostatic urethra through the urethra. The external sphincter can be located using real-time video transmission from the cystoscope. The balloon can be positioned near the external sphincter and within the prostatic urethra.
[0086] In some embodiments, when treating the prostate, it is preferred to place the proximal balloon waist into the external sphincter so that the external sphincter is not distended. It is also preferred to design the size of the balloon so that when the balloon waist is in the external sphincter, the balloon neck (e.g., the most distal balloon neck) is aligned with the bladder neck. This arrangement provides a clamping force so that the balloon does not slip during expansion. If the balloon neck cannot be aligned with the bladder neck, it is preferred to slowly inflate the balloon so that the prostate can yield as the balloon is inflated.
[0087] Once correctly positioned, the balloon is expanded, such as using an inflatable device with a pressure gauge. The balloon can be slowly inflated, allowing the prostate tissue to yield and reducing the tendency of the balloon to slide to the bladder at the proximal end and slide back at the distal end. Although the balloon of a single neck or multi-neck shape can prevent the balloon from moving by aligning the most distal neck with the bladder neck, in some abnormal cases, such as having an enlarged middle lobe (e.g., about 10%-15% of cases), during inflation, the neck of the balloon may not remain aligned with the bladder neck, and other techniques can be used to further prevent the balloon from shifting. In some examples, inflation at a rate of about 0.5 to 1 atm / min can prevent the balloon from moving. As the tissue yields, the balloon pressure drops accordingly, allowing additional fluid to be instilled in the balloon without increasing pressure. When the pressure stabilizes for about 1-2 minutes, the pressure can be increased in 0.5 or 1 atm increments and maintained in a similar manner. The pressure can continue to increase, and after this method of increasing pressure, the pressure is allowed to stabilize after the pressure drops, and the pressure is continued to increase until the commissure incision or separation is achieved. Alternatively, extremely slowly inflating can prevent the balloon from moving to achieve commissure incision or prostate separation. Once the commissure incision or prostatic urethra and prostate separation is observed and confirmed by video transmission from the endoscope, mechanical decompression can be achieved. The balloon can remain inflated for about 1 minute to 7 days, 1 minute to 1 day or 1-10 minutes to allow the drug in the coating to be transferred to the tissue. Once treatment is completed, the balloon can be deflated, and the catheter and endoscope can be removed from the patient's body cavity.
[0088] In some embodiments, when treating the prostate, it may be desirable to pre-dilate the stenosis. In this embodiment, the pre-dilation catheter can be shorter and / or smaller in diameter than the drug-coated balloon treatment catheter. In this case, the pre-dilation catheter is positioned so that the proximal waist of the balloon is in the external sphincter and the neck region is aligned with the bladder neck. The balloon is slowly inflated as described herein to help the prostate yield while preventing the balloon from sliding. After inflation, the pre-dilation balloon is deflated and removed, and the drug-coated treatment balloon is inserted. The proximal waist of the treatment balloon is aligned with the external sphincter. If BPH is properly pre-dilated, it is not necessary to align the balloon neck with the bladder neck because the balloon will not be easy to slide as in a body cavity that is not pre-dilated.
[0089] The drug-coated balloon catheter can include an elongated balloon body with multiple main parts, two cones at the distal and proximal ends of the balloon body, an inflation lumen and a wired lumen, wherein the balloon body includes at least two main parts with a larger diameter and at least one neck portion with a smaller diameter, wherein the main part with a larger diameter and the neck portion are alternately and adjacently aligned. The elongated balloon can have a substantially cylindrical shape, with the exception of any neck portion on the balloon, any tapered portion (e.g., cone) between the neck portion and the main part with a main diameter, and any tapered or shaped portion at the longitudinal end of the balloon. Taken perpendicular to the longitudinal direction of the balloon, the elongated balloon can have any suitable profile, such as a circular (e.g., cylindrical balloon), an elliptical or polygonal (e.g., a pentagon, a hexagon, a heptagon, an octagon, etc.) or a combination thereof. The diameter of the non-cylindrical balloon can be the maximum dimension perpendicular to the longitudinal direction.
[0090] The balloon can be formed of any suitable material, such as a non-compliant or semi-compliant biocompatible material. In some embodiments, the balloon can be manufactured by blow molding to achieve the desired geometry. In some embodiments, the balloon can include a material that does not interact with the drug coating or a material such as: nylon (e.g., any suitable nylon, such as nylon 6,6 or nylon 12), polyether block amide (PEBA), polyethylene terephthalate (PET), polyvinyl chloride (PVC), polyester, polyurethane, derivatives thereof, or combinations thereof.
[0091] The balloon can have any suitable size. The balloon can be designed to fit in the prostatic urethra, with the distal portion of the balloon positioned in the bladder. The main diameter and nominal balloon diameter are in the range of about 5 mm to about 50 mm, 25 mm up to 45 mm, at least 10 mm, at least 15 mm, at least 20 mm, at least 30 mm, such as about 5 mm or less, or less than, equal to or greater than about 6 mm, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 32, 34, 36, 38, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or about 50 mm or more; the main portion diameter can be independently in any of these ranges or specified sizes. The balloon can have a length of about 20 mm to about 160 mm, 40 mm to about 80 mm, or about 20 mm or less, or less than, equal to, or greater than about 22 mm, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78 mm, or about 80 mm or longer. The balloon length and diameter can be selected based on the patient's unique prostate anatomy.
[0092] The balloon may include at least one neck portion. The neck portion is the portion of the balloon having a smaller diameter than the main nominal diameter of the balloon. The neck portion diameter may be about 5 mm to about 35 mm, 10 mm to about 35 mm, or about 5 mm or less, or less than, equal to, or greater than about 6 mm, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34 mm, or about 35 mm or more. At least one neck portion may have a diameter that is independently about 5% to about 99% of the main diameter, such as about 20% to about 99%, or about 5% or less, or less than, equal to or greater than about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or about 99% or more. In some embodiments, the neck portion diameter is 35% to 75% of the diameter of the main portion of the balloon. In some embodiments where the main portion of the balloon has a nominal diameter of 35 to 40 mm, the neck portion will have a diameter of 15 to 20 mm. In some embodiments, if the neck diameter is too similar to the main portion diameter, its ability to prevent the balloon from sliding may be weakened.
[0093] The neck portion can be a rigid or semi-rigid neck portion such that the diameter of the neck portion (e.g., the portion of the neck portion having the diameter of the neck portion) remains substantially unchanged during inflation of the balloon. The neck portion can include a substantially inelastic (e.g., non-compliant or minimally non-compliant) portion of the balloon, a reinforced portion of the balloon, or a combination thereof. The neck portion can include a non-elastic material surrounding the circumference of the neck portion, such as a suture or monofilament or multifilament of a material such as nylon, polyamide, aramid, ultra-high molecular weight polyethylene (UHMWPE), polyester, aromatic polyester, polyethylene terephthalate (PET), or a combination thereof.
[0094] In some embodiments, the neck portion of the balloon can be semi-compliant and expand at a rate different from that of the main balloon body. The compliance of the neck portion can be greater than, less than, or equal to the compliance of the balloon body. Table 2 shows exemplary measurements of a balloon having a neck portion that expands more than the balloon body. Under a test pressure range of 1-5atm, the expansion rate of the neck diameter can be higher than the expansion rate of the main body diameter. Under a test pressure range of 1-5atm, the expansion rate of the neck diameter can be in the range of 1.1 to 10 times the main body diameter (main diameter), such as in the range of 2 to 6 times the main diameter. The expansion rate of the neck diameter is 12.38% / atm. The expansion rate of the main body diameter is 2.4% / atm. The expansion rate difference is 9.98% / atm. Table 3 shows exemplary measurements of a balloon having a neck portion that expands less than the balloon body when inflated from 2 atmospheres to 4 atmospheres. Under a test pressure range of 2-4atm, the expansion rate of the neck diameter can be less than the expansion rate of the main body diameter.
[0095] Table 2. Exemplary measurements for balloons having a neck portion that is more inflated than the balloon body.
[0096]
[0097] Table 3. Exemplary measurements for balloons having a neck portion that is less inflated than the balloon body.
[0098]
[0099] The neck portion can create a wedge of tissue between the larger diameter portions of the balloon, which can hold the balloon in place. The larger portion of the balloon cannot overcome the tissue barrier created by the neck portion, so the balloon with the neck portion prevents, reduces or minimizes balloon movement during inflation. The balloon neck portions can be placed at various locations along the balloon, the number can be greater than or less than two (e.g., 1, 2, 3, 4 or more), and the diameter can be different. The neck portion placement can be designed to promote the greatest increase in traction while still maintaining therapeutic efficacy.
[0100] The neck portion may include a central narrow portion having the smallest diameter of the neck portion and an adjacent portion that may have a different diameter and that occurs between the central narrow portion and the portion of the balloon having the main diameter. Unless otherwise specified, when the neck portion diameter is referred to herein, it refers to the diameter of the central narrow portion having the smallest diameter, not to the tapered portion. The tapered portion of the balloon may be rigid, flexible (e.g., elastic), or a combination thereof. The measured neck portion (including the central narrow portion and the tapered portion adjacent thereto (e.g., a cone)) may have any suitable length, such as from about 1% to about 50% of the balloon length, or about 1% or less, or less than, equal to, or greater than about 2%, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48%, or about 50% or greater, or from about 0.5 mm to about 40 mm, or about 0.5 mm or less, or less than, equal to, or greater than about 1 mm, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, or about 40 mm.
[0101] In some embodiments, the balloon may include one neck portion and no other neck portion, such that the balloon includes two main portions separated by a neck portion. The one neck portion may have any suitable position on the balloon, such as approximately centered relative to the length of the balloon, or offset relative to the length of the balloon. The one neck portion may be offset relative to the length of the balloon and may be at the distal end of the balloon. Figure 1A An embodiment of a balloon including a neck portion that is off-center relative to the length of the balloon is shown in FIG.
[0102] In some embodiments, the balloon can include two neck portions and no other neck portion, so that the balloon includes three lobes separated by two neck portions. The two neck portions can have approximately the same diameter, or one of the neck portions can have a smaller diameter than the other neck portions. The two neck portions can be positioned symmetrically or asymmetrically relative to the balloon length center. The three main portions can have approximately equal lengths or can have different lengths. Figure 1B An embodiment of a balloon catheter having two neck portions and three main portions is shown, wherein the neck portions are symmetrically located about the center of the length of the balloon, and wherein the three main portions of the balloon have about the same length. During use, the distal neck portion (e.g., the neck portion at the distal end of the balloon catheter, which is first inserted into the body) can anchor and position the balloon at the bladder neck, while the proximal neck portion can be positioned in the prostatic urethra. In some embodiments, the distal main portion of the balloon catheter may be free of a therapeutic agent.
[0103] In some embodiments, the balloon may include three necks and no other neck portions, so that the balloon includes four portions separated by three necks. The three neck portions can be positioned along the balloon length in any suitable manner. The four main portions formed by the three neck portions may have equal or different lengths. The three neck portions may have equal diameters or different diameters. In some embodiments, two of the neck portions have equal diameters that are smaller than the diameter of the other neck portion. Figure 1C An embodiment of a balloon catheter having three neck sections and four main sections is shown, each main section having approximately equal length, wherein two neck sections have equal diameters that are smaller than the diameter of the other neck sections.
[0104] The balloon catheter can be a fixed-line balloon catheter. The outer shaft can be coupled to the proximal balloon neck, the distal end of the tapered line is coupled to the distal neck of the balloon, and the proximal end of the line and the outer shaft is coupled to the proximal connection portion of the balloon catheter (e.g., a valve, a connector, or an adapter). The balloon catheter can be a movable line catheter. The outer shaft is coupled to the proximal balloon neck, the distal end of the tapered line is coupled to the distal neck of the balloon, and the proximal end of the line is free to move relative to the connection portion of the proximal end of the balloon catheter. The balloon catheter can be a cross-line balloon catheter. The balloon catheter can be a rapid exchange balloon catheter. The balloon catheter can include a catheter shaft at the longitudinal end of the balloon (e.g., at the proximal end of the balloon, inserted into the body after the distal end is inserted), and the catheter shaft includes an internal cavity for delivering air, liquid, or a combination thereof to the inside of the balloon. The catheter shaft may include a thermoplastic material that is thermally attached (e.g., attached by heating or melting) to the balloon, such as a high-hardness material, such as a material similar or identical to the balloon material, such as a polyamide, nylon (e.g., nylon 6,6 or nylon 12), polyether block amide (PEBA) or a combination thereof. In some embodiments, the catheter shaft may be a scope (e.g., a cystoscope). High-hardness materials can help prevent, reduce or minimize crushing, and can allow for pushability and elasticity. The size of the catheter shaft outer diameter can be designed to allow for passing through a working channel of a standard cystoscope. A fluid connection may be included between the lumen and the inside of the balloon, such as a hole in the catheter shaft below the balloon attachment point, to allow the balloon to be inflated by perfusing the lumen with a medium.
[0105] In various embodiments, the catheter shaft may have an independent lumen that creates a passage for urine to flow from the bladder through the catheter shaft and out through the outer portion of the device. This embodiment may allow the drug-coated balloon catheter to remain in place for a period of time, such as 0.1 to about 7 days, while preventing bleeding and the tissue healing into a new configuration. The drug-coated balloon can be used not only for dilation and delivery of drugs, but also as a Foley catheter.
[0106] The end of the catheter shaft that remains outside the body (e.g., the proximal end) can include a connection (e.g., a valve, connector, or adapter) that provides a connection to the inner cavity of the catheter shaft. During inflation, the connection (e.g., when closed, or always) can prevent fluid or air from flowing back from the balloon. The connection can be any suitable valve, such as a Tuohy Borst adapter. The Tuohy Borst adapter is a compression seal that can be placed over the catheter shaft and tightened to provide a liquid / air tight connection to the inner cavity of the catheter shaft. A one-way stopcock can control the flow of fluid into the balloon and can be connected to the inflation device via a standard Luer.
[0107] The balloon catheter may include a catheter tip at the longitudinal end of the balloon (at the distal end that is first inserted into the body). The catheter tip may facilitate passage of the balloon through the urethra. The tip may be an atraumatic tip that helps prevent damage to the urethra during insertion into the urethra. The tip may be an atraumatic elbow. The atraumatic elbow is designed to facilitate passage of the catheter through the bends of the male urethra while preventing damage to the urethral wall during tracking. It may be a low durometer biocompatible material that is overmolded onto the catheter shaft or bonded to the shaft. For example, the elbow may be made of Or liquid silicone rubber.
[0108] Figure 2 An embodiment of a balloon catheter including a catheter shaft, a catheter tip, and a TuohyBorst adapter / stopcock assembly is shown. All materials can be biocompatible. The balloon is coated with a paclitaxel solution, but can be coated with any number of other drugs or biologics that can promote improvement of BPH symptoms. Only the proximal two major portions of the balloon are coated with drugs because the distal portion is in the bladder during use.
[0109] The balloon catheter may include an inflation device including a pressure gauge or pressure sensor, the inflation device fluidly connected to a catheter shaft of the balloon catheter.
[0110] Figure 1A , Figure 1B , Figure 1C and Figure 2 The balloon shown in FIG. 1 is blow molded in a mold including a main portion and a neck portion. A tube of balloon material is inserted into a mold having a desired shape. The balloon material tube may be pre-stretched. The balloon mold has a corresponding Figure 1A , Figure 1B , Figure 1C or Figure 2 The shape of the balloon shown in . This will include a proximal cone, at least one main body portion, at least one neck portion, at least one further main body portion and a distal cone. The balloon material can be any of the following: polyester, polyamide, nylon 12, nylon 11, polyamide 12, block copolymers of polyether and polyamide, Polyurethanes and block copolymers of polyethers and polyesters. The tube and mold are heated to a temperature above the glass transition temperature of the tube of balloon material and pressurized with a gas, air, fluid, etc., resulting in the tube material taking the shape of the mold. The formed balloon is then cooled, trimmed, and then ready for attachment to a catheter.
[0111] After the balloon is attached to the catheter, the balloon is inflated under low pressure, and the neck portion reinforcement is attached to the neck region. The neck portion reinforcement is used to control the expansion of the neck portion during balloon expansion. The neck portion can be a substantially inelastic portion of the balloon, a reinforcement portion of the balloon, or a combination thereof. The neck portion can include an inelastic material surrounding the neck portion circumference, such as a suture or monofilament or multifilament of the following material: such as steel, stainless steel, nitinol, tungsten, aluminum, copper, silver, gold, platinum, iridium, a high-temperature alloy containing the following elements, the elements including nickel (Ni), chromium (Cr), aluminum (Al), titanium (Ti), molybdenum (Mo), tungsten (W), niobium (Nb), tantalum (Ta) and cobalt (Co); nylon, polyamide, aramid, ultra-high molecular weight polyethylene (UHMWPE), polyester, aromatic polyester, polyethylene terephthalate (PET) or a combination thereof. In some embodiments, the polymeric material is in the form of a strand or filament and is wrapped multiple times around the neck portion and then secured in place using two or more spots of glue or adhesive.
[0112] The main portions of the balloon may be formed to have the same or similar diameters. In some embodiments, the diameters of the various main portions may differ from each other by as much as 30% when measured with the nominal balloon diameter. Figure 1A , Figure 1B , Figure 1C and Figure 2 In the figure, the main parts of the balloon are shown with equal diameters, i.e., the diameter of each main part is constant. In practice, at higher pressures, the diameter of the main parts will become slightly bent outwards, because the diameter in the middle of the main part may have a slightly larger diameter than the edge of the main part near the balloon cone and / or near the neck part.
[0113] For a balloon having a neck portion and a main portion (such as Figure 1A , Figure 1B , Figure 1C and Figure 2 ) and where the balloon does not have any neck portion (as shown in Figure 3In embodiments of the invention (shown in Figure 1), after assembling the balloon catheter, the balloon may be coated with at least one water-soluble additive and drug as discussed herein. In some embodiments where the balloon has multiple main sections, the distal main section may not be coated. The balloon may be coated according to the methods discussed herein. If a sheath is used, it may be placed over the balloon after coating. The catheter may then be packaged, sterilized, and labeled as known in the art.
[0114] Embodiments of the present invention relate to balloon catheters with fast-release drug coatings and methods for preparing such coated devices. The therapeutic agent according to embodiments of the present invention need not be delayed or released over a long period of time, but instead, for example, the therapeutic agent and additive are released in a very short period of time to provide a therapeutic effect when contacting the tissue. One goal of embodiments of the present invention is to promote rapid and efficient absorption of drugs by target tissues during the short deployment of the device at the target site.
[0115] The drug coating can cover any suitable proportion of the outer surface of the balloon (e.g., the proportion of the balloon surface that results in the major diameter during inflation to nominal pressure, excluding the neck and terminal taper), such as from about 1% to about 100%, or from about 50% to about 100%, or from about 80% to about 100%, or about 10% or less, or less than, equal to, or greater than 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or about 100% or more.
[0116] The drug coating may contain a water-soluble additive, for example, selected from N-acetylglucosamine, N-octyl-D-glucamide, N-nonanoyl-N-methylglucosamine, N-octanoyl-N-methylglutamine, C6-ceramide, dihydro-C6-ceramide, cerebrosides, sphingomyelins, galactocerebrosides, lactocerebrosides, N-acetyl-D-sphingosine, N-hexanoyl-D-sphingosine, N-octanoyl-D-sphingosine, N-lauroyl-D-sphingosine, N-palmitoyl-D-sphingosine, N-oleoyl-D-sphingosine, PEG caprylic / capric diglyceride, PEG 8 caprylic / capric glyceride, PEG caprylate, PEG 8 caprylate, PEG caprate, PEG caproate, glyceryl monocaprylate, glyceryl monocaprate, glyceryl monohexanoate, Glyceryl monolaurate, glyceryl monocaprate, glyceryl monocaprylate, glyceryl monomyristate, glyceryl monopalmitoleate, glyceryl monooleate, sarcosine, creatinine, agmatine, citrulline, guanidine, sucralose, aspartame, hypoxanthine, theobromine, theophylline, adenine, uracil, uridine, guanine, thymine, thymidine, xanthine, xanthine nucleoside, xanthine nucleoside monophosphate, caffeine, allantoin, (2-hydroxyethyl) urea, N,N'-bis(hydroxymethyl) urea, pentaerythritol ethoxylate, pentaerythritol propoxylate, pentaerythritol propoxylate / ethoxylate, glycerol ethoxylate, glycerol propoxylate, ethoxylated trimethylolpropane, pentaerythritol, dipentaerythritol, crown ethers, 18-crown-6, 15-crown-5, 12-crown-4, and combinations thereof. The water-soluble additive may include a first water-soluble additive that is a surfactant, such as PEG sorbitan monolaurate, PEG sorbitan monooleate, or a combination thereof. The water-soluble additive may include a second water-soluble additive that is a chemical compound having one or more moieties that are hydroxyl, amine, carbonyl, carboxyl, or ester, such as sorbitol, sorbitan, xylitol, gluconolactone, or a combination thereof. The drug coating may include a first water-soluble additive and a second water-soluble additive. In some embodiments, the distal end of the balloon may be free of a therapeutic agent.
[0117] In various embodiments, the present invention provides a method for treating a body cavity. The body cavity can be a vascular body cavity or a non-vascular body cavity. The method may include inserting a balloon catheter (e.g., any embodiment of the balloon catheter described herein) into a target site in the body cavity. The method may include inflating the balloon until (e.g., at least until) the coating contacts the wall of the body cavity stenosis at the target site and the balloon reaches the inflated balloon diameter for an inflation period. Presenting features (a), or (b), or (c), or (a) and (b), or (a) and (c), or (b) and (c), or (a) and (b) and (c): (a) the ratio of the inflated balloon diameter to the standard body cavity diameter at the target site is about 1.0 to about 20; or (b) the inflation includes inflating the balloon to a pressure equal to or greater than the nominal pressure of the balloon catheter, and the stretch ratio of the nominal diameter of the balloon catheter to the standard body cavity diameter at the target site is about 1.0 to about 20; or (c) the inflation includes inflating to a pressure greater than the nominal pressure of the balloon catheter, and the nominal diameter of the balloon catheter is less than the inflated balloon diameter; or (d) a combination of (a), (b) and (c). The method may include deflation of the balloon after the inflation period. The method may include removing the balloon catheter from the stenosis in the body cavity.
[0118] Various embodiments provide the method for treating benign prostatic hyperplasia (BPH) stenosis, urethral stenosis, ureteral stenosis, prostate cancer, esophageal stenosis, bile duct stenosis, gastric stenosis, small intestinal stenosis, duodenal stenosis, jejunal stenosis, ileal stenosis, colonic stenosis, rectal stenosis and large intestinal stenosis, asthma or chronic obstructive pulmonary disease (COPD). The method is the method for treating body cavity stenosis, such as urethral stenosis, benign prostatic hyperplasia (BPH) stenosis, ureteral stenosis, esophageal stenosis, antrum stenosis, gastric stenosis, small intestinal stenosis, duodenal stenosis, jejunal stenosis, ileal stenosis, colonic stenosis, rectal stenosis and large intestinal stenosis and bile duct stenosis. Body cavity stenosis can be benign prostatic hyperplasia (BPH) stenosis, urethral stenosis or esophageal stenosis. The method can be the method for treating benign prostatic hyperplasia, prostate cancer or its combination, wherein the body cavity is prostate.
[0119] The method may include flushing the body cavity with water, saline solution, or an aqueous solution comprising at least one water-soluble additive before, during, or after inserting the balloon into the target site.
[0120] The body cavity may be a prostate, wherein inserting the balloon catheter includes positioning the balloon catheter in the prostate using a scope (e.g., flexible or rigid, such as a cystoscope). The balloon catheter may include a scope, and the method may include positioning the target site using video transmission from the scope. The method may include positioning the balloon catheter at the target site using video transmission from the scope.
[0121] The body cavity may be a prostate, the balloon may have a plurality of main sections separated by one or more necks, and inserting the balloon catheter may include positioning one of the balloon catheter main sections in the prostate and positioning a second main section of the balloon catheter in the bladder.
[0122] Inserting may include positioning at least one neck portion of the balloon in the bladder neck. At least one neck portion of the balloon catheter may be a distal neck portion, and inserting may include positioning the distal neck portion in the bladder neck. The balloon catheter may include a proximal neck portion, and inserting may include positioning the proximal neck portion in the prostatic urethra.
[0123] The inflation period can be any suitable inflation period, such as about 0.1 minute to about 10 minutes, about 0.5 minute to about 2 minutes, or about 0.1 minute or less, or about 0.2 minutes, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.8, 2, 2.2, 2.4, 2.6, 2.8, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, or about 10 minutes or more.
[0124] Inflation can include increasing the pressure within the balloon at any suitable rate (e.g., may not include periods where the pressure drops due to tissue yielding, and may maintain the pressure during these times), such as from about 0.1 atm / minute to about 10 atm / minute, or from about 0.5 to about 1.5 atm / minute, or about 0.1 atm / minute or less, or less than, equal to, or greater than about 0.2 atm / minute, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.8, 2, 2.2, 2.4, 2.6, 2.8, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, or about 10 atm / minute or more.
[0125] Inflation can include observing the pressure in the balloon, such as by a pressure gauge. During the period when the stenosis yields (which can cause a decrease in pressure), inflation can include allowing the pressure in the balloon to stabilize during the period when the tissue yields, and maintaining the stable pressure in the balloon for a stable period, and then continuing to increase the pressure in the balloon until the desired inflated diameter is reached. The stable period can be any suitable period, such as about 0.1 minute to about 10 minutes, about 0.5 minute to about 2 minutes, or about 0.1 minute or shorter, or about 0.2 minutes, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.8, 2, 2.2, 2.4, 2.6, 2.8, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9 or about 10 minutes or longer.
[0126] like Figure 3 As shown in , in one embodiment, the medical device is a balloon catheter. The balloon catheter can be any suitable catheter for the desired use, including conventional balloon catheters known to those of ordinary skill in the art. For example, the balloon catheter 10 can include an expandable inflatable balloon 12 at the distal end of the catheter 10, a handle assembly 16 at the proximal end of the catheter 10, and an elongated flexible member 14 extending between the proximal and distal ends. The handle assembly 16 can be connected to and / or receive one or more suitable medical devices, such as an inflation medium source (e.g., air, saline, or contrast agent). The flexible member 14 can be a tube made of a suitable biocompatible material and having one or more lumens therein. At least one of the lumens is configured to receive an inflation medium and pass such medium to the balloon 12 for its expansion. The balloon catheter can be a rapid exchange or cross-line catheter and is made of any suitable biocompatible material. The material of the balloon 12 can include one or more of the following: polyester, polyamide, nylon 12, nylon 11, polyamide 12, block copolymers of polyether and polyamide, Polyurethanes and block copolymers of polyethers and polyesters.
[0127] In one embodiment, the present invention provides a balloon catheter for delivering a therapeutic agent to a tissue, such as a vascular tissue or a non-vascular tissue. The device includes a layer applied to the outer surface of the balloon catheter. The layer includes a therapeutic agent and one or more additives. The additive can be any suitable additive. The layer can include one additive, or the layer can include more than one additive, such as a water-soluble first additive and a water-soluble second additive. For example, Figure 4A As shown in the embodiment depicted in FIG, the balloon 12 is coated with a layer 20 comprising a therapeutic agent and an additive. In some embodiments, the layer consists essentially of the therapeutic agent and the additive, for example, the layer only comprises the therapeutic agent and the additive without any other substantial significant components. In some embodiments, the device may optionally include an adhesive layer. For example, as Figure 4B As shown in the embodiment depicted in , the balloon 12 is coated with an adhesive layer 22. A layer 24 comprising a therapeutic agent and an additive is overlaid on the adhesive layer. The adhesive layer is a separate layer beneath the drug coating that improves the adhesion of the drug coating to the outer surface of the medical device and protects the integrity of the coating. For example, if the drug and additive have different adhesion to the medical device, the adhesive layer can prevent differential loss of the components and maintain the drug / additive ratio in the coating during transfer to the target site for therapeutic intervention. In addition, the adhesive layer can function to promote rapid release of the coating components from the surface of the device when contacting the target site of the tissue. In other embodiments, the device may include a top layer. For example, as Figure 4CAs shown in the embodiment depicted in FIG, the balloon 12 is coated with an adhesive layer 22, a layer 26 containing therapeutic agents and additives and covering the adhesive layer, and a top layer 28. The top layer can reduce the loss of the drug layer before it comes into contact with the target tissue, such as during transportation of the balloon 12 to the site of therapeutic intervention or during the initial moments of inflating the balloon 12 before pressing the coating 20 into direct contact with the target tissue.
[0128] Embodiments of the present invention relate to treating body cavity stenosis by delivering an effective amount of therapeutic agents, such as anti-inflammatory drugs and antiproliferative drugs (e.g., rapamycin, paclitaxel, or their analogs). Body cavity stenosis includes vascular stenosis, urethral stenosis, ureteral stenosis, esophageal stenosis, achalasia stenosis, stent stenosis, antral stenosis, gastric stenosis, small intestinal stenosis, duodenal stenosis, jejunal stenosis, ileal stenosis, colonic stenosis, rectal stenosis and large intestinal stenosis and biliary stenosis. Embodiments of the present invention relate to methods for treating at least one of the following: vascular stenosis, benign prostatic hyperplasia (BPH), urethral tissue, prostate cancer, asthma and chronic obstructive pulmonary disease (COPD). According to an embodiment, the method involves delivering therapeutic agents, such as anti-inflammatory drugs and antiproliferative drugs (e.g., rapamycin, paclitaxel, or their analogs) through a coated medical device (such as a balloon catheter). The therapeutic agent can be coated on the medical device alone or with one or more additives.
[0129] In one embodiment, the present invention relates to a method for treating body cavity stenosis, comprising inserting a balloon catheter comprising a coating into a stenosis, wherein the stenosis is one of: urethral stenosis, ureteral stenosis, esophageal stenosis, sinus stenosis, achalasia stenosis, stent stenosis, gastric stenosis, small intestinal stenosis, duodenal stenosis, jejunal stenosis, ileal stenosis, colonic stenosis, rectal stenosis and large intestinal stenosis and biliary stenosis, wherein the coating comprises a drug and an additive; inflating the balloon catheter and releasing the drug to the wall of the stenosis, deflated the balloon; and removing the balloon catheter, wherein the residual drug can be about 1% to 70% of the total drug load on the balloon catheter, wherein the drug in the wall of the body cavity can be about 0.1% to 25% of the total drug load on the balloon catheter. In one aspect of this embodiment, the additive enhances the absorption of the drug into the tissue of the body cavity stenosis.
[0130] In one embodiment, the present invention relates to a method for treating body cavity stenosis, which comprises inserting a balloon catheter comprising a coating into a body cavity, wherein the body cavity is one of: esophagus, airway, antrum, trachea, colon, bile duct, stomach, small intestine, duodenum, jejunum, ileum, rectum, large intestine, urinary tract, prostate, urethra, ureter and other cavities, wherein the coating comprises a drug and an additive; inflating the balloon catheter and releasing the drug to the wall of the body cavity, deflate the balloon; and removing the balloon catheter, wherein the residual drug can be about 1 to 70% of the total drug load on the balloon catheter, wherein the drug in the wall of the body cavity can be about 0.1 to 25% of the total drug load on the balloon catheter. In one aspect of this embodiment, the additive enhances the absorption of the drug into the tissue of the body cavity. In another aspect of this embodiment, the additive comprises a hydrophilic portion and a drug-affinity portion, wherein the drug-affinity portion is at least one of: a hydrophobic portion, a portion having an affinity for a therapeutic agent by hydrogen bonding, and a portion having an affinity for a therapeutic agent by van der Waals interactions.
[0131] In one embodiment, the present invention relates to a balloon catheter for delivering a therapeutic agent to a target site of a body lumen stenosis, the balloon catheter comprising a coating covering the outer surface of the balloon, wherein the coating comprises an initial drug loading amount of a therapeutic agent and one or more water-soluble additives; the therapeutic agent is selected from paclitaxel, docetaxel, taxol, their analogs, rapamycin, sirolimus, everolimus, tacrolimus and their analogs and combinations thereof; the water-soluble additive is selected from N-acetylglucosamine, N-octyl-D- Glucosamide, N-nonanoyl-N-methylglucosamine, N-octanoyl-N-methylglutamine, C6-ceramide, dihydro-C6-ceramide, cerebrosides, sphingomyelin, galactocerebroside, lactocerebroside, N-acetyl-D-sphingosine, N-hexanoyl-D-sphingosine, N-octanoyl-D-sphingosine, N-lauroyl-D-sphingosine, N-palmitoyl-D-sphingosine, N-oleoyl-D-sphingosine, PEG caprylic / capric diglyceride, PE G8 Caprylic / Capric Glycerides, PEG Caprylate, PEG8 Caprylate, PEG Caproate, PEG Hexanoate, Glyceryl Monocaprylate, Glyceryl Monocaprate, Glyceryl Monohexanoate, Glyceryl Monolaurate, Glyceryl Monocaprate, Glyceryl Monocaprylate, Glyceryl Monomyristate, Glyceryl Monopalmitoleate, Glyceryl Monooleate, Sarcosine, Creatinine, Agmatine, Citrulline, Guanidine, Sucralose, Aspartame, Hypoxanthine, Theobromine, Theophylline, Adenine, Uracil, Uridine, Guanine, thymine, thymidine, xanthine, xanthine nucleoside, xanthine nucleoside monophosphate, caffeine, allantoin, (2-hydroxyethyl) urea, N,N'-bis(hydroxymethyl) urea, pentaerythritol ethoxylate, pentaerythritol propoxylate, pentaerythritol propoxylate / ethoxylate, glycerol ethoxylate, glycerol propoxylate, ethoxylated trimethylolpropane, pentaerythritol, dipentaerythritol, crown ethers, 18-crown-6, 15-crown-5, 12-crown-4, and combinations thereof.
[0132] In one embodiment of the balloon catheter, one or more water-soluble additives promote rapid release of the therapeutic agent from the balloon, and thereby rapid release includes a residual amount of the therapeutic agent remaining on the balloon after the balloon is inflated at a target site in a body cavity for an inflation period of about 0.1 minutes to 10 minutes and then removed from the body cavity.
[0133] In one embodiment of the balloon catheter, the weight ratio of the therapeutic (e.g., hydrophobic) agent in the coating to the total weight of one or more additives in the coating can be about 0.05 to about 20, about 0.1 to about 10, about 0.1 to about 5, about 0.5 to about 8, about 0.5 to about 3, about 2 to about 6, or about 0.05 or less, or less than, equal to, or greater than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or about 20 or more. In one embodiment of the balloon catheter, the weight ratio of the therapeutic agent in the coating to the total weight of one or more water-soluble additives in the coating (e.g., the first and second water-soluble additives, or the total weight of the first, second and third water-soluble additives in the coating) is about 0.05 to about 20, about 0.1 to about 10, about 0.1 to about 5, about 0.5 to about 8, about 0.5 to about 3, about 2 to about 6, or about 0.05 or less, or less than, equal to, or greater than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or about 20 or more.
[0134] In one embodiment, the present invention relates to a method for treating body cavity stenosis, the method comprising flushing the body cavity with water, saline solution or an aqueous solution containing at least one water-soluble additive; inserting a balloon catheter into a target site in the body cavity stenosis, the balloon catheter comprising a balloon and a coating covering the outer surface of the balloon. The coating comprises at least one water-soluble additive and an initial drug loading amount of a therapeutic agent; the therapeutic agent is selected from paclitaxel, docetaxel, paclitaxel, their analogs, rapamycin, sirolimus, everolimus, tacrolimus, their analogs and combinations thereof; the water-soluble additive is selected from N-acetylglucosamine, N-octyl-D-glucosamine, N-nonanoyl-N-methylglucosamine, N-octanoyl-N-methylglutamine, C6-ceramide, dihydro-C6-ceramide, cerebroside, sphingomyelin, galactose Cerebrosides, lactocerebroside, N-acetyl-D-sphingosine, N-hexanoyl-D-sphingosine, N-capryl-D-sphingosine, N-lauroyl-D-sphingosine, N-palmitoyl-D-sphingosine, N-oleoyl-D-sphingosine, PEG caprylic / capric diglyceride, PEG8 caprylic / capric glyceride, PEG caprylate, PEG8 caprylate, PEG caprate, PEG caproate, glyceryl monocaprylate, glyceryl monocaprate, glyceryl monohexanoate, glyceryl monolaurate , monocapric glyceryl, monocaprylic glyceryl, monomyristic glyceryl, monopalmitoleic glyceryl, monooleic glyceryl, sarcosine, creatinine, agmatine, citrulline, guanidine, sucralose, aspartame, hypoxanthine, theobromine, theophylline, adenine, uracil, uridine, guanine, thymine, thymidine, xanthine, xanthine nucleoside, xanthine nucleoside monophosphate, caffeine, allantoin, (2-hydroxyethyl) urea, N,N'-bis(hydroxymethyl) urea, pentaerythritol ethoxylate, pentaerythritol propoxylate The invention relates to a method of coating a balloon with a stenotic pressure of at least 200 μm and a diameter of at least 100 μm. The method comprises the following steps: coating the balloon with a stenotic pressure of at least 200 μm and a diameter of at least 100 μm. The method comprises the following steps: coating the balloon with a stenotic pressure of at least 200 μm and a diameter of at least 100 μm. The method comprises the following steps: coating the balloon with a stenotic pressure of at least 200 μm and a diameter of at least 100 μm. The method comprises the following steps: coating the balloon with a stenotic pressure of at least 200 μm and a diameter of at least 100 μm. The method comprises the following steps:The inflated balloon catheter diameter can be such that the ratio of the inflated balloon diameter to the standard diameter of the treated body lumen can be about 1.0 to about 20, or about 1.1 to about 15, or about 1.2 to about 10, or about 1.0 or less, or less than, equal to, or greater than about 1.01, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.8, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, or about 2. 0 or greater; the stretch ratio of the nominal balloon diameter to the standard diameter at the body cavity treatment location can be about 1.0 to about 20, or about 1.1 to about 15, or about 1.2 to about 10, or about 1.0 or less, or less than, equal to or greater than about 1.01, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.8, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18 or about 20 or more. Optionally, inflation can include inflation to a pressure equal to or greater than the nominal pressure of the balloon catheter.
[0135] The balloon may have a residual amount of drug on it after removal. Any suitable residual amount of drug may be left after removal, such as greater than, equal to, or less than about 90 wt%, 88 wt%, 86 wt%, 84 wt%, 82 wt%, 80 wt%, 78 wt%, 76 wt%, 74 wt%, 72 wt%, 70 wt%, 68 wt%, 66 wt%, 64 wt%, 62 wt%, 60 wt%, 58 wt%, 56 wt%, 54 wt%, 52 wt%, 50 wt%, 4 8wt%, 46wt%, 44wt%, 42wt%, 40wt%, 38wt%, 36wt%, 34wt%, 32wt%, 30wt%, 28wt%, 26wt%, 24wt%, 22wt%, 20wt%, 18wt%, 16wt%, 14wt%, 12wt%, 10wt%, 8wt%, 6wt%, 4wt%, 3wt%, 2wt%, 1wt% or about 0wt%.
[0136] In one embodiment, the present invention relates to a method for treating at least one of benign prostatic hyperplasia and prostate cancer, the method comprising flushing the prostate with water, saline solution or an aqueous solution containing at least one water-soluble additive; inserting a balloon catheter into a target site in the prostate, the balloon catheter comprising a balloon and a coating covering the outer surface of the balloon. The coating may contain one or more water-soluble additives and an initial drug loading amount of a therapeutic agent; inflating the balloon until the coating contacts the wall of the benign prostatic hyperplasia or prostate cancer at the target site, and the balloon reaches an inflated balloon diameter for an inflation period; deflate the balloon after the inflation period, wherein the inflation period is 0.1 minutes to 10 minutes; and removing the balloon catheter from the prostate. The ratio of the inflated balloon diameter to the standard diameter of the body cavity can be about 1.0 to about 20, or about 1.01 to about 15, or about 1.01 or less, or less than, equal to, or greater than about 1.01, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.8, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, or about 20 or more; the stretch ratio of the nominal balloon diameter to the standard diameter at the body cavity treatment location can be about 1.0 to about 20, or about 1.1 to about 15, or about 1.2 to about 10, or about 1.0 or less, or less than, equal to, or greater than about 1.01, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.8, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, or about 20 or more. Optionally, inflating may include inflating to a pressure equal to or greater than a nominal pressure of the balloon catheter.
[0137] In one embodiment, the present invention is a method for treating urethral stricture, the method comprising flushing a urethral stricture with water, a saline solution, or an aqueous solution comprising at least one water-soluble additive; inserting a balloon catheter into a target site of urethral stricture, the balloon catheter comprising a balloon and a coating covering the outer surface of the balloon, wherein the coating comprises at least one water-soluble additive and an initial drug loading amount of a therapeutic agent; and the weight ratio of the therapeutic agent in the coating to the total weight of the one or more water-soluble additives in the coating is about 0.05 to 20; inflating the balloon until the coating contacts the wall of the urethral stricture at the target site and the balloon reaches an inflated balloon diameter for an inflation period; deflating the balloon after the inflation period, wherein the inflation period is 0.1 minutes to 10 minutes; and removing the balloon catheter from the urethral stricture. The ratio of the inflated balloon diameter to the standard diameter at the urethral stricture location can be about 1.0 to about 20, or about 1.01 to about 15, or about 1.01 or less, or less than, equal to, or greater than about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.8, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, or about 20 or more; the stretch ratio of the nominal balloon diameter to the standard diameter at the body cavity treatment location can be about 1.0 to about 20, or about 1.1 to about 15, or about 1.2 to about 10, or about 1.0 or less, or less than, equal to, or greater than about 1.01, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.8, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, or about 20 or more. After dilation, the diameter of the urethral stricture can be 6.7 mm or greater, such as about 6.7 mm to about 50 mm, or about 6.7 mm to about 20 mm, or less than, equal to, or greater than about 6.7, 6.8, 6.9, 7.0, 7.2, 7.4, 7.6, 7.8, 8, 8.5, 9, 9.5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45 mm, or about 50 mm or greater. Optionally, inflation can include inflation to a pressure equal to or greater than the nominal pressure of the balloon catheter.
[0138] In one embodiment, the present invention is directed to a method for treating esophageal strictures, such as achalasia strictures, comprising flushing the esophageal stricture with water, saline solution, or an aqueous solution comprising at least one water-soluble additive, optionally before, during, or after inserting a balloon catheter; inserting the balloon catheter into a target site of the esophageal stricture, the balloon catheter comprising a balloon and a coating covering the outer surface of the balloon, wherein the coating comprises at least one water-soluble second additive and a therapeutic agent, and the initial drug loading is 1 to 6 micrograms of the therapeutic agent per square millimeter of the balloon at a nominal diameter; the weight ratio of the therapeutic agent in the coating to the total weight of the one or more water-soluble additives in the coating is about 0.05 to 20; inflating the balloon until the coating contacts the wall of the esophageal stricture at the target site and the balloon reaches an inflated balloon diameter for an inflation period; deflating the balloon after the inflation period, wherein the inflation period is 0.1 minutes to 10 minutes; and removing the balloon catheter from the esophageal stricture. The ratio of the balloon diameter to the standard diameter at the location of esophageal stricture can be about 1.0 to about 20, or about 1.01 to about 20, or about 1.01 or less, or less than, equal to, or greater than about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.8, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, or about 20 or more; the stretch ratio of the nominal balloon diameter to the standard diameter at the location of esophageal stricture can be about 1.0 to about 20, or about 1.1 to about 15, or about 1.2 to about 10, or about 1.0 or less, or less than, equal to, or greater than about 1.01, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.8, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, or about 20 or more. In some embodiments, the balloon catheter properties are equivalent to or similar to those given in Table 4, with a slower growth rate at higher pressures. Compliance is the percentage change in balloon diameter from nominal diameter to rated burst pressure (RBP) diameter, calculated as follows: RBP diameter (diameter at RBP - diameter at nominal pressure) / diameter at nominal pressure)*100%. Optionally, inflation can include inflation to a pressure equal to or greater than the nominal pressure of the balloon catheter.
[0139] Table 4. Examples of properties of balloon catheters used to treat esophageal and gastrointestinal strictures.
[0140]
[0141]
[0142] In one embodiment, the present invention is directed to a method for treating esophageal strictures, such as achalasia strictures, comprising flushing the esophageal stricture with water, saline solution, or an aqueous solution comprising at least one water-soluble additive, optionally before, during, or after inserting a balloon catheter; inserting the balloon catheter into a target site of the esophageal stricture, the balloon catheter comprising a balloon and a coating covering the outer surface of the balloon, wherein the coating comprises at least one water-soluble second additive and a therapeutic agent, wherein the initial drug loading is 1 to 6 mg of the therapeutic agent per square millimeter of the balloon at a nominal diameter; and the weight ratio of the therapeutic agent in the coating to the total weight of the one or more water-soluble additives in the coating is about 0.05 to 20; inflating the balloon until the coating contacts the wall of the esophageal stricture at the target site and the balloon reaches an inflated balloon diameter for an inflation period; deflating the balloon after the inflation period, wherein the inflation period is 0.1 to 10 minutes; and removing the balloon catheter from the esophageal stricture. The ratio of the inflated balloon diameter to the standard diameter at the location of the esophageal stricture can be about 1.0 to about 20, or about 1.01 to about 20, or about 1.31 to 20, or about 1.01 or less, or less than, equal to, or greater than about 1.1, 1.2, 1.3, 1.31, 1.4, 1.5, 1.6, 1.8, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, or about 20 or more; the nominal balloon diameter to the standard diameter of the esophageal stricture can be about 1.0 to about 20, or about 1.01 to about 20, or about 1.31 to 20, or about 1.01 or less, or less than, equal to, or greater than about 1.1, 1.2, 1.3, 1.31, 1.4, 1.5, 1.6, 1.8, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, or about 20 or more; The stretch ratio of the standard diameter at the esophageal stricture position can be about 1.0 to about 20, or about 1.1 to about 15, or about 1.2 to about 10, or about 1.31 to 20, or about 1.0 or less, or less than, equal to or greater than about 1.01, 1.1, 1.2, 1.3, 1.31, 1.4, 1.5, 1.6, 1.8, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18 or about 20 or more. Optionally, inflation can include inflation to a pressure equal to or greater than the nominal pressure of the balloon catheter. In some embodiments, the balloon catheter properties are equal to or similar to those given in Table 5, and the single balloon catheter has the ability to reach a wide range of balloon diameters at relatively high working pressures compared to conventional compliance balloons. The balloon in Table 5 has a unique feature, with three increasing balloon diameters at three increasing inflation pressure stages. The nominal inflated diameter is the diameter at stage I. The diameter increases by about 0.5-4 mm, preferably 0.75-3 mm, and most preferably 0.9-2 mm, for each stage of pressure increase. For example, a balloon having a diameter of 15 mm at pressure I (3 ATM) has a diameter of 16.5 mm at pressure II (4.5 ATM), and has a diameter of 18 mm at pressure III (7 ATM).
[0143] Table 5. Examples of properties of balloon catheters used to treat esophageal and gastrointestinal strictures.
[0144]
[0145] In one embodiment, the present invention relates to a method for treating gastrointestinal stenosis, which includes gastric stenosis, small intestinal stenosis, duodenal stenosis, jejunal stenosis, ileal stenosis, colonic stenosis, rectal stenosis and large intestinal stenosis and bile duct stenosis, the method comprising flushing the gastrointestinal stenosis with water, saline solution or an aqueous solution containing at least one water-soluble additive; inserting a balloon catheter into a target site of the gastrointestinal stenosis, the balloon catheter comprising a balloon and a coating covering the outer surface of the balloon, wherein the coating comprises at least one water-soluble second additive and a therapeutic agent, the initial drug loading is 1 to 6 micrograms of the therapeutic agent per square millimeter of the balloon at a nominal diameter; and the weight ratio of the therapeutic agent in the coating to the total weight of the one or more water-soluble additives in the coating is about 0.05 to 20; inflating the balloon until the coating contacts the wall of the esophageal stenosis at the target site and the balloon reaches the inflated balloon diameter for an inflation period; deflating the balloon after the inflation period, wherein the inflation period is 0.1 minutes to 10 minutes; and removing the balloon catheter from the esophageal stenosis. The inflated balloon catheter diameter may be such that the ratio of the balloon diameter to the standard diameter at the location of the esophageal stricture may be about 1.0 to about 20, or about 1.31 to about 20, or about 1.01 to about 15, or about 1.01 or less, or less than, equal to, or greater than about 1.1, 1.2, 1.3, 1.31, 1.4, 1.5, 1.6, 1.8, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, or about 20 or more; nominal The stretch ratio of the balloon diameter to the standard diameter at the location of esophageal stenosis can be about 1.0 to about 20, or about 1.31 to about 20, or about 1.1 to about 15, or about 1.2 to about 10, or about 1.0 or less, or less than, equal to or greater than about 1.01, 1.1, 1.2, 1.3, 1.31, 1.4, 1.5, 1.6, 1.8, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18 or about 20 or more. Optionally, inflation can include inflation to a pressure equal to or greater than the nominal pressure of the balloon catheter. In some embodiments, the balloon catheter has properties equivalent to or similar to those given in Tables 4 and 5, with a slowed growth rate at higher pressures, and a single balloon catheter has the ability to reach a wide range of balloon diameters at high working pressures.
[0146] In various embodiments, the drug-coated balloon catheter for treating esophageal stricture, achalasia stricture, gastrointestinal stricture including gastric stricture, small intestinal stricture, duodenal stricture, jejunal stricture, ileal stricture, colonic stricture, rectal stricture and large intestinal stricture and biliary stricture has a catheter design of fixed wire, wire-guided, over-the-wire catheter or rapid exchange design catheter.
[0147] In one embodiment, the present invention relates to a method for treating sinus stenosis, the method comprising: flushing the sinus stenosis with water, saline solution or an aqueous solution containing at least one water-soluble additive; inserting a balloon catheter into the target site of the sinus stenosis, the balloon catheter comprising a balloon and a coating covering the outer surface of the balloon, wherein the coating comprises at least one water-soluble additive and a therapeutic agent, and the initial drug loading is 1 to 6 micrograms of the therapeutic agent / square millimeter of the nominal diameter of the balloon; the therapeutic agent is selected from budesonide, flunisolide, triamcinolone, beclomethasone, fluticasone, mometasone, mometasone furoate, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, cortisone, betamethasone, triamcinolone Naide and combinations thereof; water-soluble additives selected from N-acetylglucosamine, N-octyl-D-glucosamine, N-nonanoyl-N-methylglucosamine, N-octanoyl-N-methylglutamine, C6-ceramide, dihydro-C6-ceramide, cerebrosides, sphingomyelins, galactocerebrosides, lactocerebrosides, N-acetyl-D-sphingosine, N-hexanoyl-D-sphingosine, N-octanoyl-D-sphingosine, N-lauroyl-D-sphingosine, N-palmitoyl-D-sphingosine, N-oleoyl-D-sphingosine, PEG caprylic / capric diglyceride, PEG8 caprylic / capric glyceride, PEG caprylate, PEG 8 Caprylate, PEG caprate, PEG caproate, glyceryl monocaprylate, glyceryl monocaprate, glyceryl monohexanoate, monolaurin, monocapric glyceryl, monocaprylic glyceryl, monomyristic glyceryl, monopalmitoleic glyceryl, monooleic glyceryl, sarcosine, creatinine, agmatine, citrulline, guanidine, sucralose, aspartame, hypoxanthine, theobromine, theophylline, adenine, uracil, uridine, guanine, thymine, thymidine, xanthine, xanthine nucleoside, xanthine nucleoside monophosphate, caffeine, allantoin, (2-hydroxyethyl) urea, N,N'-bis(hydroxymethyl) urea, pentaerythritol ethoxylate, quaternary Pentaerythritol propoxylate, pentaerythritol propoxylate / ethoxylate, glycerol ethoxylate, glycerol propoxylate, ethoxylated trimethylolpropane, pentaerythritol, dipentaerythritol, crown ethers, 18-crown-6, 15-crown-5, 12-crown-4, and combinations thereof; and the weight ratio of the therapeutic agent in the coating to the total weight of the one or more water-soluble additives in the coating is about 0.05 to 20; inflating the balloon until the coating contacts the wall of the sinus stenosis at the target site and the balloon reaches an inflated balloon diameter for an inflation period; deflating the balloon after the inflation period, wherein the inflation period is 0.1 minutes to 10 minutes; and removing the balloon catheter from the sinus stenosis.
[0148] In some embodiments, it may be desirable to pre-dilate a target area of a body cavity (such as a prostate) prior to using a drug-coated balloon. In some embodiments, the pre-dilution balloon is selected to be slightly shorter than the treatment balloon and / or to have a slightly smaller nominal diameter than the treatment balloon. If the pre-dilution balloon is shorter than the treatment balloon, the entire pre-dilution zone or pre-dilution area will be more likely to be treated by the treatment balloon. In some embodiments, it may be desirable to dilate the target area of the body cavity directly without pre-dilution.
[0149] Embodiments of the present invention relate to balloon catheters with fast-release drug coatings and methods for preparing such coated devices. The therapeutic agent according to embodiments of the present invention need not be delayed or released over a long period of time, but instead, for example, the therapeutic agent and additive are released in a very short period of time to provide a therapeutic effect when contacting the tissue. One goal of embodiments of the present invention is to promote rapid and efficient absorption of drugs by target tissues during the short deployment of the device at the target site.
[0150] In various embodiments, the balloon catheter can have one or more (e.g., 2) neck portions along the balloon body. The neck portion has a nominal diameter smaller than the nominal balloon body diameter (e.g., 1.5 to 2.5x smaller), and can be any length, such as about 10-20 mm long. The neck portion can separate the balloon symmetrically, or can cause some balloon body portions to be longer than other portions. The nominal balloon diameter can be in the range of 6-45 mm, and the working length is 20 to 160 mm.
[0151] exist Figure 1A In one embodiment, a balloon having one neck portion is shown. Balloon 100 has waist 101, cone 102, first body portion 103, neck 104, second body portion 105, cone 106, and waist 107. When assembled into a balloon catheter, waists 101 and 107 will be attached or bonded to a catheter shaft (not shown) as is known in the art. During inflation, waists 101 and 107 are not inflated when attached to the catheter shaft. In Figure 1B In one embodiment, a balloon having two neck portions is shown. Balloon 120 has a waist 121, a cone 122, a first body portion 123, a first neck 124, a second body portion 125, a second neck 126, a third body portion 127, a cone 128, and a waist 129. When assembled into a balloon catheter, waists 121 and 129 will be attached or bonded, etc. to the catheter shaft, as is known in the art. During inflation, waists 121 and 129 are not inflated when attached to the catheter shaft. Although neck portions 124 and 126 are shown as the same diameter in the current inflated state, they can be the same or different diameters and have the same or different compliances. In Figure 1CIn one embodiment, a balloon having three neck portions is shown. Balloon 140 has waist 141, cone 142, first body portion 143, first neck 144, second body portion 145, second neck 146, third body portion 147, third neck 148, fourth body portion 149, cone 150, and waist 151. When assembled into a balloon catheter, waists 141 and 151 will be attached or bonded to the catheter shaft, etc., as known in the art. During inflation, waists 141 and 151 are not inflated when attached to the catheter shaft. Although neck portions 144, 146, and 148 are shown as having different diameters in the current inflated state, they can be the same or different diameters, with the same or different compliances.
[0152] like Figure 2 As shown in, in one embodiment, the medical device is a balloon catheter, a fixed-line balloon catheter, a movable line catheter, a cross-line balloon catheter, a rapid exchange balloon catheter, including conventional balloon catheters known to those of ordinary skill in the art. For example, the balloon catheter 150 may include an expandable, inflatable balloon at the distal end of the catheter 150, a handle assembly 160 at the proximal end of the catheter 150, an elongated flexible member 164 extending between the proximal and distal ends, and an anti-injury elbow 163. The handle assembly 160 may be connected to and / or receive one or more suitable medical devices, such as a source of inflation medium (e.g., air, saline or contrast agent). The flexible member 164 may be a tube made of a suitable biocompatible material and having one or more lumens therein. At least one lumen is configured to receive an inflation medium and deliver such a medium to the balloon 162 so that it expands. The balloon catheter may be a fixed-line or rapid exchange or cross-line catheter and may be made of any suitable biocompatible material. The material of balloon 162 may include one or more of the following: polyester, polyamide, nylon 12, nylon 11, polyamide 12, block copolymers of polyether and polyamide, Polyurethanes and block copolymers of polyethers and polyesters. Figure 2 In one embodiment, a balloon having two neck portions is shown. Balloon 162 has waist 151, cone 152, first body portion 153, first neck 154, second body portion 155, second neck 156, third body portion 157, cone 158, and waist 159. When assembled into a balloon catheter, waists 151 and 159 will be attached or bonded to the catheter shaft, etc., as known in the art. During inflation, waists 151 and 159 are not inflated when attached to the catheter shaft. Although neck portions 154 and 156 are shown as the same diameter in the current inflated state, they can be the same or different diameters, with the same or different compliances.
[0153] like Figure 3As shown in, in one embodiment, the medical device is a balloon catheter. The balloon catheter can be any suitable catheter for the desired use, including a fixed-line balloon catheter, a removable line catheter, a cross-line balloon catheter, a rapid exchange balloon catheter, including conventional balloon catheters known to those of ordinary skill in the art. For example, the balloon catheter 10 can include an expandable inflatable balloon 12 at the distal end of the catheter 10, a handle assembly 16 at the proximal end of the catheter 10, and an elongated flexible member 14 extending between the proximal end and the distal end. The handle assembly 16 can be connected to and / or receive one or more suitable medical devices, such as a source of inflation medium (e.g., air, saline or contrast agent). The flexible member 14 can be a tube made of suitable biocompatible materials and having one or more lumens therein. Wherein at least one lumen is configured to receive inflation medium, and such medium is delivered to the balloon 12 so that it expands. The balloon catheter can be a rapid exchange type or cross-line catheter, and is made of any suitable biocompatible material. The material of the balloon 12 may include one or more of the following: polyester, polyamide, nylon 12, nylon 11, polyamide 12, block copolymers of polyether and polyamide, Polyurethanes and block copolymers of polyethers and polyesters.
[0154] In one embodiment, the present invention provides a medical device for delivering a therapeutic agent to a diseased tissue or a stenosis (such as vascular tissue or non-vascular tissue). The device includes a layer applied to the outer surface of a balloon catheter. The layer includes a therapeutic agent and one or more additives. The additive can be any suitable additive. The layer can include one additive, or the layer can include more than one additive, such as a water-soluble first additive and a water-soluble second additive. For example, Figure 4A As shown in the embodiment depicted in FIG, the balloon 12 is coated with a layer 20 comprising a therapeutic agent and an additive. In some embodiments, the layer consists essentially of the therapeutic agent and the additive, for example, the layer only comprises the therapeutic agent and the additive without any other substantial significant components. In some embodiments, the device may optionally include an adhesive layer. For example, as Figure 4BAs shown in the embodiment depicted in , the balloon 12 is coated with an adhesion layer 22. A layer 24 containing therapeutic agents and additives is covered on the adhesion layer. The adhesion layer is an independent layer below the drug coating that improves the adhesion of the drug coating to the outer surface of the medical device and protects the integrity of the coating. For example, if the drug and additive have different adhesion to the medical device, the adhesion layer can prevent the differential loss of the components and maintain the drug / additive ratio in the coating during transfer to the target site for therapeutic intervention. In addition, the adhesion layer can play a role in promoting the rapid release of the coating components from the device surface when contacting the target site of the tissue. In other embodiments, the device may include a top layer. The top layer can reduce the loss of the drug layer before contact with the target tissue, such as during the initial moment of inflating the balloon 12 during transportation to the treatment intervention site or before the coating 20 is pressed into direct contact with the target tissue.
[0155] Embodiments of the present invention relate to treating non-vascular body lumen strictures by delivering an effective amount of a therapeutic agent, such as an anti-inflammatory and anti-proliferative agent (e.g., rapamycin, sirolimus, everolimus, tacrolimus, paclitaxel, taxol, docetaxel, or their analogs). Non-vascular body lumen strictures include urethral strictures, ureteral strictures, esophageal strictures, sinus strictures, achalasia strictures, stent strictures, gastric strictures, small intestinal strictures, duodenal strictures, jejunal strictures, ileal strictures, colonic strictures, rectal strictures, and large intestinal strictures and biliary strictures. Embodiments of the present invention relate to a method for treating at least one of benign prostatic hyperplasia (BPH), prostate cancer, asthma, and chronic obstructive pulmonary disease (COPD). According to various embodiments, the method involves delivering a therapeutic agent, such as an anti-inflammatory and anti-proliferative agent (e.g., rapamycin, sirolimus, everolimus, tacrolimus, paclitaxel, taxol, docetaxel, or their analogs) by a coated balloon catheter. The anti-inflammatory and anti-proliferative drugs may be coated on the medical device alone or together with one or more additives.
[0156] A method for treating non-vascular body lumen stenosis includes inserting a balloon catheter comprising a coating into a body lumen, wherein the coating comprises a drug and an additive; inflating the balloon catheter and releasing the drug to the wall of the non-vascular body lumen, deflated the balloon; and removing the balloon catheter, wherein the residual drug can be about 1% to 70% of the total drug load on the balloon catheter, wherein the drug in the wall of the body lumen can be about 0.1% to 25% of the total drug load on the balloon catheter. The method may include flushing the body lumen with water, saline solution, or an aqueous solution comprising at least one water-soluble additive before, during, or after inserting the balloon into the target site. In one aspect of this embodiment, the additive enhances the absorption of the drug into the tissue of the non-vascular body lumen. In another aspect of this embodiment, the additive comprises a hydrophilic portion and a drug-affinity portion, wherein the drug-affinity portion is at least one of the following: a hydrophobic portion, a portion having an affinity for the therapeutic agent by hydrogen bonding, and a portion having an affinity for the therapeutic agent by van der Waals interactions.
[0157] A balloon catheter for delivering a therapeutic agent to a target site in a non-vascular body cavity may include a coating covering the outer surface of the balloon, wherein the coating comprises an initial drug loading amount of a therapeutic agent and one or more water-soluble additives; the therapeutic agent is selected from paclitaxel, taxol, docetaxel, their analogs, rapamycin, sirolimus, everolimus and their analogs, and combinations thereof; the water-soluble additive is selected from N-acetylglucosamine, N-octyl-D-glucosamine, N-nonanoyl-N-methyl Glucosamine, N-octanoyl-N-methylglutamine, C6-ceramide, dihydro-C6-ceramide, cerebrosides, sphingomyelin, galactocerebroside, lactocerebroside, N-acetyl-D-sphingosine, N-hexanoyl-D-sphingosine, N-capryl-D-sphingosine, N-lauroyl-D-sphingosine, N-palmitoyl-D-sphingosine, N-oleoyl-D-sphingosine, PEG caprylic / capric diglyceride, PEG8 caprylic / capric glyceride , PEG caprylate, PEG8 caprylate, PEG caprate, PEG caproate, glyceryl monocaprylate, glyceryl monocaprate, glyceryl monohexanoate, glyceryl monolaurate, glyceryl monocaprate, glyceryl monocaprylate, glyceryl monomyristate, glyceryl monopalmitoleate, glyceryl monooleate, sarcosine, creatinine, agmatine, citrulline, guanidine, sucralose, aspartame, hypoxanthine, theobromine, theophylline, adenine, uracil, uridine, guanine, thymus Adenine, thymidine, xanthine, xanthine nucleoside, xanthine nucleoside monophosphate, caffeine, allantoin, (2-hydroxyethyl) urea, N,N'-bis(hydroxymethyl) urea, pentaerythritol ethoxylate, pentaerythritol propoxylate, pentaerythritol propoxylate / ethoxylate, glycerol ethoxylate, glycerol propoxylate, ethoxylated trimethylolpropane, pentaerythritol, dipentaerythritol, crown ethers, 18-crown-6, 15-crown-5, 12-crown-4, and combinations thereof.
[0158] The non-vascular body lumen can be one of the following: esophagus, airway, sinus, trachea, colon, bile duct, stomach, small intestine, duodenum, jejunum, ileum, rectum, large intestine, urinary tract, prostate, urethra, ureter, and other non-vascular lumens.
[0159] In some embodiments, one or more water-soluble additives can promote rapid release of the therapeutic agent from the balloon, and thereby rapid release includes a residual amount of the therapeutic agent remaining on the balloon after the balloon is inflated at a non-vascular body lumen target site for an inflation period of about 0.1 minutes to 10 minutes and then removed from the non-vascular lumen.
[0160] The weight ratio of the therapeutic agent in the coating to the total weight of the one or more additives in the coating can be about 0.05 to about 20, about 0.1 to about 10, about 0.1 to about 5, about 0.5 to about 8, about 0.5 to about 3, about 2 to about 6, or about 0.05 or less, or less than, equal to, or greater than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or about 20 or more. The weight ratio of the therapeutic agent in the coating to the one or more water-soluble additives in the coating (e.g., the first and second water-soluble additives, or the total weight of the first, second, and third water-soluble additives in the coating) can be about 0.05 to about 20, about 0.1 to about 10, about 0.1 to about 5, about 0.5 to about 8, about 0.5 to about 3, about 2 to about 6, or about 0.05 or less, or less than, equal to, or greater than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or about 20 or more.
[0161] The initial drug load may be 1 microgram to 20 micrograms of therapeutic agent per square millimeter of balloon (i.e., the outer surface area of the balloon per nominal diameter), or about 2 to about 6 micrograms, or about 1 microgram or less, or less than, equal to, or greater than about 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, or about 20 micrograms or more. The residual drug amount may be 70% or less of the initial drug load.
[0162] The method for treating non-vascular body cavity stenosis comprises flushing the non-vascular body cavity with water, saline solution or aqueous solution containing at least one water-soluble additive; inserting a balloon catheter into the target site of the non-vascular body cavity stenosis, the balloon catheter comprising a balloon and a coating covering the outer surface of the balloon. The coating comprises at least one water-soluble additive and an initial drug loading amount of a therapeutic agent; the therapeutic agent is selected from paclitaxel, taxol, docetaxel, their analogs, rapamycin, sirolimus, everolimus and their analogs and combinations thereof; the water-soluble additive is selected from N-acetylglucosamine, N-octyl-D-glucosamine, N-nonanoyl-N-methylglucosamine, N-octanoyl-N-methylglutamine, C6-ceramide, dihydro-C6-ceramide, cerebroside, sphingomyelin, galactocerebroside, lactone Glucocerebroside, N-acetyl-D-sphingosine, N-hexanoyl-D-sphingosine, N-capryl-D-sphingosine, N-lauroyl-D-sphingosine, N-palmitoyl-D-sphingosine, N-oleoyl-D-sphingosine, PEG caprylic / capric diglyceride, PEG8 caprylic / capric glyceride, PEG caprylate, PEG8 caprylate, PEG caprate, PEG caproate, glyceryl monocaprylate, glyceryl monocaprate, glyceryl monohexanoate, monolaurin, glyceryl monocaprate Esters, monocaprylic acid glyceryl, monomyristic acid glyceryl, monopalmitoleic acid glyceryl, monooleic acid glyceryl, sarcosine, creatinine, agmatine, citrulline, guanidine, sucralose, aspartame, hypoxanthine, theobromine, theophylline, adenine, uracil, uridine, guanine, thymine, thymidine, xanthine, xanthine nucleoside, xanthine nucleoside monophosphate, caffeine, allantoin, (2-hydroxyethyl) urea, N,N'-bis(hydroxymethyl) urea, pentaerythritol ethoxylate, pentaerythritol propoxylate, pentaerythritol Tetraol propoxylate / ethoxylate, glycerol ethoxylate, glycerol propoxylate, ethoxylated trimethylolpropane, pentaerythritol, dipentaerythritol, crown ethers, 18-crown-6, 15-crown-5, 12-crown-4, and combinations thereof; inflating the balloon until the coating contacts the wall of the non-vascular body lumen stenosis at the target site and the balloon reaches the inflated balloon diameter for an inflation period; deflating the balloon after the inflation period, wherein the inflation period is 0.1 to 10 minutes; and removing the balloon catheter from the non-vascular body lumen stenosis. In some embodiments, the balloon diameter at a nominal inflation pressure of 6 atm is 10 mm. The ratio of the inflated balloon diameter to the standard diameter of the target body cavity site can be about 1.01 to about 20; the stretch ratio of the nominal balloon diameter to the standard diameter at the body cavity treatment location can be about 1.0 to about 20, or about 1.1 to about 15, or about 1.2 to about 10, or about 1.0 or less, or less than, equal to or greater than about 1.01, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.8, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18 or about 20 or more.Optionally, inflating may include inflating to a pressure equal to or greater than a nominal pressure of the balloon catheter.
[0163] The balloon may have a residual amount of drug on it after removal. Any suitable residual amount of drug may be left after removal, such as greater than, equal to, or less than about 70wt%, 65wt%, 60wt%, 55wt%, 50wt%, 45wt%, 40wt%, 35wt%, 30wt%, 25wt%, 20wt%, 15wt%, 10wt%, 5wt%, or about 0wt%.
[0164] The weight ratio of the therapeutic agent in the coating to the total weight of the one or more additives in the coating can be about 0.05 to about 20, about 0.1 to about 10, about 0.1 to about 5, about 0.5 to about 8, about 0.5 to about 3, about 2 to about 6, or about 0.05 or less, or less than, equal to, or greater than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or about 20 or more.
[0165] In various embodiments, the coating may include one or more water-soluble additives and an initial drug loading of a therapeutic agent; the therapeutic agent is selected from paclitaxel, a paclitaxel analog, rapamycin, a rapamycin analog, and a combination thereof; the water-soluble additive is selected from N-acetylglucosamine, N-octyl-D-glucosamine, N-nonanoyl-N-methylglucosamine, N-octanoyl-N-methylglutamine, C6-ceramide, dihydro-C6-ceramide, cerebrosides, sphingomyelins, galactocerebrosides, lactocerebrosides, N-acetyl-D-sphingosine, N-hexanoyl-D-sphingosine, N-octanoyl-D-sphingosine, N-lauroyl-D-sphingosine, N-palmitoyl-D-sphingosine, N-oleoyl-D-sphingosine, PEG caprylic / capric diglyceride, PEG caprylic / capric glyceride, PEG caprylate, PEG caprylate, PEG caprate, P6-caprylate, and PEG-8-caprylic acid. EG caproate, glyceryl monocaprylate, glyceryl monocaprate, glyceryl monocaproate, glyceryl monolaurate, glyceryl monocaprate, glyceryl monocaprylate, glyceryl monomyristate, glyceryl monopalmitoleate, glyceryl monooleate, sarcosine, creatinine, agmatine, citrulline, guanidine, sucralose, aspartame, hypoxanthine, theobromine, theophylline, adenine, uracil, uridine, guanine, thymine, thymidine, xanthine, xanthine Purine nucleosides, xanthine nucleoside monophosphates, caffeine, allantoin, (2-hydroxyethyl) urea, N,N'-bis(hydroxymethyl) urea, pentaerythritol ethoxylate, pentaerythritol propoxylate, pentaerythritol propoxylate / ethoxylate, glycerol ethoxylate, glycerol propoxylate, ethoxylated trimethylolpropane, pentaerythritol, dipentaerythritol, crown ethers, 18-crown-6, 15-crown-5, 12-crown-4, and combinations thereof.
[0166] A method for treating one of benign prostatic hyperplasia and prostate cancer may include flushing the prostate with water, saline solution, or an aqueous solution containing at least one water-soluble additive; inserting a balloon catheter into a target site of the prostate, the balloon catheter comprising a balloon and a coating covering the outer surface of the balloon. The method may include inflating the balloon until the coating contacts the wall of the target site of benign prostatic hyperplasia or prostate cancer and the balloon reaches an inflated balloon diameter for an inflation period; deflating the balloon after the inflation period, wherein the inflation period is 0.1 minutes to 10 minutes; and removing the balloon catheter from the prostate. The ratio of the inflated balloon diameter to the diameter of the standard body cavity at the target site can be about 1.01 to about 20, or about 1.31 to about 20, or about 1.1 to about 15, or about 1.2 to about 10, or greater than about 1.1, 1.2, 1.3, 1.31, 1.4, 1.5, 1.6, 1.8, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, or about 20 or more; the nominal balloon diameter to the body cavity treatment diameter can be about 1.01 to about 20, or about 1.31 to about 20, or about 1.1 to about 15, or about 1.2 to about 10, or greater than about 1.1, 1.2, 1.3, 1.31, 1.4, 1.5, 1.6, 1.8, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, or about 20 or more; The stretch ratio of the standard diameter at the position can be about 1.0 to about 20, or about 1.31 to about 20, or about 1.1 to about 15, or about 1.2 to about 10, or about 1.0 or less, or less than, equal to, or greater than about 1.01, 1.1, 1.2, 1.3, 1.31, 1.4, 1.5, 1.6, 1.8, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, or about 20 or more. Optionally, inflation can include inflation to a pressure equal to or greater than the nominal pressure of the balloon catheter.
[0167] The method for treating urethral stricture comprises flushing a urethral stricture with water, saline solution or an aqueous solution containing at least one water-soluble additive; inserting a balloon catheter into a target site of urethral stricture, the balloon catheter comprising a balloon and a coating covering the outer surface of the balloon, wherein the coating comprises at least one water-soluble additive and an initial drug loading amount of a therapeutic agent; and the weight ratio of the therapeutic agent in the coating to the total weight of the one or more water-soluble additives in the coating is about 0.05 to 20; inflating the balloon until the coating contacts the wall of the urethral stricture at the target site and the balloon reaches an inflated balloon diameter for an inflation period; deflating the balloon after the inflation period, wherein the inflation period is 0.1 minutes to 10 minutes; and removing the balloon catheter from the urethral stricture. The ratio of the inflated balloon diameter to the standard diameter of the urethral stricture site of the body cavity can be about 1.01 to about 20, or about 1.31 to about 20, or about 1.1 to about 15, or about 1.2 to about 10, or greater than about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.8, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18 or about 20 or more; the ratio of the nominal balloon diameter to the standard diameter of the body cavity treatment site can be about 1.01 to about 20, or about 1.31 to about 20, or about 1.1 to about 15, or about 1.2 to about 10, or greater than about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.8, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18 or about 20 or more; The stretch ratio of the standard diameter at the position can be about 1.0 to about 20, or about 1.31 to about 20, or about 1.1 to about 15, or about 1.2 to about 10, or about 1.0 or less, or less than, equal to, or greater than about 1.01, 1.1, 1.2, 1.3, 1.31, 1.4, 1.5, 1.6, 1.8, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, or about 20 or more. After dilation, the diameter of the urethral stricture can be 6.7 mm or greater, such as about 6.7 mm to about 50 mm, or about 6.7 mm to about 20 mm, or less than, equal to, or greater than about 6.7, 6.8, 6.9, 7.0, 7.2, 7.4, 7.6, 7.8, 8, 8.5, 9, 9.5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45 mm, or about 50 mm or greater. Optionally, inflation can include inflation to a pressure equal to or greater than the nominal pressure of the balloon catheter.
[0168] In one embodiment, the balloon has less than 70% of the initial drug load residual drug thereon after removal.
[0169] The method for treating esophageal stricture comprises flushing the esophageal stricture with water, saline solution or an aqueous solution containing at least one water-soluble additive; inserting a balloon catheter into the target site of the esophageal stricture, the balloon catheter comprising a balloon and a coating covering the outer surface of the balloon, wherein the coating comprises at least one water-soluble second additive and a therapeutic agent, and the initial drug loading is 1 to 6 micrograms of therapeutic agent per square millimeter of the balloon; the therapeutic agent is selected from paclitaxel, taxol, docetaxel, rapamycin, sirolimus, tacrolimus, everolimus, mTOR inhibitors, or analogs thereof and combinations thereof; the water-soluble additive is selected from N-acetylglucosamine, N-octyl- D-Glucosamide, N-nonanoyl-N-methylglucosamine, N-octanoyl-N-methylglutamine, C6-ceramide, dihydro-C6-ceramide, cerebrosides, sphingomyelins, galactocerebrosides, lactocerebrosides, N-acetyl-D-sphingosine, N-hexanoyl-D-sphingosine, N-octanoyl-D-sphingosine, N-lauroyl-D-sphingosine, N-palmitoyl-D-sphingosine, N-oleoyl-D-sphingosine, PEG caprylic / capric diglyceride, PEG8 caprylic / capric glyceride, PEG caprylate, PEG8 caprylate, PEG caprate, PEG caproate, glyceryl Oleyl monocaprylate, glyceryl monocaprate, glyceryl monohexanoate, glyceryl monolaurate, glyceryl monocaprate, glyceryl monocaprylate, glyceryl monomyristate, glyceryl monopalmitoleate, glyceryl monooleate, sarcosine, creatinine, agmatine, citrulline, guanidine, sucralose, aspartame, hypoxanthine, theobromine, theophylline, adenine, uracil, uridine, guanine, thymine, thymidine, xanthine, xanthine nucleoside, xanthine nucleoside monophosphate, caffeine, allantoin, (2-hydroxyethyl) urea, N,N'-bis(hydroxymethyl) urea, pentaerythritol ethoxylate, pentaerythritol propoxylate, pentaerythritol Tetraol propoxylates / ethoxylates, glycerol ethoxylates, glycerol propoxylates, ethoxylated trimethylolpropane, pentaerythritol, dipentaerythritol, crown ethers, 18-crown-6, 15-crown-5, 12-crown-4, and combinations thereof; and the weight ratio of the therapeutic agent in the coating to the total weight of the one or more water-soluble additives in the coating is about 0.05 to 20; inflating the balloon until the coating contacts the wall of the esophageal stricture at the target site and the balloon reaches an inflated balloon diameter for an inflation period; deflating the balloon after the inflation period, wherein the inflation period is 0.1 to 10 minutes; and removing the balloon catheter from the esophageal stricture.The ratio of the inflated balloon diameter to the standard diameter at the location of the esophageal stricture can be about 1.01 to about 20, 1.31 to 20, or about 1.1 to about 15, or about 1.3 to about 10, or about 1.31 to 10, or about or greater than about 1.1, 1.2, 1.3, 1.31, 1.4, 1.5, 1.6, 1.8, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, or about 20 or more; the ratio of the nominal balloon diameter to the body cavity treatment location can be about 1.01 to about 20, 1.31 to 20, or about 1.1 to about 15, or about 1.3 to about 10, or about 1.31 to 10, or about or greater than about 1.1, 1.2, 1.3, 1.31, 1.4, 1.5, 1.6, 1.8, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, or about 20 or more; The stretch ratio of the standard diameter at can be about 1.0 to about 20, 1.31 to 20, or about 1.1 to about 15, or about 1.2 to about 10, or about 1.3 to 10, or about 1.31 to 10, or about 1.0 or less, or less than, equal to, or greater than about 1.01, 1.1, 1.2, 1.3, 1.31, 1.4, 1.5, 1.6, 1.8, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, or about 20 or more. Optionally, inflation can include inflation to a pressure equal to or greater than the nominal pressure of the balloon catheter.
[0170] The method for treating sinus stenosis comprises flushing the sinus stenosis with water, saline solution or an aqueous solution containing at least one water-soluble additive; inserting a balloon catheter into the target site of sinus stenosis, the balloon catheter comprising a balloon and a coating covering the outer surface of the balloon, wherein the coating comprises at least one water-soluble additive and a therapeutic agent, and the initial drug loading is 1 to 6 micrograms of therapeutic agent per square millimeter of balloon; the therapeutic agent is selected from budesonide, flunisolide, triamcinolone, beclomethasone, fluticasone, mometasone, mometasone furoate, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, cortisone, betamethasone, triamcinolone acetonide and combinations thereof; the water-soluble additive is selected from N -Acetyl glucosamine, N-octyl-D-glucamide, N-nonanoyl-N-methylglucosamine, N-octanoyl-N-methylglutamine, C6-ceramide, dihydro-C6-ceramide, cerebrosides, sphingomyelin, galactocerebrosides, lactocerebrosides, N-acetyl-D-sphingosine, N-hexanoyl-D-sphingosine, N-capryl-D-sphingosine, N-lauroyl-D-sphingosine, N-palmitoyl-D-sphingosine, N-oleoyl-D-sphingosine, PEG caprylic / capric diglyceride, PEG8 caprylic / capric glyceride, PEG caprylate, PEG8 caprylate, PEG caprate , PEG caproate, glyceryl monocaprylate, glyceryl monocaprate, glyceryl monocaproate, glyceryl monolaurate, glyceryl monocaprate, glyceryl monocaprylate, glyceryl monomyristate, glyceryl monopalmitoleate, glyceryl monooleate, sarcosine, creatinine, agmatine, citrulline, guanidine, sucralose, aspartame, hypoxanthine, theobromine, theophylline, adenine, uracil, uridine, guanine, thymine, thymidine, xanthine, xanthine nucleoside, xanthine nucleoside monophosphate, caffeine, allantoin, (2-hydroxyethyl) urea, N,N'-bis(hydroxymethyl) urea, pentaerythritol ethoxylate, pentaerythritol propoxylate The invention relates to a method for treating a stenotic sinus with a balloon. The method comprises applying a stenotic sinus with a balloon having a weight ratio of about 0.05 to about 20 to about 100 weight ratios of the weight ratios of the therapeutic agent in the coating to the total weight of the one or more water-soluble additives in the coating; inflating the balloon until the coating contacts the wall of the sinus stenosis at the target site and the balloon reaches an inflated balloon diameter for an inflation period; deflating the balloon after the inflation period, wherein the inflation period is from 0.1 minutes to 10 minutes; and removing the balloon catheter from the sinus stenosis.
[0171] additive.
[0172] In various embodiments, the additive may have two parts. One part is hydrophilic, and the other part is a pro-drug part. The pro-drug part is a hydrophobic part, and / or has an affinity for therapeutic agents through hydrogen bonding and / or van der Waals interactions. The pro-drug part of the additive can be combined with lipophilic drugs, such as rapamycin or paclitaxel. The hydrophilic part accelerates diffusion and increases drug penetration into tissues. The hydrophilic part can promote rapid movement of drugs away from medical devices by preventing hydrophobic drug molecules from agglomerating with each other and agglomerating on the device during deployment at the target site, thereby improving the drug solubility in the interstitial space, and / or accelerating the drug lumen to reach the lipid bilayer of the cell membrane of the target tissue through the polar head group. The additive of an embodiment of the present invention has two parts, which are used together to promote the rapid release of drugs from the device surface and the uptake of target tissues (by accelerating the contact of the drug with high affinity tissues) during deployment, while preventing the drug from being released prematurely from the device surface before the device is deployed at the target site.
[0173] In embodiments of the present invention, after the medical device is brought into contact with the tissue, the therapeutic agent is rapidly released and rapidly absorbed. For example, certain embodiments of the device of the present invention include a drug-coated balloon that delivers a lipophilic antiproliferative drug (such as paclitaxel or rapamycin) to non-vascular tissues by simple, direct pressure contact at high drug concentrations during balloon non-vascular body balloon expansion. The lipophilic drug, for example, is retained at the delivery site of the target tissue, where it inhibits hyperplasia and restenosis and also allows endothelial growth. In these embodiments, the coating formulation of the present invention not only promotes the rapid release of the drug from the balloon surface during deployment and transmits the drug to the target tissue, but also prevents the drug from diffusing out of the device during transportation through the curved anatomical structure before reaching the target site, and prevents the drug from bursting out of the device during the initial stage of balloon inflation before squeezing the drug coating to directly contact the surface of the body cavity.
[0174] The additive according to some embodiments has a drug-loving part and a hydrophilic part. The drug-loving part is a hydrophobic part, and / or has affinity for therapeutic agents through hydrogen bonding and / or van der Waals interactions. The drug-loving part can include aliphatic and aromatic organic hydrocarbon compounds, such as benzene, toluene and alkanes, etc. These parts are insoluble in water. They can all bind hydrophobic drugs (they share structural similarity with hydrophobic drugs) and lipids of cell membranes. The drug-loving part can include functional groups that can form hydrogen bonds with drugs and with themselves. The hydrophilic part can include hydroxyl groups, amine groups, amide groups, carbonyl groups, carboxylic acids and anhydrides, diethyl ether, ethyl glycol, polyethylene glycol, ascorbic acid, amino acids, amino alcohols, glucose, sucrose, sorbitan, glycerol, polyols, phosphates, sulfates, organic salts and molecules substituted therewith, etc. One or more hydroxyl groups, carboxyl groups, acids, amides or amine groups, for example, can be advantageous because they easily replace hydrogen to bind to water molecules of polar head groups and surface proteins of cell membranes, and can be used to remove this barrier between hydrophobic drugs and cell membrane lipids. These moieties are soluble in water and polar solvents.The additives of embodiments of the present invention have components that bind the drug and promote rapid movement of the drug out of the medical device during deployment and into the target tissue.
[0175] The additive in the embodiment of the present invention can be a surfactant and a chemical compound with one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide or ester moieties. Surfactants include ionic, nonionic, aliphatic and aromatic surfactants. The chemical compound with one or more hydroxyl, amino, carboxyl, acid, amide or ester moieties is selected from amino alcohols, hydroxycarboxylic acids and anhydrides, diethyl ether, ethyl glycol, amino acids, peptides, proteins, sugars, glucose, sucrose, sorbitan, glycerol, polyols, phosphates, sulfates, organic acids, esters, salts, vitamins and substituted molecules thereof.
[0176] As is well known in the art, the terms "hydrophilic" and "hydrophobic" are relative terms. For use as additives in accordance with exemplary embodiments of the present invention, compounds include a polar or charged hydrophilic portion and a non-polar hydrophobic (lipophilic) portion.
[0177] An empirical parameter commonly used in medicinal chemistry to characterize the relative hydrophilicity and hydrophobicity of a drug compound is the partition coefficient, P, i.e., the ratio of the concentrations of the unionized compound in the two phases of a mixture of two immiscible solvents (usually octanol and water), such that P = ([solute] octanol / [solute] water). The higher the log P, the more hydrophobic the compound, while the lower the log P, the more hydrophilic the compound. The Lipinski rule states that a drug compound with a log P < 5 may be more membrane permeable. For the purposes of certain embodiments of the present invention, for example, the additive has a log P that is less than the log P of the drug to be formulated (as an example, the log P of paclitaxel is 7.4). A greater difference in log P between the drug and the additive may facilitate phase separation of the drug. For example, if the log P of the additive is much lower than the log P of the drug, the additive may accelerate the release of the drug from the surface of the device to which the drug may otherwise be tightly adhered in an aqueous environment, thereby accelerating the delivery of the drug to the tissue during facile deployment at the intervention site. In certain embodiments of the present invention, the log P of the additive is negative. In other embodiments, the log P of the additive is less than the log P of the drug. While the octanol-water partition coefficient, P, or log P, of a compound can be used as a measure of relative hydrophilicity and hydrophobicity, it is only a rough criteria that may be useful in defining suitable additives for use in embodiments of the invention.
[0178] Suitable additives that can be used in embodiments of the present invention include, but are not limited to, organic and inorganic pharmaceutical excipients, natural products and derivatives thereof (such as sugars, vitamins, amino acids, peptides, proteins and fatty acids), low molecular weight oligomers, surfactants (anions, cations, nonionics and ionics) and mixtures thereof. The additives described herein that can be used in the present invention are provided only for exemplary purposes and are not intended to be comprehensive. Many other additives can be used for purposes of the present invention.
[0179] Surfactants.
[0180] Surfactant can be any surfactant suitable for pharmaceutical composition.Such surfactant can be anionic, cationic, zwitterionic or nonionic.Mixture of surfactant is also within the scope of various embodiments of the present invention, and the combination of surfactant and other additives is also within the scope of various embodiments of the present invention.Surfactant often has one or more long aliphatic chains, such as fatty acid, which can be directly inserted into the lipid bilayer of cell membrane to form part of lipid structure, while other components of surfactant loosen lipid structure and enhance drug penetration and absorption.Contrast agent iopromide does not have these characteristics.
[0181] An empirical parameter often used to characterize the relative hydrophilicity and hydrophobicity of surfactants is the hydrophilic-lipophilic balance ("HLB" value). Surfactants with lower HLB values are more hydrophobic and have greater solubility in oils, while surfactants with higher HLB values are more hydrophilic and have greater solubility in aqueous solutions. Using the HLB value as a rough standard, hydrophilic surfactants are generally considered to be those compounds with an HLB value greater than about 10, as well as anionic, cationic, or zwitterionic compounds for which the HLB measurement is generally not applicable. Similarly, hydrophobic surfactants are compounds with an HLB value less than about 10. In certain embodiments of the present invention, higher HLB values are used because increased hydrophilicity can promote the release of hydrophobic drugs from the device surface. In one embodiment, the HLB of the surfactant additive is greater than 10. The additive HLB can be greater than 14. Alternatively, surfactants with lower HLBs can be used to prevent drug loss prior to device deployment at the target site, for example, in a top layer over a drug layer with a very hydrophilic additive.
[0182] The HLB value of a surfactant is only a rough standard that is generally used to achieve, for example, the preparation of industrial, pharmaceutical and cosmetic emulsions. For many important surfactants, including several polyethoxylated surfactants, it has been reported that the HLB values can vary by up to about 8 HLB units, depending on the empirical method chosen to determine the HLB value (Schott, J. Pharm. Sciences, 79 (1), 87-88 (1990)). Keeping these inherent difficulties in mind and using the HLB value as a standard, as described herein, surfactants having suitable hydrophilicity or hydrophobicity for use in embodiments of the present invention as described herein can be identified.
[0183] PEG-fatty acids and PEG-fatty acid mono- and diesters.
[0184] The present invention relates to the invention of the present invention. The present invention relates to the invention of the present invention. The present invention relates to the invention of the present invention. The present invention relates to the present invention of the present invention. The present invention relates to the present invention of the present invention. The present invention relates to the present invention of the present invention. The present invention relates to the present invention of the present invention. The present invention relates to the present invention of the present invention. The present invention relates to the present invention of the present invention. The present invention relates to the present invention of the present invention. The present invention relates to the present invention of the present invention. The present invention relates to the present invention of the present invention. The present invention relates to the present invention of the present invention. The present invention relates to the present invention of the present invention. The present invention relates to the present invention of the present invention. The present invention relates to the present invention of the present invention. The present invention relates to the present invention of the present invention. The present invention relates to the present invention of the present invention. The present invention relates to the present invention of the present invention.
[0185] Polyethylene glycol fatty acid diesters are also suitable for use as surfactants in the compositions of embodiments of the present invention. Hydrophilic surfactants include PEG-20 dilaurate, PEG-20 dioleate, PEG-20 distearate, PEG-32 dilaurate, and PEG-32 dioleate. HLB values are in the range of 5-15.
[0186] In general, mixtures of surfactants may also be used in embodiments of the present invention, including mixtures of two or more commercial surfactants and mixtures of a surfactant with another additive or additives.Several PEG-fatty acid esters are commercially available as mixtures or monoesters and diesters.
[0187] Polyethylene glycol glycerides fatty acid esters.
[0188] The hydrophilic surfactant may include PEG-20 glyceryl laurate, PEG-30 glyceryl laurate, PEG-40 glyceryl laurate, PEG-20 glyceryl oleate, and PEG-30 glyceryl oleate.
[0189] Alcohol-oil transesterification products.
[0190] Many surfactants with different hydrophobic and hydrophilic degrees can be prepared by the reaction of alcohol or polyol with various natural and / or hydrogenated oils. Most usually, the oil used is castor oil or hydrogenated castor oil, or edible vegetable oil, such as corn oil, olive oil, peanut oil, palm kernel oil, apricot kernel oil or almond oil. Alcohol comprises glycerine, propylene glycol, ethylene glycol, polyethylene glycol, sorbitol and pentaerythritol. Among the surfactants of these alcohol-oil transesterifications, hydrophilic surfactant is PEG-35 castor oil (Incrocas-35), PEG-40 hydrogenated castor oil (Cremophor RH40), PEG-25 trioleate (TAGAT.R TM .TO), PEG-60 corn glycerides (Crovol M70), PEG-60 almond oil (Crovol A70), PEG-40 palm kernel oil (Crovol PK70), PEG-50 castor oil (Emalex C-50), PEG-50 hydrogenated castor oil (Emalex HC-50), PEG-8 caprylic / capric glycerides (Labrasol), and PEG-6 caprylic / capric glycerides (Softigen 767). For example, hydrophobic surfactants belonging to this category include PEG-5 hydrogenated castor oil, PEG-7 hydrogenated castor oil, PEG-9 hydrogenated castor oil, PEG-6 corn oil (Labrafil TM M 2125CS), PEG-6 almond oil (Labrafil TMM1966CS), PEG-6 apricot kernel oil (Labrafil TM M 1944CS), PEG-6 olive oil (Labrafil TM M 1980 CS), PEG-6 peanut oil (Labrafil TM M 1969CS), PEG-6 hydrogenated palm kernel oil (Labrafil TM M 2130 BS), PEG-6 palm kernel oil (Labrafil TM M 2130 CS), PEG-6 trioleylglycerol (Labrafil TM b M 2735CS), PEG-8 corn oil (Labrafil TM WL 2609BS), PEG-20 corn glycerides (Crovol M40) and PEG-20 almond glycerides (Crovol A40).
[0191] Polyglycerol fatty acids.
[0192] The polyglycerol esters of fatty acids are also suitable surfactants for embodiments of the present invention. Among the polyglycerol fatty acid esters, hydrophobic surfactants include polyglycerol oleate (Plurol Oleique), polyglycerol-2 dioleate (Nikkol DGDO), polyglycerol-10 trioleate, polyglycerol stearate, polyglycerol laurate, polyglycerol myristate, polyglycerol palmitate and polyglycerol linoleate. Hydrophilic surfactants include polyglycerol-10 laurate (Nikkol Decaglyn 1-L), polyglycerol-10 oleate (Nikkol Decaglyn 1-O) and polyglycerol-10 mono / dioleate (CaproI TM PEG 860), polyglyceryl-10 stearate, polyglyceryl-10 laurate, polyglyceryl-10 myristate, polyglyceryl-10 palmitate, polyglyceryl-10 linoleate, polyglyceryl-6 stearate, polyglyceryl-6 laurate, polyglyceryl-6 myristate, polyglyceryl-6 palmitate and polyglyceryl-6 linoleate. Polyglyceryl polyricinoleate (Polymuls) is also a surfactant.
[0193] Propylene glycol fatty acid esters.
[0194] Esters of propylene glycol and fatty acids are suitable surfactants for use in embodiments of the present invention. In this class of surfactants, hydrophobic surfactants include propylene glycol monolaurate (Lauroglycol FCC), propylene glycol ricinoleate (Propymuls), propylene glycol monooleate (Myverol P-06), propylene glycol dicaprylate / dicaprate (Captex TM 200) and propylene glycol dicaprylate (Captex TM 800).
[0195] Sterols and sterol derivatives.
[0196] Sterols and derivatives of sterols are suitable surfactants for use in embodiments of the present invention. Derivatives include polyethylene glycol derivatives. A surfactant belonging to this class is PEG-24 cholesterol ether (Solulan C-24).
[0197] Polyethylene glycol sorbitan fatty acid esters.
[0198] Various PEG-sorbitan fatty acid esters are available and suitable for use as surfactants in embodiments of the present invention. Among the PEG-sorbitan fatty acid esters, surfactants include PEG-20 sorbitan monolaurate (Tween-20), PEG-20 sorbitan monopalmitate (Tween-40), PEG-20 sorbitan monostearate (Tween-60). PEG-20 sorbitan monooleate (Tween-80). In some embodiments, laurates are used because they have short lipid chains compared to oleates, thereby improving drug absorption.
[0199] Polyethylene glycol alkyl ether.
[0200] Esters of polyethylene glycol and alkyl alcohols are suitable surfactants for use in embodiments of the present invention. Ethers include PEG-3 oleyl ether (Volpo 3) and PEG-4 lauryl ether (Brij 30).
[0201] Sugar and its derivatives.
[0202] Sugar derivatives are suitable surfactants for embodiments of the present invention. Surfactants belonging to this category include sucrose monopalmitate, sucrose monolaurate, decanoyl-N-methylglucamide, n-decyl-β-D-pyranoglucoside, n-decyl-β-D-maltopyranoside, n-dodecyl-β-D-pyranoglucoside, n-dodecyl-β-D-maltoside, heptanoyl-N-methylglucamide, n-heptyl-β-D-pyranoglucoside, n-heptyl-β-D-thioglucoside, n-hexyl-β-D-pyranoglucoside, nonanoyl-N-methylglucamide, n-nonyl-β-D-pyranoglucoside, octanoyl-N-methylglucamide, n-octyl-β-D-pyranoglucoside and octyl-β-D-thioglucoside.
[0203] Polyethylene glycol alkylphenol.
[0204] Several PEG-alkylphenol surfactants are available, such as PEG-10-100 nonylphenol and PEG-15-100 octylphenol ether, Tyloxapol, octoxynol, octoxynol-9, nonoxynol ether, and are suitable for use in embodiments of the present invention.
[0205] Polyoxyethylene-polyoxypropylene (POE-POP) block copolymer.
[0206] POE-POP block copolymers are a unique class of polymeric surfactants. The unique structure of the surfactant, in which the hydrophilic POE and hydrophobic POP portions are in well-defined ratios and positions, provides a wide variety of surfactants suitable for use in embodiments of the present invention. These surfactants are available under various trade names, including Synperonic PE series (ICI), Pluronic TM series (BASF), Emkalyx, Lutrol (BASF), Supronic, Monolan, Pluracare and Plurodac. The generic term for these polymers is "poloxamer" (CAS 9003-11-6). These polymers have the following formula: HO(C2H4O) a (C3H6O) b (C2H4O) a H, wherein "a" and "b" represent the number of polyoxyethylene and polypropylene units, respectively.
[0207] This class of hydrophilic surfactants includes Poloxamer 108, 188, 217, 238, 288, 338 and 407. Hydrophobic surfactants belonging to this class include Poloxamer 124, 182, 183, 212, 331 and 335.
[0208] Sorbitan fatty acid esters.
[0209] Sorbitan esters of fatty acids are suitable surfactants for use in embodiments of the present invention. Among these esters, hydrophobic surfactants include sorbitan monolaurate (Arlacel 20), sorbitan monopalmitate (Span-40) and sorbitan monooleate (Span-80), sorbitan monostearate.
[0210] Sorbitan monopalmitate, an amphipathic derivative of vitamin C (which has vitamin C activity) can play two important functions in a solubilizing system. First, it has an effective polar group that can adjust the microenvironment. These polar groups are the same groups that make vitamin C itself (ascorbic acid) become one of the most water-soluble organic solid compounds available: ascorbic acid can be dissolved in water at about 30wt / wt% (very close to the solubility of, for example, sodium chloride). Secondly, increase pH so that a portion of ascorbyl palmitate is converted into a more soluble salt, such as sodium ascorbyl palmitate.
[0211] Ionic surfactants.
[0212] Ionic surfactants (including cations, anions and zwitterionic surfactants) are suitable hydrophilic surfactants for embodiments of the present invention. Ionic surfactants include quaternary ammonium salts, fatty acid salts and bile salts. Specifically, ionic surfactants include benzalkonium chloride, benzethonium chloride, cetylpyridinium chloride, dodecyltrimethylammonium bromide, sodium lauryl sulfate, dialkylmethylbenzyl ammonium chloride, ediroxyl chloride, dofenthion bromide, dialkyl esters of sodium sulfosuccinate, dioctyl sodium sulfosuccinate, sodium cholate and sodium taurocholate. They can all be dissolved in organic solvents (such as ethanol, acetone and toluene) and water. This is particularly useful for medical device coatings because it simplifies preparation and coating processes and has good adhesion properties. Water-insoluble drugs are often dissolved in organic solvents.
[0213] Some surfactants described herein are extremely stable under heating. They still exist after the ethylene oxide sterilization process. They do not react with drugs (such as paclitaxel or rapamycin) during the sterilization process. Hydroxyl, ester, amino groups are used because they are unlikely to react with drugs, while amine and acidic groups often react with paclitaxel or rapamycin during sterilization. In addition, surfactant additives improve the integrity and quality of the coating so that the particles will not fall off during processing. When the surfactant described herein is formulated with paclitaxel, it is empirically protected from premature release of the drug during the device delivery process, while promoting rapid release and elution of paclitaxel at the target site during a very brief deployment time of 0.2 to 10 minutes. According to experience, drug absorption at the tissue target site is unexpectedly high. Having one or more hydroxyl groups, A chemical compound having an amino, carboxyl, acid, amide, or ester moiety.
[0214] Chemical compounds having one or more hydroxyl, amino, carboxyl, acid, amide or ester moieties include creatine, creatinine, agmatine, citrulline, guanidine, sucralose, aspartame, hypoxanthine, theobromine, theophylline, adenine, uracil, uridine, guanine, thymine, thymidine, xanthine, xanthine nucleoside, xanthine nucleoside monophosphate, caffeine, allantoin, (2-hydroxyethyl) urea, N,N'-bis(hydroxymethyl) urea, pentaerythritol ethoxylate, pentaerythritol propoxylate, pentaerythritol propoxylate / ethoxylate, glycerol ethoxylate, glycerol propoxylate, ethoxylated trimethylolpropane, pentaerythritol alcohol, dipentaerythritol, crown ethers, 18-crown-6, 15-crown-5, 12-crown-4, N-acetylglucosamine, n-octyl-D-glucosamide, C6-ceramide, dihydro-C6-ceramide, cerebrosides, sphingomyelins, galactocerebrosides, lactocerebrosides, N-acetyl-D-sphingosine, N-hexanoyl-D-sphingosine, N-capryl-D-sphingosine, N-lauroyl-D-sphingosine, N-palmitoyl-D-sphingosine, N-oleoyl-D-sphingosine, PEG caprylic / capric diglyceride, PEG 8 caprylic / capric glyceride, PEG caprylate, PEG 8 caprylate (e.g., ), PEG caprate, PEG caproate, glyceryl monocaprylate, glyceryl monocaprate, glyceryl monocaproate, glyceryl monolaurate, glyceryl monocaprate, glyceryl monolaurate, glyceryl monomyristate, glyceryl monopalmitoleate, and glyceryl monooleate.
[0215] Chemical compounds with one or more hydroxyl, amino, carboxyl, acid, amide or ester moieties include amino alcohols, hydroxycarboxylic acids, esters, anhydrides, hydroxyketones, hydroxylactones, hydroxyesters, sugar phosphates, sugar phosphates, sugar sulfates, diethyl ether, ethyl glycol, amino acids, peptides, proteins, sorbitan, glycerol, polyols, phosphates, sulfates, organic acids, esters, salts, vitamins, combinations of amino alcohols and organic acids, and substituted molecules thereof. Hydrophilic chemical compounds with one or more hydroxyl, amino, carboxyl, acid, amide or ester moieties and a molecular weight of less than 5,000-10,000 are used in certain embodiments. In other embodiments, the molecular weight of the additive with one or more hydroxyl, amino, carboxyl, acid, amide or ester moieties is less than 1000-5,000 or less than 750-1,000 or less than 750. In these embodiments, the molecular weight of the additive is less than the drug to be delivered. In addition, the molecular weight of the additive is higher than 80 because molecules with a molecular weight of less than 80 are extremely volatile and do not remain in the coating of the medical device. Small molecules can diffuse rapidly. They can easily release themselves from the delivery balloon, thereby accelerating drug release, and they can diffuse away from the drug as it binds to tissues in the body cavity.
[0216] In certain embodiments, additives with more than four hydroxyl groups are used, for example, in the case of high molecular weight additives. Macromolecules diffuse slowly. If the molecular weight of the additive or chemical compound is high, for example, if the molecular weight is higher than 800, higher than 1000, higher than 1200, higher than 1500 or higher than 2000, the macromolecules can be eluted from the surface of the medical device quite slowly to release the drug within 2 minutes. If these macromolecules contain more than four hydroxyl groups, they have increased hydrophilic properties, which is necessary for relatively large molecules to release drugs quickly. Increased hydrophilicity helps the coating to elute from the balloon, accelerates the release of the drug, and improves or promotes the movement of the drug through the water barrier and the polar head group of the lipid bilayer to penetrate the tissue. In one embodiment, hydroxyl groups are used as hydrophilic parts because it is impossible to react with water-insoluble drugs (such as paclitaxel or rapamycin). In some embodiments, compounds with more than four hydroxyl groups have a melting point of 120°C or less. In some embodiments, the chemical compound with more than four hydroxyl groups has three adjacent hydroxyl groups, and these three adjacent hydroxyl groups are all on the same side of the molecule in the stereo configuration. For example, sorbitol and xylitol have three adjacent hydroxyl groups that are all on the same side of the molecule in the stereo configuration, while galactitol does not. This difference affects the physical properties of the isomer, such as melting temperature. The stereo configuration of three adjacent hydroxyl groups can enhance drug binding. This will cause water-insoluble drugs and hydrophilic additive compatibility to increase, and improved tissue uptake and absorption of the drug.
[0217] As described herein, some chemical compounds with one or more hydroxyl, amine, carbonyl, carboxyl or ester moieties are extremely stable under heating. They still exist after the ethylene oxide sterilization process and do not react with the water-insoluble drugs paclitaxel or rapamycin during sterilization. On the other hand, L-ascorbic acid and its salts and diethanolamine do not necessarily exist after the sterilization process, and they react with paclitaxel. Therefore, different sterilization methods are used for L-ascorbic acid and diethanolamine. For example, hydroxyl, ester and amide groups are used because they are unlikely to react with therapeutic agents (such as paclitaxel or rapamycin). Sometimes, amines and acidic groups do react with paclitaxel, for example, experimentally, benzoic acid, gentisic acid, diethanolamine and ascorbic acid are unstable under ethylene oxide sterilization, heating and aging processes, and react with paclitaxel. When the compounds described herein are formulated with paclitaxel, a top coating may be advantageous to prevent premature loss of drugs during the device delivery process before deployment at the target site, because hydrophilic small molecules sometimes release drugs too easily. The chemical compounds herein rapidly elute the drug from the balloon during deployment at the target site. Surprisingly, when the coating contains these additives, although some drug is lost during transport from the device to the target site, based on experience, the drug uptake by the tissue is unexpectedly high after only 0.2-10 minutes of deployment, for example, with additive hydroxylactones such as ribonolactone and gluconolactone.
[0218] Fat-soluble vitamins and their salts.
[0219] Vitamins A, D, E and K, many of their various forms as well as the provitamin forms are considered fat-soluble vitamins, and in addition to these, several other vitamins and vitamin sources or close relatives are also fat-soluble and have polar groups and relatively high octanol-water partition coefficients. Clearly, compounds of this general class have a history of safe use and a high efficacy / risk ratio, making them useful as additives in embodiments of the present invention.
[0220] The following examples of fat-soluble vitamin derivatives and / or sources can also be used as additives: alpha-tocopherol, beta-tocopherol, gamma-tocopherol, delta-tocopherol, tocopherol acetate, ergosterol, 1-alpha-hydroxycholecalciferol, vitamin D2, vitamin D3, alpha-carotene, beta-carotene, gamma-carotene, vitamin A, fursultiamine, hydroxymethylriboflavin, octylthiamine, propylthiamine, riboflavin, benzoylethylenethiamine, dihydrovitamin K1, dihydronaphthoquinone diacetate, naphthoquinone dibutyrate, naphthoquinone disulfate, naphthoquinone, vitamin K1, vitamin K1 oxide, vitamin K2 and vitamin K--S (II). Folic acid is also of this type, and although it is soluble in water at physiological pH, it can be formulated in free acid form. Other derivatives of fat-soluble vitamins that can be used in embodiments of the present invention can be easily obtained by well-known chemical reactions with hydrophilic molecules.
[0221] Water-soluble vitamins and their amphiphilic derivatives.
[0222] Many of their various forms of vitamin B, C, U, pantothenic acid, folic acid and some menadione-related vitamins / provitamins are considered to be water-soluble vitamins. These can also be conjugated or compounded with hydrophobic parts or multivalent ions to form amphiphilic forms with relatively high octanol-water partition coefficients and polar groups. Again, such compounds can have low toxicity and high efficiency / risk ratio, so that they can be used as additives in embodiments of the present invention. The salts of these compounds can also be used as additives in the present invention. Examples of water-soluble vitamins and derivatives include but are not limited to acetylthiamine, benfotiamine, pantothenic acid, cimetropium, cyclothiamine, dexpanthenol, nicotinamide, nicotinic acid, 5-pyridoxal phosphate, ascorbic acid nicotinamide, riboflavin, riboflavin phosphate, thiamine, folic acid, naphthalene diphosphate, sodium menadione bisulfite, naphthalene, vitamin B12, vitamin K5, vitamin K6, vitamin K6 and vitamin U. In addition, as mentioned above, folic acid is soluble in water as a salt in a wide pH range including physiological pH.
[0223] Compounds in which there is an amino group or other basic groups can be easily modified by a simple acid-base reaction with an acid containing a hydrophobic group, such as a fatty acid (especially lauric acid, oleic acid, myristic acid, palmitic acid, stearic acid or 2-ethylhexanoic acid), a low-solubility amino acid, benzoic acid, salicylic acid or an acidic fat-soluble vitamin (such as riboflavin). Other compounds can be obtained by reacting another group (such as a hydroxyl group) on such an acid with a vitamin to form a bond (such as an ester bond, etc.). The derivative of the water-soluble vitamin containing an acidic group can be generated in a reaction with a reactant (such as stearylamine or riboflavin) containing a hydrophobic group, such as to produce a compound that can be used in embodiments of the present invention. The connection of a palmitate chain to vitamin C produces ascorbyl palmitate.
[0224] Amino acids and their salts.
[0225] Alanine, arginine, asparagine, aspartic acid, cysteine, cystine, glutamic acid, glutamine, glycine, histidine, proline, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine, and derivatives thereof are other useful additives in embodiments of the present invention.
[0226] Certain amino acids (in their zwitterionic form and / or in salt form with monovalent or multivalent ions) have polar groups, relatively high octanol-water partition coefficients, and can be used in embodiments of the present invention. In the context of this disclosure, we use "low solubility amino acids" to mean amino acids that have a solubility of less than about 4% (40 mg / ml) in unbuffered water. These include cystine, tyrosine, tryptophan, leucine, isoleucine, phenylalanine, asparagine, aspartic acid, glutamic acid, and methionine.
[0227] Amino acid dimers, glycoconjugates and other derivatives are also useful. Hydrophilic molecules can be linked to hydrophobic amino acids, or hydrophobic molecules to hydrophilic amino acids, by simple reactions well known in the art, so that additional additives can be used in embodiments of the present invention.
[0228] Catecholamines such as dopamine, levodopa, carbidopa and DOPA may also be used as additives.
[0229] Oligopeptides, peptides and proteins.
[0230] Oligopeptides and peptides can be used as additives because hydrophobic and hydrophilic amino acids can be easily coupled, and various sequences of amino acids can be tested to maximize drug penetration into tissues.
[0231] Proteins can also be used as additives in embodiments of the present invention. For example, serum albumin is a useful additive because it is soluble in water and contains an important hydrophobic portion that binds the drug: paclitaxel is 89% to 98% bound to protein after intravenous infusion in humans, and rapamycin is 92% bound to protein, primarily (97%) bound to albumin. In addition, the solubility of paclitaxel in PBS increases more than 20-fold with the addition of BSA. Albumin is naturally present in serum at high concentrations and is therefore very safe for human use.
[0232] Other useful proteins include, but are not limited to, other albumins, immunoglobulins, caseins, hemoglobin, lysozyme, immunoglobulins, alpha-2-macroglobulin, fibronectin, vitronectin, fibrinogen, lipase, and the like.
[0233] Organic acids and their esters and anhydrides.
[0234] Examples include acetic acid and anhydride, benzoic acid and anhydride, diethylenetriaminepentaacetic dianhydride, ethylenediaminetetraacetic dianhydride, maleic acid and anhydride, succinic acid and anhydride, diglycolic anhydride, glutaric anhydride, ascorbic acid, citric acid, tartaric acid, lactic acid, oxalic acid, aspartic acid, nicotinic acid, 2-pyrrolidone-5-carboxylic acid, and 2-pyrrolidone.
[0235] These esters and anhydrides are soluble in organic solvents such as ethanol, acetone, methyl ethyl ketone, ethyl acetate. Water-soluble drugs can be dissolved in organic solvents with these esters and anhydrides, then easily coated on medical devices, and then hydrolyzed under high pH conditions. The hydrolyzed anhydride or ester is an acid or alcohol that is soluble in water and can effectively carry the drug from the device to the wall of the body cavity.
[0236] Other compounds having one or more hydroxyl, amine, carbonyl, carboxyl or ester moieties.
[0237] Additives according to embodiments include amino alcohols, alcohols, amines, acids, amides, and hydroxy acids in the form of cyclic and linear aliphatic and aromatic groups. Examples are L-ascorbic acid and its salts, D-glucosaccharoascorbic acid and its salts, tromethamine, triethanolamine, diethanolamine, meglumine, glucosamine, amino alcohols, glucoheptonic acid, gluconic acid, hydroxyketones, hydroxylactones, gluconolactone, gluceptolactone, glucocinolactone, gulonic acid lactone, mannolactone, ribonolactone, lactobionic acid, glucosamine, glutamic acid, benzyl alcohol, benzoic acid, hydroxybenzoic acid, propyl 4-hydroxybenzoate, lysine acetate, gentisic acid, lactobionic acid, lactitol, sorbitol, glucitol, sugar phosphates, pyranose glucose phosphates, sugar sulfates, sinapinic acid, vanillic acid diacetylamide, vanillin, methylparaben, propylparaben, xylitol, 2-ethoxyethanol, sugars, galactose, glucose, ribose, mannose, xylose, sucrose, lactose, Maltose, arabinose, lyxose, fructose, cyclodextrin, (2-hydroxypropyl)-cyclodextrin, acetaminophen, ibuprofen, retinoic acid, lysine acetate, gentisic acid, catechin, catechin gallate, tiletamine, ketamine, propofol, lactic acid, acetic acid, salts of any organic acid and amine described herein, polyglycidol, glycerol, polyglycerol (e.g., a chemical compound having multiple hydroxyl, amino, carbonyl, carboxyl or ester moieties), galactitol, di(ethylene glycol), tri(ethylene glycol), tetra(ethylene glycol), penta(ethylene glycol), poly(ethylene glycol) oligomers, di(propylene glycol), tri(propylene glycol), tetra(propylene glycol) and penta(propylene glycol), poly(propylene glycol) oligomers, block copolymers of polyethylene glycol and polypropylene glycol, and derivatives and combinations thereof.
[0238] Combinations of additives may also be used for the purposes of the present invention. One embodiment includes a combination or mixture of two additives, for example, a first additive comprising a surfactant and a second additive comprising a chemical compound having one or more hydroxyl, amine, carbonyl, carboxyl or ester moieties.
[0239] The combination or mixture of surfactant and water-soluble small molecule (chemical compound with one or more hydroxyl, amine, carbonyl, carboxyl or ester moiety) has advantages. The preparation comprising a mixture of two additives and water-insoluble drugs is superior to the mixture comprising only any one additive in some cases. It is more difficult for hydrophobic drugs to bind highly water-soluble small molecules than for them to bind surfactants. The hydrophobic drug is often phase-separated from the water-soluble small molecule, which may lead to suboptimal coating uniformity and integrity. The Log P that water-insoluble drugs have is higher than both surfactants and water-soluble small molecules. However, the Log P of surfactants is typically higher than the Log P of chemical compounds with one or more hydroxyl, amine, carbonyl, carboxyl or ester moieties. The surfactant has a relatively high Log P (generally higher than 0), and water-soluble molecules have a low Log P (e.g., lower than 0). Some surfactants are so strongly adhered to the surface of water-soluble drugs and medical devices when used as additives in embodiments of the present invention that the drug cannot be quickly released from the surface of the medical device at the target site. On the other hand, some of the water-soluble small molecules (having one or more hydroxyl, amine, carbonyl, carboxyl or ester moieties) adhere so weakly to the medical device that during the delivery of the coated balloon catheter to the targeted site for intervention, they release the drug before the medical device reaches the target site, such as entering the serum. Surprisingly, by adjusting the concentration ratio of the hydrophilic small molecules and the surfactant in the preparation, the inventors have found that during the delivery period and during the rapid drug release period when the balloon catheter is inflated and the tissue of the lumen wall at the target site of the therapeutic intervention is squeezed, the coating stability is better than the preparation containing only any one additive in some cases. In addition, the presence of the surfactant improves the miscibility and compatibility of water-insoluble drugs and highly water-soluble molecules. The surfactant also improves the coating uniformity and integrity by its good adhesion to drugs and small molecules. The long-chain hydrophobic part of the surfactant is tightly bound to the drug, while the hydrophilic part of the surfactant is bound to the water-soluble small molecules.
[0240] The surfactant in the mixture or combination includes all surfactants described herein for embodiments of the present invention. The surfactant in the mixture can be selected from PEG sorbitan fatty acid esters; PEG omega-3 fatty acid esters, ethers and alcohols; glycerol fatty acid esters, sorbitan fatty acid esters, PEG glycerol fatty acid esters, PEG fatty acid esters and alcohols, sugar fatty acid esters, PEG sugar esters, Tween 20, Tween 40, Tween 60, p-isononylphenoxy polyglycidol, PEG laurate, PEG oleate, PEG stearate, PEG glyceryl laurate, PEG glyceryl oleate, PEG glyceryl stearate, polyglyceryl laurate, polyglyceryl oleate, polyglyceryl myristate, polyglyceryl palmitate, polyglyceryl-6 laurate, polyglyceryl-6 oleate, polyglyceryl-6 myristate, polyglyceryl-6 palmitate, polyglyceryl-10 laurate, polyglyceryl-10 oleate, polyglyceryl-10 myristate, polyglyceryl-10 palmitate, PEG sorbitan monolaurate, PEG sorbitan monolaurate, PEG sorbitan monolaurate, PEG sorbitan monooleate, PEG sorbitan stearate, PEG oleyl ether, PEG lauryl ether, Tween 20, Tween 40, Tween 60, Tween 80, octoxynol, octoxynol-9, nonoxynol ether, tyloxapol, sucrose monopalmitate, sucrose monolaurate, decanoyl-N-methylglucamide, n-decyl-β-D-pyranoglucoside, n-decyl-β-D-maltopyranoside, n-dodecyl- β-D-pyranoglucoside, n-dodecyl-β-D-maltoside, heptyl-N-methylglucamide, n-heptyl-β-D-pyranoglucoside, n-heptyl-β-D-thioglucoside, n-hexyl-β-D-pyranoglucoside, nonanoyl-N-methylglucamide, n-nonyl-β-D-pyranoglucoside, octanoyl-N-methylglucamide, n-octyl-β-D-pyranoglucoside, octyl-β-D-thioglucoside and their derivatives.
[0241] Embodiments of chemical compounds having one or more hydroxyl, amine, carbonyl, carboxyl or ester moieties in a mixture or combination may include any chemical compound having one or more hydroxyl, amine, carbonyl, carboxyl or ester moieties described herein for embodiments of the present invention. In various embodiments, the chemical compound having one or more hydroxyl, amine, carbonyl, carboxyl or ester moieties in a mixture has at least one hydroxyl group. In certain embodiments, additives having more than four hydroxyl groups are used, such as in the case of high molecular weight additives. In some embodiments, compounds having more than four hydroxyl groups have a melting point of 120° C. or less. Macromolecules diffuse slowly. If the molecular weight of the additive or chemical compound is high, for example, if the molecular weight is higher than 800, higher than 1000, higher than 1200, higher than 1500 or higher than 2000, then the macromolecule can be eluted from the surface of the medical device quite slowly to release the drug within 2 minutes. If these macromolecules contain more than four hydroxyl groups, then they have an increased hydrophilic property, which is necessary for relatively large molecules to release drugs rapidly. Increased hydrophilicity aids in elution of the coating from the balloon, accelerates drug release, and improves or facilitates drug mobility across the water barrier and penetration of the polar head group of the lipid bilayer into tissue. In one embodiment, a hydroxyl group is used as the hydrophilic moiety because it is unlikely to react with water-insoluble drugs such as paclitaxel or rapamycin.
[0242] The chemical compound having one or more hydroxyl, amine, carbonyl, carboxyl or ester moieties in the mixture is selected from L-ascorbic acid and its salts, D-glucosaccharoascorbic acid and its salts, tromethamine, triethanolamine, diethanolamine, meglumine, glucosamine, amino alcohol, glucoheptonic acid, gluconic acid, hydroxyketone, hydroxylactone, gluconolactone, glucoheptonic acid lactone, glucocinolide, gulonic acid lactone, mannolactone, ribonic acid lactone, lactobionic acid, glucosamine, glutamic acid, benzyl alcohol, benzoic acid, hydroxybenzoic acid, 4-hydroxybenzoic acid propyl ester, lysine acetate, gentisic acid, lactobionic acid, lactobionic acid, Sugar alcohol, sorbitol, glucitol, sugar phosphate, pyranose glucose phosphate, sugar sulfate, sinapinic acid, vanillic acid, vanillin, methyl paraben, propyl paraben, xylitol, 2-ethoxyethanol, sugar, galactose, glucose, ribose, mannose, xylose, sucrose, lactose, maltose, arabinose, lyxose, fructose, cyclodextrin, (2-hydroxypropyl)-cyclodextrin, acetaminophen, ibuprofen, retinoic acid, lysine acetate, gentisic acid, catechin, catechin gallate, tiletamine, ketamine, propofol, lactic acid, acetic acid, any of the above Salts of organic acids and amines, polyglycidol, glycerol, polyglycerol, galactitol, glyceryl monolaurate, glyceryl monocaprate, glyceryl monolaurate, glyceryl monomyristate, glyceryl monopalmitoleate, glyceryl monooleate, creatine, creatinine, agmatine, citrulline, guanidine, sucralose, aspartame, hypoxanthine, theobromine, theophylline, adenine, uracil, uridine, guanine, thymine, thymidine, xanthine, xanthine nucleoside, xanthine nucleoside monophosphate, caffeine, allantoin, (2-hydroxyethyl) urea, N,N'-bis(hydroxymethyl) urea, pentaerythritol ethoxylate The invention also includes but is not limited to propylene glycol, propylene glycol, propylene glycol, propylene glycol and propylene glycol. The invention also includes but is not limited to propylene glycol, propylene glycol, propylene glycol and propylene glycol. The invention also includes but is not limited to propylene glycol, propylene glycol, propylene glycol and propylene glycol.
[0243] A mixture or combination of surfactants and water-soluble small molecules gives the advantages of both additives. Water-insoluble drugs often have poor compatibility with highly water-soluble chemical compounds, and surfactants improve compatibility. Surfactants also improve coating quality, uniformity, and integrity, and particles do not fall off the balloon during handling. Surfactants reduce drug losses during delivery to the target site. Water-soluble chemical compounds improve the release of drugs from the balloon, as well as drug absorption by tissues. Experimentally, the combination is unexpectedly effective in preventing drug release during delivery and achieving high drug levels in tissues after a very brief 0.2 to 2 minute deployment. In addition, in animal studies, the combination is effective in reducing stenosis and late lumen loss.
[0244] Some of the mixtures or combinations of surfactants and water-soluble small molecules are very stable when heated. They still exist after the ethylene oxide sterilization process and do not react with the water-soluble drugs paclitaxel or rapamycin during sterilization. In one embodiment, hydroxyl, ester, amide groups are used because they are unlikely to react with therapeutic agents (such as paclitaxel or rapamycin). Sometimes, amine and acidic groups do react with paclitaxel and are unstable during ethylene oxide sterilization, heating and aging. When the mixture or combination described herein is formulated with paclitaxel, a top coating may be advantageous to protect the drug layer and prevent premature drug loss during the device.
[0245] Examples of the additive include p-isononylphenoxy polyglycidol, PEG glycerol oleate, PEG glycerol stearate, polyglycerol laurate, polyglycerol oleate, polyglycerol myristate, polyglycerol palmitate, polyglycerol-6 laurate, polyglycerol-6 oleate, polyglycerol-6 myristate, polyglycerol-6 palmitate, polyglycerol-10 laurate, polyglycerol-10 oleate, polyglycerol-10 myristate, polyglycerol-10 palmitate, PEG sorbitan monolaurate, PEG sorbitan monolaurate, PEG sorbitan monooleate, PEG sorbitan stearate, octoxynol, octoxynol-9, nonoxynol ether, tyloxapol, sucrose monopalmitate, sucrose monolaurate, decanoyl-N-methylglucamide, n-decyl-β-D-glucopyranoside, n-decyl-β-D-maltopyranoside, n-dodecyl-β-D-glucopyranoside , n-dodecyl-β-D-maltoside, heptyl-N-methylglucamide, n-heptyl-β-D-pyranoglucoside, n-heptyl-β-D-thioglucoside, n-hexyl-β-D-pyranoglucoside, nonanoyl-N-methylglucamide, n-nonyl-β-D-pyranoglucoside, octanoyl-N-methylglucamide, n-octyl-β-D-pyranoglucoside, octyl-β-D-thioglucoside; cystine, tyrosine, tryptophan, Leucine, isoleucine, phenylalanine, asparagine, aspartic acid, glutamic acid and methionine (amino acids), cimetropium, cyclothionine, dexpanthenol, niacinamide, niacin and its salts, pyridoxal 5-phosphate, niacinamide ascorbate, riboflavin, riboflavin phosphate, thiamine, folic acid, menadione diphosphate, menadione sodium bisulfite, menadoxine, vitamin B12, vitamin K5, vitamin K6, vitamin K6 and vitamin U (vitamins);Albumin, immunoglobulin, casein, hemoglobin, lysozyme, immunoglobulin, α-2-macroglobulin, fibronectin, vitronectin, fibrinogen, lipase, benzalkonium chloride, benzethonium chloride, dodecyltrimethylammonium bromide, sodium dodecyl sulfate, dialkylmethylbenzyl ammonium chloride, and dialkyl esters of sodium sulfosuccinate, L-ascorbic acid and its salts, D-glucosaccharoascorbic acid and its salts, tromethamine, triethanolamine, diethanolamine, meglumine, glucosamine, amino alcohol, glucoheptonic acid, gluconic acid, hydroxyketone, hydroxylactone, gluconic acid lactone, glucohept ... Octanolide, gulonic acid lactone, mannolide, ribonolactone, lactobionic acid, glucosamine, glutamic acid, benzyl alcohol, benzoic acid, hydroxybenzoic acid, 4-hydroxybenzoic acid propyl ester, lysine acetate, gentisic acid, lactobionic acid, lactitol, sinapic acid, vanillic acid, vanillin, methylparaben, propylparaben, sorbitol, xylitol, cyclodextrin, (2-hydroxypropyl)-cyclodextrin, acetaminophen, ibuprofen, retinoic acid, lysine acetate, gentisic acid, catechin, catechin gallate, tiletamine, ketamine, propofol, lactic acid, acetic acid, any Salts of organic acids and organic amines, polyglycidol, glycerol, polyglycerol, galactitol, glyceryl monolaurate, glyceryl monocaprate, glyceryl monolaurate, glyceryl monomyristate, glyceryl monopalmitoleate, glyceryl monooleate, creatine, creatinine, agmatine, citrulline, guanidine, sucralose, aspartame, hypoxanthine, theobromine, theophylline, adenine, uracil, uridine, guanine, thymine, thymidine, xanthine, xanthine nucleoside, xanthine nucleoside monophosphate, caffeine, allantoin, (2-hydroxyethyl) urea, N,N'-bis(hydroxymethyl) urea, pentaerythritol ethyl Oxylate, pentaerythritol propoxylate, pentaerythritol propoxylate / ethoxylate, glycerol ethoxylate, glycerol propoxylate, ethoxylated trimethylolpropane, pentaerythritol, dipentaerythritol, crown ether, 18-crown-6, 15-crown-5, 12-crown-4, di(ethylene glycol), tri(ethylene glycol), tetra(ethylene glycol), penta(ethylene glycol), poly(ethylene glycol) oligomers, di(propylene glycol), tri(propylene glycol), tetra(propylene glycol) and penta(propylene glycol), poly(propylene glycol) oligomers, block copolymers of polyethylene glycol and polypropylene glycol, and derivatives and combinations thereof. (Chemical compounds having one or more hydroxyl, amino, carbonyl, carboxyl or ester moieties). Some of these additives are both soluble in water and soluble in organic solvents. They have good adhesion properties and adhere to the surface of polyamide medical devices (such as balloon catheters). Therefore, they can be used in the adhesion layer, top layer and / or drug layer in the embodiments of the present invention. Aromatic and aliphatic groups increase the solubility of water-soluble drugs in the coating solution, and polar groups of alcohol and acid accelerate drug penetration into tissues. ;
[0246] Other additives according to embodiments of the present invention include hydroxyketones, hydroxylactones, hydroxyacids, hydroxyesters and hydroxyamides. Examples are gluconolactone, D-glucose heptadecanoe-1,4-lactone, gluconolactone, gulonic acid lactone, mannolactone, trihydroxybutyric acid, ribonolactone, glucuronic acid, gluconic acid, gentisic acid, lactobionic acid, lactic acid, acetaminophen, vanillic acid, sinapinic acid, hydroxybenzoic acid, methylparaben, propylparaben and derivatives thereof.
[0247] From a structural point of view, these additives share structural similarities and are compatible with water-insoluble drugs such as paclitaxel and rapamycin. They often contain double bonds in aromatic or aliphatic structures, such as C=C, C=N, C=O. These additives also contain amines, alcohols, esters, amides, anhydrides, carboxylic acids, and / or hydroxyl groups. They can form hydrogen bonds and / or van der Waals interactions with the drug. They can also be used in the top layer in the coating. Compounds containing one or more hydroxyl, carboxyl or amine groups are particularly useful as additives, for example, because they promote the release of drugs from the surface of the device and easily displace water from surface proteins next to polar head groups and cell membranes, and thus can remove this permeation barrier to hydrophobic drugs. They accelerate the movement of hydrophobic drugs away from the balloon to the lipid layer and tissue of the cell membrane to which they have a very high affinity. The additive can also carry or accelerate the movement of drugs away from the balloon into a more water-containing environment such as the interstitial space of, for example, non-vascular tissues that have been damaged by balloon angioplasty or stent expansion. Additives such as polyglycerol fatty acid esters, ascorbic acid esters of fatty acids, sugar esters, alcohols and ethers of fatty acids have a fatty chain that can be integrated into the lipid structure of the target tissue membrane, thereby carrying the drug to the lipid structure. The structure of some of the amino acids, vitamins and organic acids has an aromatic C=N group, as well as amino, hydroxyl and carboxyl components. They have a structural part that can be combined or complexed with a hydrophobic drug such as paclitaxel or rapamycin, and they also have a structural part that promotes tissue penetration by removing the barrier between the hydrophobic drug and the lipid structure of the cell membrane.
[0248] For example, the hydrophilic part of isononylphenyl polyglycidol (Olin-10G and surfactant-10G), PEG glycerol monooleate, sorbitan monolaurate (Arlacel 20), sorbitan monopalmitate (Span-40), sorbitan monooleate (Span-80), sorbitan monostearate, polyglyceryl-10 oleate, polyglyceryl-10 laurate, polyglyceryl-10 palmitate and polyglyceryl-10 stearate all has more than four hydroxyl groups. These hydroxyl groups have very good affinity to the wall of the body cavity and can replace hydrogen-bonded water molecules. At the same time, they have long chains of fatty acids, alcohols, ethers and esters, which can be compounded with hydrophobic drugs and integrated into the lipid structure of the cell membrane to form part of the lipid structure. This deformation or relaxation of the lipid membrane of the target cell can further accelerate the penetration of hydrophobic drugs into the tissue.
[0249] For another example, L-ascorbic acid, thiamine, maleic acid, nicotinamide and 2-pyrrolidone-5-carboxylic acid all have very high water and ethanol solubility as well as low molecular weight and small size. They also have structural components including aromatic C=N, amino, hydroxyl and carboxyl groups. These structures have very good compatibility with paclitaxel and rapamycin, and can improve the solubility of these water-insoluble drugs in water and enhance their absorption in tissues. However, they generally have poor adhesion to the surface of medical devices. Therefore, they are used in combination with other additives in the drug layer and top layer, where they can be used to enhance drug absorption. Vitamin D2 and D3 are particularly useful because they have anti-restenotic effects themselves and reduce thrombosis, especially when used in combination with paclitaxel.
[0250] In embodiments of the present invention, the additive is soluble in aqueous solvents and soluble in organic solvents. Extremely hydrophobic compounds that lack sufficient hydrophilic parts and are insoluble in aqueous solvents (such as the dye Sudan Red) cannot be used as additives in these embodiments. Sudan Red also has genotoxicity.
[0251] In one embodiment, the concentration density of at least one therapeutic agent applied to the surface of the medical device is about 1 to 20 μg / mm 2 , or about 2 to 6 μg / mm 2 , or about 0.5 μg / mm 2 or less, or less than, equal to, or greater than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, or about 20 micrograms / mm 2 or greater. If the medical device is a balloon, these measurements are calculated based on the nominal diameter. In one embodiment, the concentration of at least one additive applied to the surface of the medical device is about 0.5 to 20 μg / mm 2 , or about 2 to 6 μg / mm2 , or about 0.5 μg / mm 2 or less, or less than, equal to, or greater than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, or about 20 micrograms / mm 2 The weight ratio of the additive to the drug in the coating in the embodiments of the present invention may be about 20 to 0.05, about 10 to 0.1, or about 5 to 0.15.
[0252] The relative amounts of the therapeutic agent and the additive in the coating can vary depending on the applicable environment. The optimal amount of the additive can depend on, for example, the specific therapeutic agent and additive selected, the critical micelle concentration of the surface modifier in the case of micelle formation, the hydrophilic-lipophilic balance (HLB) of the surfactant or the octanol-water partition coefficient (P) of the additive, the melting point of the additive, the water solubility of the additive and / or the therapeutic agent, the surface tension of the aqueous solution of the surface modifier, etc.
[0253] Other considerations will further dictate the selection of specific ratios of the various additives. These considerations include the degree of bioacceptability of the additives and the desired dose of the therapeutic agent to be provided.
[0254] Therapeutic agent.
[0255] The therapeutic agent that can be used in the embodiments of the present invention can be any drug or bioactive material. The therapeutic agent can be a hydrophobic therapeutic agent, an antiproliferative therapeutic agent, an anti-inflammatory agent or a combination thereof. The drug can have different physical states, for example, molecular distribution, crystal form or cluster form. The example of the drug that can be used in the embodiments of the present invention is a substantially lipophilic water-soluble drug, such as paclitaxel, rapamycin, daunorubicin, doxorubicin, lapachone, vitamin D2 and D3 and analogs and derivatives thereof. These drugs are particularly suitable for use in the coating on the balloon catheter for treating the tissue of the vascular system. Therapeutic agents, such as antiproliferative drugs, such as paclitaxel, taxol, docetaxel, rapamycin, sirolimus, tacrolimus, everolimus, mTOR inhibitors (i.e., a class of drugs that inhibit the mechanical target of rapamycin) or their analogs can be delivered to the wall of the body cavity to treat narrowing or stenosis.
[0256] Other drugs that can be used in embodiments of the present invention include, but are not limited to, glucocorticoids (e.g., dexamethasone, betamethasone), hirudin, angiostatin, aspirin, growth factors, antisense agents, anticancer agents, antiproliferative agents, oligonucleotides, and more generally antiplatelet agents, anticoagulants, antimitotic agents, antioxidants, antimetabolites, antichemotactic agents, anti-inflammatory agents, and combinations thereof.
[0257] Some drugs that can be used in various embodiments, such as particularly for the airways, sinuses and other nasal cavities, but also for urethral administration are corticosteroids, such as budesonide, flunisolide, triamcinolone, beclomethasone, fluticasone, mometasone, mometasone furoate, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, cortisone, betamethasone, triamcinolone acetonide, etc. Some other suitable drugs are terbutaline, albuterol, ipratropium, pirbuterol, epinephrine, salmeterol, levalbuterol, formoterol, etc.; the drug can be a bronchodilator or a vasoconstrictor.
[0258] Also useful in embodiments of the invention are polynucleotides, antisense RNAi or siRNA, for example, that inhibit inflammation and / or smooth muscle cell or fibroblast proliferation.
[0259] Antiplatelet agents can include drugs such as aspirin and dipyridamole. Aspirin is classified as analgesic, antipyretic, anti-inflammatory and antiplatelet drugs. Dipyridamole is a drug similar to aspirin, and its similarity is that it has antiplatelet characteristics. Dipyridamole is also classified as a coronary vasodilator. Anticoagulants for embodiments of the present invention can include drugs such as heparin, protamine, hirudin and tick anticoagulant protein. Antioxidants can include probucol. Antiproliferative agents can include drugs such as amlodipine and doxazosin. Antimitotic agents and antimetabolites that can be used in embodiments of the present invention include drugs such as methotrexate, azathioprine, vincristine, vinblastine, 5-fluorouracil, adriamycin and mutamycin. Antibiotics used in embodiments of the present invention include penicillin, cefoxitin, oxacillin, tobramycin and gentamicin. Suitable antioxidants used in embodiments of the present invention include probucol. In addition, genes or nucleic acids or parts thereof can be used as therapeutic agents in embodiments of the present invention. In addition, collagen synthesis inhibitors (such as tranilast) can be used as therapeutic agents in embodiments of the present invention.
[0260] Photosensitizers used in photodynamic or radiotherapy, including various porphyrin compounds such as porfimer, for example, may also be used as medicaments in embodiments of the present invention.
[0261] Drugs used in embodiments of the present invention also include everolimus, somatostatin, tacrolimus, roxithromycin, dunaimycin, ascomycin, bafilomycin, erythromycin, midecamycin, josamycin, concanamycin, clarithromycin, troleandomycin, folimycin, cerivastatin, and sirolimus. statin), simvastatin, lovastatin, fluvastatin, rosuvastatin, atorvastatin, pravastatin, pitavastatin, vinblastine, vincristine, vindesine, vinorelbine, etoposide, teniposide, nimustine, carmustine, lomustine, cyclophosphamide, 4-hydroxycyclophosphamide, estramustine, melphalan, ifosfamide, trofosfamide, chlorambucil, bendamustine, dacarbazine, busulfan, procarbazine, treosulfan, temozolomide, thiotepa thiotepa), daunorubicin, doxorubicin, aclarubicin, epirubicin, mitoxantrone, idarubicin, bleomycin, mitomycin, dactinomycin, methotrexate, fludarabine, fludarabine-5'-dihydrofludarabine phosphate, cladribine, mercaptopurine, thioguanine, cytarabine, fluorouracil,gemcitabine, capecitabine, docetaxel, carboplatin, cisplatin, oxaliplatin, amsacrine, irinotecan, topotecan, hydroxycarbamide, miltefosine, pentostatin, aldesleukin, tretinoin, asparaginase se), pegaspargase, anastrozole, exemestane, letrozole, formestane, aminoglutethimide, doxorubicin, azithromycin, spiramycin, cepharantin, smc inhibitor-2w, epothilone A and B, mitoxantrone, azathioprine, mycophenolate mofetil mofetil), antisense c-myc, antisense b-myc, betulinic acid, camptothecin, lapachol, β-lapachone, podophyllotoxin, betulin, podophyllotoxin 2-ethylhydrazine, molgramostim (rhuGM-CSF), pegylated interferon a-2b, lenograstim (r-HuG-CSF), filgrastim, polyethylene glycol, dacarbazine, basiliximab, daclizumab, selectins (cytokine antagonists), CETP inhibitors, cadherin glycoproteins, mitogen inhibitors, COX-2 inhibitors, NFkB, ciprofloxacin, ciprofloxacin, camptothecin, fluoroblastin, monoclonal antibodies (which inhibit muscle cell proliferation), bFGF antagonists, probucol, prostaglandins, 1,11-dimethoxyferroxan-6-one, 1-hydroxy-11-methoxyferroxan-6-one, scopoletin, colchicine, NO donors such as pentaerythritol tetranitrate and syndnoeimine, S-nitroso derivatives,Tamoxifen, staurosporine, beta-estradiol, alpha-estradiol, estriol, estrone, ethinyl estradiol, fosfestrol, medroxyprogesterone, estradiol cypionate, estradiol benzoate, tropol, kamebakaurin and other terpenoids (which are used in cancer treatment), verapamil, tyrphostine, cyclosporine A, 6-alpha-hydroxypaclitaxel, baccatin, taxotere and other macrocyclic tricarbon dioxides oligomers (MCS) and their derivatives, mofebutazone, acemetacin, diclofenac, lonazolac, dapsone, o-carbafenacetic acid, lidocaine, ketoprofen, mefenamic acid, piroxicam, meloxicam, chloroquine phosphate, penicillamine, hydroxychloroquine, auranofin, gold disodium thiobutyrate, oxacerolide (o xaceprol, celecoxib, β-sitosterol, adenosylmethionine, myrtecaine, polidocanol, nonivamide, levomenthol, benzocaine, aescin, ellipticine, D-24851 (Calbiochem), colchicine, cytochalasin AE, indanocine, nocodazole, S100 protein, bacitracin, vitronectin receptor antagonist, azelastine, guanidinyl cyclase stimulation of metalloproteinases-1 and -2 tissue inhibitors of agents, free nucleic acids, nucleic acids incorporated into viral transmitters, DNA and RNA fragments, plasminogen activator inhibitor-1, plasminogen activator inhibitor-2, antisense oligonucleotides, VEGF inhibitors, IGF-1, active agents from the group of antibiotics (such as cefadroxil, cefazolin, cefaclor, cefotaxim, tobramycin, gentamycin, penicillins such as dicloxacillin, oxacillin), sulfonamides, metronidazol, antithrombotic agents such as argatroban, aspirin,abciximab, synthetic antithrombin, bivalirudin, coumadin, enoxaparin, desulfated and N-acetylated heparin, tissue plasminogen activator, GpIIb / IIIa platelet membrane receptor, factor Xa inhibitor antibody, heparin, hirudin, r-hirudin, PPACK, protamine, prourokinase, streptokinase, warfarin, urokinase; vasodilators such as dipyramidole, trapidil, nitroprusside; PDGF antagonists such as triazolopyrimidines and chromopyrimidines Seramin, ACE inhibitors such as captopril, cilazapril, lisinopril, enalapril, losartan, thiol protease inhibitors, prostacyclin, vapiprost, interferon alpha, beta, and gamma, histamine antagonists, serotonin blockers, apoptosis inhibitors, apoptosis modulators such as p65NF-kB or Bcl-xL antisense oligonucleotides, halofuginone, nifedipine, tronisandramine (molsidomine), tea polyphenols, epicatechin gallate, epigallocatechin gallate, boswellic acid and its derivatives, leflunomide, anakinra, etanercept, sulfasalazine, etoposide, dicloxacillin, tetracycline, triamcinolone, mutamycin, procainamide, retinoic acid, quinidine, disopyramide, flecamide, propafenone (pr opafenone), sotalol, amidorone, naturally and synthetically obtained steroids such as bryophyllin A, inotodiol, maquiroside A, ghalakinoside, mansonine, strebloside, hydrocortisone, betamethasone, dexamethasone, nonsteroidal anti-inflammatory drugs (NSAIDS) such as fenoprofen, ibuprofen, indomethacin, naproxen,Phenylbutazone and other antiviral agents such as acyclovir, ganciclovir and zidovudine; antifungal agents such as clotrimazole, flucytosine, griseofulvin, ketoconazole, miconazole, nystatin, terbinafine; antiprotozoal agents such as chloroquine, mefloquine, quinine; other natural terpenoids such as hippocaesculin, barbarin-C21-angelate, 14-dehydroindole 14-dehydroagrostistachin, agroskerin, indoline, 17-hydroxyindoline, ovatodiolids, 4,7-oxocyclohexanone, baccharinoids B1, B2, B3 and B7, tubeimoside, bruceanol A, B and C, bruceantinoside C, yadanziosides N and P, isodeoxyelephantopin, tomenphantopin A and B, coronarin A, B, C and D, ursolic acid, hyptatic acid acid) A, zeorin, iso-irisaldehyde, maytenfoliol, effusantin A, sedum acetone A and B, kauretin B, sedum acetone C, kamebaunin, leukamenin A and B, 13,18-dehydro-6-a-senecioyloxy chaparrin), taxamairin A and B, regenilol, triptolide, other magnetosides, apocymarin, aristolochic acid, anopterin, hydroxyanopterin, anemonin, protoanemonin, berberine,Cheliburin chloride, cictoxin, sinococuline, bombrestatin A and B, cudraisoflavonei A, curcumin, dihydrozanthine, zanthine chloride, 12-β-hydroxypregnanediethylenetriamine-3,20-dione, ginkgol, ginkgolic acid, helenalin, indicine, indicine-N-oxide, helenethrin, inonotinol, glycoside 1a, podophyllotoxin, usticidin A and B, larreatin, malloterin, malloterin benzodihydropyran ochromanol), isobutylmallotochromanol, maquiroside A, marchantin A, maytansine, lycoridicin, margetine, pancratistatin, liriodenine, bisparthenolidine, oxoushinsunine, aristolochic acid-AII, bisparthenolidine, periplocoside A A), ghalakinoside, ursolic acid, deoxypsorospermin, psychorubin, ricin A, sanguinarine, manwu wheat acid, methylsorbifolin, sphatheliachromen, stizophyllin, mansonine, strebloside, akagerine, dihydrousambarensine, hydroxyusambarine, strychnopentamine, strychnophylline, usambarine, usambarensine, berberine,Liriodenine, oxoushinsunine, daphnoretin, lariciresinol, methoxylariciresinol, syringaresinol, umbelliferon, afromoson, acetylvismione B, desacetylvismione A, and vismione A and B.
[0262] The combination of medicines can also be used in embodiments of the present invention. Some combinations have an additive effect because they have different mechanisms, such as paclitaxel and rapamycin, paclitaxel and active vitamin D, paclitaxel and lapachone, rapamycin and active vitamin D, rapamycin and lapachone. Due to the presence of an additive effect, the dosage of the medicine can also be reduced. These combinations can reduce complications caused by using high-dose drugs.
[0263] Solvent.
[0264] The solvent for preparing the coating may include, for example, one or a combination of: (a) water, (b) alkanes such as hexane, octane, cyclohexane and heptane, (c) aromatic solvents such as benzene, toluene and xylene, (d) alcohols such as ethanol, propanol and isopropanol, diethylamide, ethylene glycol monoethyl ether, Trascutol and benzyl alcohol, (e) ethers such as dioxane, dimethyl ether and tetrahydrofuran, (f) esters / acetates such as ethyl acetate and isobutyl acetate, (g) ketones such as acetone, acetonitrile, diethyl ketone and methyl ethyl ketone, and (h) mixtures of water and organic solvents such as water / ethanol, water / acetone, water / methanol, water / tetrahydrofuran. The solvent in the top coating is, for example, methanol, ethanol and acetone.
[0265] Organic solvents such as short chain alcohols, dioxane, tetrahydrofuran, dimethylformamide, acetonitrile, dimethylsulfoxide, and the like are particularly useful in embodiments of the present invention because these organic solvents generally disrupt collagen aggregates and dissolve all components together in the coating solution.
[0266] The therapeutic agent and one or more additives may be dispersed, dissolved or otherwise mixed in the solvent. The weight percentage of the drug and additives in the solvent may be in the range of 0.1 wt% to 80 wt%, preferably 2 wt% to 20 wt%.
[0267] Various embodiments provide methods for preparing a balloon catheter. First, a coating solution or suspension comprising at least one solvent, at least one therapeutic agent, and at least one additive is prepared. In at least one embodiment, the coating solution or suspension includes only these three components. The content of the therapeutic agent in the coating solution can be 0.5wt% to 50wt% based on the total weight of the solution. The content of the additive in the coating solution can be about 0.1wt% to about 45wt%, about 0.2wt% to about 40wt% (by weight), about 0.3wt% to about 15wt%, or about 0.1wt% or less, or less than, equal to or greater than about 0.2wt%, 0.3wt%, 0.4wt%, 0.5wt%, 0.6wt%, 0.8wt%, 1wt%, 2wt%, 3wt%, 4wt%, 5wt%, 6wt%, 7wt%, 8wt%, 9wt%, 10wt%, 12wt%, 14wt%, 16wt%, 18wt%, 20wt%, 22wt%, 24wt%, 26wt%, 28wt%, 30wt%, 35wt%, 40wt% or about 45wt% or more based on the total weight of the solution. The amount of solvent used depends on the coating process and viscosity. The solvent will affect the uniformity of the drug-additive coating, but will be evaporated.
[0268] In other embodiments, two or more solvents, two or more therapeutic agents, and / or two or more additives may be used in the coating solution.
[0269] In other embodiments, the therapeutic agent, additives and polymer material can be used in a coating solution for a balloon catheter. In the coating, the therapeutic agent is not encapsulated in polymer particles.
[0270] Various techniques can be used to apply the coating solution to the medical device, such as pouring, fixed volume liquid distribution, metering (e.g., based on volume, a fixed amount of solvent is distributed to the balloon), spin coating, spraying, dip coating (immersion), inkjet printing, electrostatic techniques, and combinations of these processes. During the application of the coating solution, the balloon can be at least partially inflated. It can be metered in any suitable manner, such as by pumping a liquid coating solution from a reservoir to a nozzle near the balloon surface (e.g., the surface of the at least partially inflated balloon). The nozzle can dispense liquid from it, and due to the proximity of the nozzle, the liquid can be immediately transferred to the outside of the balloon (e.g., the nozzle can be very close to the balloon, so that the liquid from the nozzle can contact and transfer to the outside of the balloon before the liquid leaving the nozzle drops). The nozzle can distribute the liquid to the outside of the balloon so that substantially no liquid is lost. The balloon can rotate along its longitudinal axis during the distribution of liquid from the nozzle. The nozzle can move during distribution, such as along the outside of the balloon parallel to the longitudinal axis of the balloon. In some embodiments, the balloon can be rotated along its longitudinal axis during dispensing and the nozzle can be moved parallel to the longitudinal axis of the balloon so that substantially all of the balloon surface is coated with the coating solution (e.g., similar to the motion of a woodworking chisel on a cylindrical block of wood turning in a lathe).
[0271] The choice of application technique depends primarily on the viscosity and surface tension of the solution.In some embodiments of the invention, metering may be used because it is easier to control the uniformity of the coating thickness and the concentration of the therapeutic agent applied to the medical device.
[0272] In one embodiment of the invention, the balloon is inflated or partially inflated, and the coating solution is applied to the inflated balloon by metering while the balloon is inflated and rotated along its longitudinal axis. The balloon is then allowed to dry and then deflated, folded and sheathed.
[0273] The description of the embodiment of the coating apparatus, fixture and metering technique is an example.Any suitable metering or other technique may be used to coat the balloon catheter.
[0274] After the medical device is coated with the coating solution, the coated balloon is subjected to drying, wherein the solvent in the coating is evaporated. This produces a coating matrix on the balloon containing the therapeutic agent. An example of a drying technique is to place the coated balloon in an oven at about 20° C. or higher for about 24 hours. Any other suitable method of drying the coating solution may be used. The time, temperature, and relative humidity may vary depending on the specific additives and therapeutic agents.
[0275] One embodiment of the present invention relates to a method for treating benign prostatic hyperplasia. The method includes inserting a coated medical device into the prostatic urethra. The coating includes a therapeutic agent and an additive. In this embodiment, the medical device can be configured to have at least one expandable portion. Some examples of such devices include balloon catheters, fixed-line balloon catheters, cross-line balloon catheters, rapid exchange catheters, perfusion balloon catheters, infusion catheters (e.g., distal perforated drug infusion catheters, perforated balloons, separate double balloons, porous balloons and infiltration balloons, cutting balloon catheters), separate double balloons, cutting balloon catheters, scored balloon catheters, self-expanding and balloon-expandable stents, guide catheters, guide wires, embolus protection devices, and various imaging devices.
[0276] As mentioned herein, an example of a medical device that can be particularly used for the present invention is a coated balloon catheter. A balloon catheter typically has a long narrow hollow tube with a micro deflated balloon. In an embodiment of the present invention, the balloon is coated with a drug solution. Then, the balloon is manipulated to pass through the stenosis of the non-vascular body cavity to reach the obstruction, occlusion site or other tissues that require a therapeutic agent. Once in the appropriate position, the balloon is inflated and contacts the wall and / or obstruction or occlusion of the stenosis of the non-vascular body cavity. The purpose of an embodiment of the present invention is to rapidly deliver the drug to the target tissue and promote absorption of the target tissue. In various embodiments, when the device is deployed at the target site, it may be advantageous to efficiently deliver the drug to the tissue in the shortest possible time. The therapeutic agent can be released into such tissues, such as the lumen wall, within a balloon inflation time of about 0.1 to 30 minutes, for example, or about 0.1 to 10 minutes, or about 0.2 to 2 minutes, or about 0.1 to 1 minutes of extruded drug coating to contact the lesion non-vascular tissue.
[0277] Given that therapeutically effective amounts of drugs can be delivered to, for example, the prostate gland via embodiments of the present invention, the need for stents may be eliminated in some cases, thereby avoiding complications of fracture and the instillations associated therewith.
[0278] Balloon catheters can be used alone to treat non-vascular tissue / diseases, or used in conjunction with other methods and medical devices for treating non-vascular systems, such as direct visual internal urethrotomy (DVIU) for stenosis and transurethral resection of the prostate (TURP) for BPH. DVIU is a surgery for opening urethral stenosis. Specifically, DVIU is a surgery for making a relaxing incision in the stenosis to produce a urethral cavity gain. DVIU can be performed using a cold knife (urethrotomy) or a hot knife (electrode). The cutter is inserted into the body and advanced through the urethra to the narrowed area. After making the relaxing incision, a coated balloon of an embodiment of the present invention can be used for balloon dilatation. In addition, stenting can be performed thereafter, or the coated balloon as described herein can be expanded at the same time. In another embodiment, a coated balloon of an embodiment of the present invention can be used for balloon dilatation in a stent. For TURP, the medical device commonly used is a hot knife (electrode) or a laser. In either case, the device is inserted into the body and advanced through the urethra to the narrowed area. After resection of the prostate tissue, balloon dilatation can be performed using a coated balloon of an embodiment of the present invention. In addition, stenting can be performed thereafter, or a coated balloon as described herein can be expanded simultaneously. In another embodiment, a self-expanding stent coated with a therapeutic agent and additive of the present invention is delivered and placed in a body cavity stricture, including esophageal stricture, achalasia stricture, bile duct stricture, gastric stricture, small intestinal stricture, duodenal stricture, jejunal stricture, ileal stricture, colonic stricture, rectal stricture, and large intestinal stricture.
[0279] preparation.
[0280] Various embodiments of the present invention provide a method of forming a balloon. The method may include placing a tube containing balloon material in a balloon mold having any suitable shape, such as a shape including a proximal cone, at least one main body portion, at least one neck portion having a diameter smaller than the at least one main body portion, another at least one main body portion, and a distal cone. The method may include applying pressure to the interior of the tube of balloon material. The method may also include expanding the tube of balloon material into contact with the interior of the mold.
[0281] Various embodiments of the present invention provide methods for forming a balloon and then shrinking it to obtain a large diameter range. The method includes placing a tube containing a balloon material in a balloon mold, wherein the balloon mold has a shape including a proximal cone, at least one main body portion and a distal cone. The method includes pressurizing the interior of the balloon material tube. The method includes expanding the balloon material tube to contact the interior of the mold at a pressure of 200-400psi and a temperature of 100°C-200°C. The formed balloon is then shrunk by annealing the balloon at a temperature lower than the molding process and a low inflation pressure for a specified amount of time, preferably 1-30psi, 70°C-90°C, for 3-30 seconds. Once the balloon is shrunk, it can be attached to a catheter shaft and coated with a drug. Any manufacturing technique, method for treating a body cavity, or balloon described in the following patents can be used in embodiments of the present invention, U.S. Patent Nos. 7,163,522 and 7,108,826, which are incorporated herein by reference as if their entire contents were reproduced herein.
[0282] The medical device and coating of embodiments of the present invention can be manufactured according to various methods. For example, the coating solution can be prepared by dispersing, dissolving or otherwise mixing all ingredients (such as therapeutic agent, additive and solvent) together at the same time. In addition, the coating solution can be prepared by adding each component in sequence based on solubility or any other parameter. For example, the coating solution can be prepared by first adding the therapeutic agent to the solvent and then adding the additive. Alternatively, the additive can be first added to the solvent and then the therapeutic agent can be added. If the solvent used is not enough to fully dissolve the drug, it is useful to first add the additive to the solvent and then add the drug because the additive will increase the drug solubility of the solvent.
[0283] International Prostate Symptom Score (IPSS) and Q max .
[0284] Q max It is a measurement of the maximum urine flow rate obtained during urodynamic testing. It is the maximum volumetric flow rate of urine during urination. It is a measure of the amount of urine produced in a specified period of time (per second or per minute). It can be measured using uroflowmetry. max Refers to the maximum flow rate. max Used as an indicator for diagnosing enlarged prostate or other urinary tract obstruction or stenosis. max A lower number can indicate an enlarged prostate putting pressure on the urethra or a urethral stricture with a partially blocked urethra.
[0285] By using the present invention, for example, Figure 3 balloon shown, patients with urethral strictures can experience Q max Increase. Typical Q of a person with urethral stricture maxIn the range of 0 to 10 mL / s. After treatment with the balloon of the present invention (usually measured between the 14th and 30th day after treatment), Q is expected to max The amount of Q is increased to 9 to 52 mL / s, or to a minimum of 15 mL / s, or in some embodiments, to a minimum of 20 mL / s, or in some embodiments, to less than, equal to, or greater than about 8 mL / s, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 24, 26, 28, 30, 35, 40, 45, or about 50 mL / s or more. This treatment has been shown to have an effect on Q max Has long-term effects. In some embodiments, after 6 months, Q max Still can be or above 15mL / s, 20mL / s or in the range of 6 to 50mL / s, or less than, equal to or greater than about 8mL / s, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 24, 26, 28, 30, 35, 40, 45 or about 50mL / s or greater. After 12 months, in various embodiments, Q max It can still be above 15 mL / s, 20 mL / s, or in the range of 6 to 50 mL / s, 9 to 32 mL / s, or less than, equal to, or greater than about 8 mL / s, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 24, 26, 28, 30, 35, 40, 45, or about 50 mL / s or more.
[0286] By using the present invention, for example, Figure 1A , Figure 1B , Figure 1C or Figure 2 As shown in the balloon, patients with benign prostatic hyperplasia can experience Q max Increase. Typical Q of a person with BPH max In the range of 5 to 12 mL / s. After treatment with the balloon of the present invention, in various embodiments, Q max It can be increased to a minimum of 16 mL / s, to a range of 4 to 35 mL / s, or less than, equal to, or greater than about 8 mL / s, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 24, 26, 28, 30, 35, 40, 45, or about 50 mL / s or greater. max Has long-term effects. After 6 months, Q maxIt may be above a minimum of 16 mL / s, or in some embodiments, in the range of 16 to 32 mL / s, or less than, equal to, or greater than about 8 mL / s, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 24, 26, 28, 30, 35, 40, 45, or about 50 mL / s or greater. After 12 months, Q max Can be above minimum 16mL / s, or in some embodiments, in the range of 16 to 30mL / s, or less than, equal to, or greater than about 8mL / s, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 24, 26, 28, 30, 35, 40, 45, or about 50mL / s or more. These effects distinguish the present invention from the devices and methods of the prior art.
[0287] The International Prostate Symptom Score (IPSS) is a validated patient-reported outcome measure (PROM) scoring system. Urologists worldwide recognize this system and use it to screen for the diagnosis of benign prostatic hyperplasia (BPH) as well as to monitor symptoms and guide decisions about how to manage the disease. The IPSS is based on responses to eight questions, seven about disease symptoms and one about the patient's quality of life. For the symptom questions, the patient is asked to select the rating that best represents his condition. The scale ranges from 0 to 5, with 5 representing the most severe symptomatic disease. The seven symptom scores are added together to give a total maximum score of 35. Quality of life responses are scored on a scale of 0 to 6. According to these scoring systems, scores can be categorized as follows: if the score is 7 or less, the symptoms are mild; if the score is 8 to 19, the symptoms are moderate; and if the score is 20 to 35, the symptoms are severe.
[0288] By using the present invention, for example, Figure 3With the balloon shown, patients with urethral strictures can experience a reduction in IPSS. Typical IPSS for people with urethral strictures ranges from 15 to 35. After treatment with the balloon of the present invention, it is expected that the IPSS will be a maximum of 14, or in some embodiments, in the range of 0 to 13, 4 to 13, 0 to 11, or 0, or less than, equal to, or greater than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or about 14. This treatment has been shown to have a long-term effect on IPSS. After 6 months, the IPSS is still below a maximum of 14, and in some embodiments ranges from 0 to 13, 1 to 13, 0 to 11, or is 0, or is less than, equal to, or greater than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or about 14. After 12 months, the IPSS is still below a maximum of 14, or can be 0 to 7, or is 0, or is less than, equal to, or greater than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or about 14. These effects distinguish the present invention from prior art devices and methods.
[0289] By using the present invention, for example, Figure 1A , Figure 1B , Figure 1C or Figure 2 With the balloon catheter shown in FIG. 1 , patients with benign prostatic hyperplasia can experience a reduction in IPSS. Typical IPSS for people with BPH ranges from 15 to 35. After treatment with the balloon of the present invention, the IPSS can be a maximum of 14, or in some embodiments, in the range of 4 to 13, or 0, or less than, equal to, or greater than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or about 14. This treatment can have a long-term effect on IPSS. After 6 months, the IPSS can still be a maximum of 14, and in some embodiments, in the range of 1 to 13, or 0, or less than, equal to, or greater than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or about 14. After 12 months, the IPSS can still be below a maximum of 14, or in some embodiments, in the range of 1 to 14, or 0, or less than, equal to, or greater than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or about 14. These effects distinguish the present invention from prior art devices and methods.
[0290] To obtain Q maxIn order to achieve the desired increase or decrease in IPSS, in one embodiment, a balloon coated with a therapeutic agent (such as an antiproliferative or anti-inflammatory drug) and one or more water-soluble additives as described herein is placed in the urethral stricture area or in the prostate. For strictures, the balloon is then inflated to a diameter that is 1.0 to 20 times larger than the natural urethra (e.g., the standard diameter of the urethra to be treated), such as about 1.2 to 3 times. For BPH treatment, the balloon is inflated to a diameter that may be about 1.0 to 20 times or about 1.2 to 10 times larger than the natural (unlesioned) prostatic urethra. That is, the ratio of the inflated balloon diameter to the standard diameter of the body cavity at the urethral stricture treatment location can be 1.2 to 3, and the ratio to the standard diameter of the body cavity at the BPH treatment location can be 1.2 to 10; the stretch ratio can be the same or different. The balloon can be inflated for 0.1 to 10 minutes to allow drug delivery to the urethra. In some embodiments, a scope (such as a cystoscope) can be used to help place the balloon. In some embodiments, the balloon catheter shaft can be in the lumen of the endoscope, and in other embodiments, can be placed side by side with the endoscope. In some embodiments, the stenosis or prostate can be pre-dilated by a non-drug-coated balloon and then treated by a drug-coated balloon. In some embodiments, the pre-dilation balloon will be slightly shorter than the treatment balloon to ensure that the entire area of the pre-dilated urethra or prostate is subsequently treated by the drug-coated balloon. In some embodiments, the lumen and / or drug-coated balloon are rinsed or soaked in water, saline, urine, or an aqueous solution containing at least one water-soluble additive, and then the drug-coated balloon is inserted. The drug-coated balloon can be covered with a sheath to provide protection during delivery to the treatment site. The sheath can be removed before inflating the balloon.
[0291] Although various embodiments have been specifically shown and described herein, it will be appreciated that modifications and variations of the invention are covered by the above teachings and within the purview of the appended claims without departing from the spirit and intended scope of the invention.
[0292] Except in the operating examples, or where otherwise indicated, all numbers expressing quantities of components used in layers, reaction conditions, and so forth, in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless otherwise indicated to the contrary, the numerical parameters set forth in the specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present disclosure.
[0293] Example
[0294] Various embodiments of the present invention may be better understood by reference to the following examples which are provided by way of illustration.The present invention is not limited to the examples given herein.
[0295] In all embodiments, unless otherwise stated, the stretch ratio is calculated as the ratio of the nominal balloon diameter to the standard diameter at the body cavity treatment location. The standard diameter at the body cavity treatment location is the standard diameter at the body cavity treatment location and can be calculated as the average diameter of healthy tissue adjacent to the stricture (stenosis) or lesion (i.e., the proximal and distal ends of the lumen stricture or lesion). For the pressure used during the inflation period, the inflated balloon diameter is approximately equal to the nominal balloon diameter and is within 10% of the nominal balloon diameter.
[0296] Part I.
[0297] Example I-1. Preparation of coating solution.
[0298] Formulation 1: Mix 50-150 mg (0.06-0.18 mmole) paclitaxel, 25-300 mg PEG8 caprylic / capric glyceride and 2-6 ml ethanol.
[0299] Formulation 2: Mix 50-150 mg (0.06-0.18 mmole) paclitaxel, 25-300 mg PEG8 caprylic / capric glyceride, 25-300 mg uracil and 2-6 ml ethanol.
[0300] Formulation 3: Mix 50-150 mg (0.06-0.18 mmole) paclitaxel, 25-300 mg PEG8 caprylic / capric glyceride, 25-300 mg uridine and 2-6 ml ethanol.
[0301] Formulation 4: 50-150 mg (0.06-0.18 mmole) paclitaxel, 25-300 mg PEG8 caprylic / capric glyceride, 25-300 mg sucralose and 2-6 ml ethanol were mixed.
[0302] Formulation 4a: 50-150 mg (0.06-0.18 mmole) paclitaxel, 25-300 mg PEG8 caprylic / capric glyceride, 25-300 mg sucralose and 2-6 ml ethanol were mixed, with the mass ratio of paclitaxel:PEG8 caprylic / capric glyceride:sucralose being 1:1:1.
[0303] Formulation 4b: 50-150 mg (0.06-0.18 mmole) paclitaxel, 25-300 mg PEG8 caprylic / capric glyceride, 25-300 mg sucralose and 2-6 ml ethanol were mixed, with the mass ratio of paclitaxel:PEG8 caprylic / capric glyceride:sucralose being 1:1:2.
[0304] Formulation 5: Mix 50-150 mg (0.06-0.18 mmole) paclitaxel, 25-300 mg PEG8 caprylic / capric glyceride, 25-300 mg creatinine and 2-6 ml ethanol.
[0305] Formulation 6: 50-150 mg (0.06-0.18 mmole) paclitaxel, 25-300 mg PEG6 caprylic / capric glyceride, 25-300 mg uracil and 2-6 ml ethanol were mixed.
[0306] Formulation 7: Mix 50-150 mg (0.06-0.18 mmole) paclitaxel, 25-300 mg C6-ceramide and 2-6 ml ethanol.
[0307] Formulation 8: Mix 50-150 mg (0.06-0.18 mmole) paclitaxel, 25-300 mg monolaurin, 25-300 mg sucralose and 2-6 ml ethanol.
[0308] Formulation 9: Mix 50-150 mg (0.06-0.18 mmole) paclitaxel, 25-300 mg sucralose and 2-6 ml ethanol.
[0309] Formulation 10: Mix 50-150 mg (0.06-0.18 mmole) paclitaxel, 25-300 mg PEG8 monocaprylate / decanoate and 1-6 ml ethanol.
[0310] Formulation 11: Mix 50-150 mg (0.06-0.18 mmole) paclitaxel, 25-300 mg PEG8 monocaprylate / decanoate, 25-300 mg sucralose and 1-6 ml ethanol.
[0311] Formulation 12: Mix 50-150 mg (0.06-0.18 mmole) paclitaxel, 25-300 mg thymidine and 1-6 ml (96 / 4 v / v) THF / water.
[0312] Formulation 13: Mix 50-150 mg (0.06-0.18 mmole) paclitaxel, 25-300 mg uridine and 1-6 ml (96 / 4 v / v) THF / water.
[0313] Formulation 14: Mix 50-150 mg (0.06-0.18 mmole) paclitaxel, 25-300 mg caffeine and 1-6 ml (96 / 4 v / v) THF / water.
[0314] Formulation 15: Mix 50-150 mg (0.06-0.18 mmole) of paclitaxel, 25-300 mg of 18 Crown 6 and 1-6 ml of ethanol.
[0315] Formulation 16: Mix 50-150 mg (0.06-0.18 mmole) of paclitaxel, 25-300 mg of 18 Crown 6 and 1-6 ml of ethanol.
[0316] Formulation 17: 50-150 mg (0.06-0.18 mmole) of paclitaxel, 10-100 mg of 18 crown 6, 10-100 mg of pentaerythritol ethoxylate (15 / 4) and 1-6 ml of ethanol were mixed.
[0317] Formulation 18: Mix 50-150 mg (0.06-0.18 mmole) paclitaxel, 25-300 mg pentaerythritol ethoxylate (15 / 4) and 1-6 ml ethanol.
[0318] Formulation 19: 50-150 mg (0.06-0.18 mmole) of paclitaxel, 25-300 mg of trimethylolpropane ethoxylate (Mw about 1014)) and 1-6 ml of ethanol were mixed.
[0319] Formulation 20: 50-150 mg (0.06-0.18 mmole) paclitaxel, 25-300 mg pentaerythritol ethoxylate (3 / 4) and 1-6 ml ethanol were mixed.
[0320] Formulation 21: Mix 50-150 mg (0.06-0.18 mmole) of paclitaxel, 25-300 mg of 15 crown 5 and 1-6 ml of ethanol.
[0321] Formulation 22: Mix 25-100 mg (0.03-0.12 mmole) paclitaxel, 25-300 mg thymidine and 1-6 ml (90 / 10 v / v) THF / water.
[0322] Formulation 23: 50-150 mg (0.06-0.18 mmole) paclitaxel, 5-75 mg pentaerythritol ethoxylate (15 / 4), 10-200 mg pentaerythritol ethoxylate (3 / 4) and 1-6 ml ethanol were mixed.
[0323] Formulation 24: 50-150 mg (0.06-0.18 mmole) of paclitaxel, 25-300 mg of trimethylolpropane ethoxylate (Mw about 170)) and 1-6 ml of ethanol were mixed.
[0324] Example I-2. Clinical Study 1 & 2 Sample Preparation.
[0325] Twenty-one balloon catheters (twelve 4 mm diameter and 40 mm long, six 8 mm diameter and 40 mm long, three 20 mm diameter and 50 mm long) were inflated to 1 to 2 atmospheres and wiped with ethanol to clean the balloon surface. Next, the balloons were coated with various formulations (1-6) from Example 1-1, with the coating solution sufficient to achieve 2-4 micrograms of paclitaxel / square millimeter of balloon surface. The balloons were then dried, folded, sheathed, and packaged in Tyvek bags and sterilized with ethylene oxide in preparation for animal testing.
[0326] Example I-3. Clinical Studies 1 & 2 Treatment.
[0327] For this study, male dogs were used. Before drug-coated balloon treatment, baseline urethrograms were obtained and the inner diameter of the urethral treatment site was measured. Using the drug-coated balloon catheter prepared in Example 1-2, the pelvic, bulbar and distal urethra at the proximal end of the penis were treated without overlap. The penile urethra was not treated. The treatment site diameter was about 3.5-4.5 mm. The balloon catheter was selected so that the stretch ratio of the prostatic urethra balloon was about 4-10. For the anterior urethra, a balloon catheter was selected so that the stretch ratio was about 1.8-2.3. Before inserting the catheter, the urethra was flushed with about 5 mL of saline. A 18-20 mm nominal diameter balloon was inflated in the prostatic urethra, and an 8 mm nominal diameter balloon was inflated in the anterior urethra. The 18 to 20 mm nominal diameter balloon was inflated to 4 atmospheres at the treatment site for 10 min, the drug and additives were released, then contracted, and removed from the dog. The 8 mm nominal diameter balloon was inflated to 12 atmospheres at the treatment site for 10 min to release the drug and additives, then deflated and removed from the dog. The stretch ratio of the inflated 20 mm nominal diameter balloon was 4.4 to 6.3. The stretch ratio of the inflated 8 mm nominal diameter balloon was 2.0 to 2.5. The amount of drug in the treated urethral tissue of the sacrificed animals was measured after 4 hours and 1 day, and the residual drug left on the balloon after use was analyzed.
[0328] The drug-coated balloon catheter prepared in Example 1-2 was inserted into the left ureter and urethra of a female pig. A 4 mm nominal diameter balloon was inflated to 14 atmospheres in the ureter, and an 8 mm balloon was inflated to 12 atmospheres in the urethra. The balloon was inflated for 10 min at the treatment site to release the drug and additives, then deflated and removed from the pig. The stretch ratio of the 4 mm nominal diameter balloon was 2 to 2.5. The stretch ratio of the 8 mm nominal diameter balloon was 2.0 to 2.5. The drug concentration in the urethra and prostate tissue of the sacrificed animals was measured after 4 hours. The residual drug left on the balloon after use was analyzed.
[0329] Example I-4. Preclinical studies 1 & 2 tissue and balloon residual drug content.
[0330] Using formulation 4a, the dog tissue drug concentration of the prostatic urethra sample from Example I-3 was 0.4 μg / g at 4 hours. Using formulation 4a, the dog tissue drug concentration of the prostatic sample from Example I-3 was 0.367 μg / g at 4 hours. Using formulation 4b, the dog tissue drug concentration of the pelvic urethra sample from Example I-3 was 11.7 μg / g at 4 hours. Using formulation 4a, the dog tissue drug concentration of the bulbar urethra sample from Example I-3 was 25.2 μg / g at 4 hours. Using formulation 4a, the dog tissue drug concentration of the prostatic urethra sample from Example I-3 was 0.586 μg / g at 1 hour. Using formulation 4a, the dog tissue drug concentration of the prostatic sample from Example I-3 was 0.429 μg / g at 1 day. Using formulation 4b, the dog tissue drug concentration of the pelvic urethra sample from Example I-3 was 26.6 μg / g at 1 day. Dog tissue drug concentrations for distal urethra samples from Example 1-3 were 2.04 μg / g at day 1 using Formulation 4a. Residual balloon content as a percentage of original drug load for samples from Example 1-3 ranged from 45% to 87% using Formulation 4a.
[0331] Using Formulation 4b, the residual balloon content as a percentage of the original drug load from the samples in Example I-3 ranged from 83% to 85%.
[0332] At 4 hours, the proximal (Formulation 4b) right ureteral porcine tissue drug concentration from the sample in Example 1-3 was 17.3 μg / g. At 4 hours, the female porcine urethra (Formulation 4a) drug concentration was 66.9 μg / g. The residual balloon content as a percentage of the original drug load from the sample in Example 1-3 ranged from 6-58%. The average residual balloon content for Formulation 4a was 52.8%. The average residual balloon content for Formulation 4b was 64.7%.
[0333] Example I-5. Preclinical study 3 sample preparation.
[0334] Twenty-three balloon catheters (twelve 8 mm diameter and 40 mm length, six 10 mm diameter and 40 mm length, four 12 mm diameter and 30 mm length, and three 10 mm diameter and 30 mm length) were inflated to 50% of their nominal inflation pressure and wiped with ethanol to clean the balloon surface. Next, the balloons were coated with various formulations (1-6) in Example I-1, with the coating solution sufficient to achieve 2 micrograms of paclitaxel / square millimeter of balloon surface. The balloons were then dried, folded, sheathed, and packaged in Tyvek bags and sterilized with ethylene oxide in preparation for animal testing.
[0335] Example I-6. Preclinical Study 3 Treatment.
[0336] For this study, male dogs were used. Before drug-coated balloon treatment, baseline retrograde urethrography was obtained and the inner diameter of the urethral treatment site was measured. Using the drug-coated balloon catheter prepared in Example 1-5, the prostate, pelvis, bulbar and distal urethra at the proximal end of the penis were treated without overlapping. The penile urethra was not treated. The treatment site diameter was about 2.1-8.5mm. The balloon catheter was selected so that the stretch ratio of the prostatic urethra balloon (the ratio of the nominal diameter of the balloon to the standard diameter of the target site) was designed to be about 1.7-3.4. For the anterior urethra, a balloon catheter was selected so that the stretch ratio was about 1.8-2.3. Before inserting the catheter, the urethra was flushed with about 5mL of saline. A 12mm nominal diameter balloon was inflated in the prostatic urethra, and 8 and 10mm nominal diameter balloons were inflated in the anterior urethra. The 12mm nominal diameter balloon was inflated to 9 atmospheres at the treatment site for 10min, released the drug and additives, then contracted, and removed from the dog. The 8 mm nominal diameter balloon was inflated to 10 atmospheres at the treatment site for 10 min to release the drug and additives, then deflated and removed from the dog. The stretch ratio of the 12 mm nominal diameter balloon was 2.0 to 3.0. The stretch ratio of the 8 and 10 mm nominal diameter balloons was 1.3 to 3.0. The amount of drug in the treated urethral tissue of the sacrificed animals was measured after 1 day and 7 days, and the residual drug left on the balloon after use was analyzed.
[0337] Example I-7. Preclinical study 3 tissue and balloon residual drug content.
[0338] Dog tissue drug concentrations from samples in Example 1-6 ranged from 4-176 μg / g on day 1 and 0.003-23 μg / g on day 7. Residual balloon content as a percentage of the original drug load from samples in Example 1-6 ranged from 5% to 98%.
[0339] Example I-8. Preclinical study 4 sample preparation.
[0340] One hundred and eight balloon catheters (forty-two 8 mm diameter and 20 mm length, twenty-seven 10 mm diameter and 40 mm length, twenty-five 12 mm diameter and 40 mm length, five 8 mm diameter and 55 mm length, and each 12 mm diameter and 55 mm length) were inflated to 50% of their nominal inflation pressure and wiped with ethanol to clean the balloon surface. Next, the balloons were divided into two groups; one group was coated with Formulation 1 and Formulation 4 from Example I-1, with a coating solution sufficient to achieve 2 micrograms of paclitaxel / square millimeter of balloon surface, and the other group was coated with the same formulation from Example I-1, with a coating solution sufficient to achieve 4 micrograms of paclitaxel / square millimeter of balloon surface. The balloons were then dried, folded, sheathed, and packaged in Tyvek bags and sterilized with ethylene oxide in preparation for animal testing.
[0341] Example I-9. Preclinical Study 4 Treatment.
[0342] For this study, male dogs were used. Before drug-coated balloon treatment, baseline retrograde urethrography was obtained and the inner diameter of the urethral treatment site was measured. Using the drug-coated balloon catheter prepared in Example 1-8, the prostate, pelvis, bulbar and distal urethra at the proximal end of the penis were treated without overlapping. The penile urethra was not treated. The treatment site diameter was about 2.6-7.7mm. The balloon catheter was selected so that the stretch ratio of the prostatic urethral balloon was designed to be about 2-4. For the anterior urethra, a balloon catheter was selected so that the stretch ratio was about 1.8-2.3. Before inserting the catheter, the urethra was flushed with about 5mL of saline. 8 and 12mm nominal diameter balloons were inflated in the prostatic urethra, and 8mm nominal diameter balloons were inflated in the anterior urethra. The prostatic urethral balloon was inflated to 6-9 atmospheres at the treatment site for 10min, the drug and additives were released, then contracted, and removed from the dog. The 8 mm nominal diameter balloon was inflated to 10 atmospheres at the treatment site for 10 min, releasing the drug and additives, then deflated and removed from the dog. The stretch ratio of the prostatic urethral balloon was 2.0 to 5, 10, 15, or 20. The stretch ratio of the anterior urethral balloon was 1.1, 1.2, 1.3, 1.4, or 1.5 to 1.75, 2.0, 2.25, 2.50, 2.75, 3.0. The urethral diameter and amount of drug of the treated urethral tissue of the animals were measured after 1 day, 7 days, and 28 days, and the residual drug left on the balloon after use was analyzed. Samples were obtained on day 28 for histological evaluation to compare the drug-coated balloon tissue with the plain old balloon and untreated tissue.
[0343] Example I-10. Preclinical study 4 pharmacokinetics, balloon residual drug content and urethral lumen gain.
[0344] The average drug concentrations in dog tissues from the samples in Example I-9 were: 582 μg / g on day 1, 0.347 μg / g on day 7, and 4 μg / g on day 28. On day 28, the average drug concentrations in dog tissues from the 2 μg / g and 4 μg / g dose density formulation 1 samples in Example I-9 were 20.34 μg / g and 0.73 μg / g, respectively. On day 28, the average drug concentrations in dog tissues from the 2 μg / g and 4 μg / g dose density formulation 4 samples in Example I-9 were 0.01 μg / g and 1.20 μg / g, respectively. The percentage of residual balloon content to the original drug load of the samples from Example I-9 ranged from 0-60%. The average residual balloon content as a percentage of the original drug load from the 2 μg / g and 4 μg / g dose density formulation 1 samples was 11.5% and 2.4%, respectively. The average residual balloon content as a percentage of the original drug load from the 2 μg / g and 4 μg / g dose density Formulation 4 samples was 12.2% and 19.9%, respectively. The average urethral gain at Day 28 (urethral diameter at the treatment site minus the urethral diameter at treatment time) ranged from 1.6 mm to a lumen loss of 4.4 mm. Examination of the histological samples showed no discernible differences between drug coated balloon treated, plain balloon treated, and untreated tissues.
[0345] Example I-11. Preclinical study 5 sample preparation.
[0346] Forty balloon catheters (twenty 6 mm diameter and 20 mm length, twenty 8 mm diameter and 20 mm length) were inflated to 50% of the nominal inflation pressure and wiped with ethanol to clean the balloon surface. Next, the balloons were divided into two groups; one group was coated with various formulations (1-6) from Example I-1, the coating solution was sufficient to achieve 3.5 micrograms of paclitaxel / square millimeter of balloon surface, and the other group was coated with various formulations (1-6) of Example I-1, the coating solution was sufficient to achieve 10 micrograms of paclitaxel / square millimeter of balloon surface. The balloons were then dried, folded, sheathed, and packaged in Tyvek bags and sterilized with ethylene oxide in preparation for animal testing.
[0347] Example I-12. Preclinical Study 5 Treatment.
[0348] For this study, female pigs were used to allow for easier access to the ureters. Prior to drug-coated balloon treatment, baseline ureterograms and urethrograms were obtained to measure the inner diameters of the ureteral and urethral treatment sites before treatment. The treatment site diameter was approximately 4.0-6.0 mm. For the urethra, a balloon catheter was selected so that the stretch ratio was approximately 1.8-2.3. Non-overlapping treatments were performed using the drug-coated balloon catheter prepared in Example I-11. Control experiments were conducted to study two process parameters: balloon-to-urethra stretch, inflation time; and one product design feature: drug dose density. The amount of drug in the treated urethral tissue of the animals was measured after 1 day, and the residual drug remaining on the balloon after use was analyzed.
[0349] Example I-13. Preclinical study of 5 balloon residual drug content and tissue drug content.
[0350] The mean porcine tissue drug concentration from the samples in Example 1-12 was 12.5 μg / g on Day 1. The residual balloon content as a percentage of the original drug load from the samples in Example 1-12 ranged from 1% to 52%.
[0351] Example I-14. Preclinical study 6 sample preparation.
[0352] Eighty-seven balloon catheters (thirty-seven with a diameter of 12 mm and a length of 20 mm, and fifty with a diameter of 8 mm and a length of 20 mm) were inflated to 50% of the nominal inflation pressure and wiped with ethanol to clean the balloon surface. Next, the balloons were divided into two groups; one group was coated with various formulations (1-6) from Example 1-1, with a coating solution sufficient to achieve 3.5 micrograms of paclitaxel / square millimeter of balloon surface, and the other group was coated with various formulations (1-6) of Example 1-1, with a coating solution sufficient to achieve 10 micrograms of paclitaxel / square millimeter of balloon surface. The balloons were then dried, folded, sheathed, and packaged in Tyvek bags and sterilized with ethylene oxide in preparation for animal testing.
[0353] Example I-15. Preclinical Study 6 Treatment.
[0354] For this study, castrated male pigs were used. Prior to drug-coated balloon treatment, baseline urethrograms were obtained to measure the inner diameter of the urethral treatment site prior to treatment. Non-overlapping treatments were performed using the drug-coated balloon catheters prepared in Example 1-14. Prior to inflation, the urethra was flushed with 5-10 mL of saline. Control experiments were conducted to study the effects of double inflation and drug dose density on the amount of drug in the treated urethral tissue. Tissue drug content was measured after 1 day and 28 days, and residual drug left on the balloon after use was analyzed. Histological samples were obtained on day 28 to compare the two catheter groups with different drug dose densities.
[0355] Example I-16. Preclinical study of 5 balloon residual drug content and tissue drug content.
[0356] The mean porcine tissue drug concentrations from the samples in Example 1-14 were 83 ng / g on day 1 and 2.5 ng / g on day 28. The residual balloon content as a percentage of the original drug load from the samples in Example 1-14 ranged from 19-73%.
[0357] Example I-17. Preclinical study 7 sample preparation.
[0358] Fifty-seven balloon catheters (forty-three with a diameter of 8 mm and a length of 20 mm, and fourteen with a diameter of 20 mm and a length of 60 mm) were inflated to 50% of the nominal inflation pressure and the balloon surface was cleaned by wiping with ethanol. The balloons were coated with various formulations (1-6) in Example I-1, and the coating solution was sufficient to achieve 3.5 micrograms of paclitaxel / square millimeter of balloon surface. The balloons were then dried, folded, sheathed, and packaged in Tyvek bags and sterilized with ethylene oxide in preparation for animal testing.
[0359] Example I-18. Preclinical Study 7 Treatment.
[0360] For this study, male dogs were used. Using a 2.4mm outer diameter endoscope, these treatments were carried out under direct vision. The endoscope utilized constant saline irrigation to flush visual field obstructions out of the visual field, so that the treatment area was always constantly flushed. The first step in treatment was to use a cutting balloon (a balloon catheter with a blade extending longitudinally along the length of the balloon) in the prostatic urethra, the middle urethra, and the distal urethra. Next, an uncoated balloon was used to expand the treatment position using the cutting balloon. Then, before the drug-coated balloon treatment, a baseline urethrography photo was obtained to measure the inner diameter of the urethral treatment site. Finally, the drug-coated balloon catheter and the uncoated balloon catheter (as a control) prepared in Example I-17 were used. A 20mm nominal diameter balloon was used in the prostatic urethra, and an 8mm nominal diameter balloon was used in the anterior urethra. The prostatic urethral balloon was inflated to 4-5 atmospheres at the treatment site for 2 minutes, released the drug and additives, then contracted, and removed from the dog. The 8 mm nominal diameter balloon was inflated to 10 atmospheres at the treatment site for 2 min to release the drug and additives, then deflated and removed from the dog. The stretch ratio for the prostatic urethral balloon was 2.9 to 9.7. The stretch ratio for the anterior urethral balloon was 1.5 to 2.8. Tissue drug content was measured after 3, 7, and 28 days and analyzed for residual drug remaining on the balloon after use. Histological samples were obtained at 3 and 28 days to compare direct drug-coated balloon treatment with drug-coated balloon treatment followed by cutting balloon pretreatment.
[0361] Example I-19. Preclinical study 7 pharmacokinetics, balloon residual drug content, lumen gain and histology.
[0362] Mean drug concentrations in dog tissues from samples in Example 1-18 were: 100 μg / g on day 3, 62 μg / g on day 7, and 33 μg / g on day 28. The residual balloon content as a percentage of the original drug load from samples in Example 1-18 ranged from 2% to 50%.
[0363] Example I-20. Preclinical study 8 sample preparation.
[0364] Thirty-nine balloon catheters (8 mm in diameter and 30 mm in length) were inflated to 3 atmospheres and wiped with ethanol to clean the balloon surface. The balloons were coated with formulations 18, 19, and 23 from Example 1-1, with the coating solution sufficient to achieve 2.5 micrograms of paclitaxel / square millimeter of balloon surface. The balloons were then dried, folded, sheathed, and packaged in Tyvek bags and sterilized with ethylene oxide in preparation for animal testing.
[0365] Example I-21. Preclinical Study 8 Treatment.
[0366] For this study, male dogs were used. Prior to drug-coated balloon treatment, baseline urethrograms were obtained and the inner diameter of the urethral treatment site was measured. The treatment site diameter was approximately 3.5-4.5 mm. The balloon catheter was selected so that the stretch ratio of the anterior urethral balloon was approximately 1.8-2.3. Using the drug-coated balloon catheter prepared in Example 1-20, the pelvic, bulbar, and distal urethra at the proximal end of the penis were treated without overlap. The penile urethra was not treated. Prior to catheter insertion, the urethra was flushed with approximately 5 mL of saline. An 8 mm nominal diameter balloon was inflated to 12 atmospheres at the treatment site for 2 minutes to release the drug and additives, then deflated and removed from the dog. The stretch ratio of the anterior urethral balloon was approximately 2.0-2.5. Tissue drug content was measured after 1 day, and residual drug remaining on the balloon after use was analyzed.
[0367] Example I-22. Preclinical study 8 tissue drug content and balloon residual drug content.
[0368] On day 1, the dog tissue drug concentrations from the pelvic urethra samples in Example 1-21 were 0.305, 1.17, 17.3, 33.4 μg / g. On day 1, the dog tissue drug concentrations from the bulbar urethra samples in Example 1-21 were 0.28, 4.31, 44.5, 57.8 μg / g. On day 1, the dog tissue drug concentrations from the distal urethra samples in Example 1-21 were 7.37, 38.9, 238, 268 μg / g. On day 1, the average drug concentrations from formulations 18, 19, and 23 were 6.5, 33.6, and 137.7 μg / g, respectively. The residual balloon content as a percentage of the original drug load from the samples in Example 1-21 ranged from 20.4% to 81.7%. The average residual balloon contents were 57.7%, 68.7% and 51.9% of the original drug load from formulations 18, 19 and 23, respectively.
[0369] Example I-23. Benchtop drug release test sample preparation.
[0370] Forty-nine balloon catheters (thirty-one 8 mm diameter and 30 mm length, six 10 mm diameter and 20 mm length, thirteen 12 mm diameter and 20 mm length) were inflated to 3 atmospheres and wiped with ethanol to clean the balloon surface. The balloons were coated with various formulations (1-34) in Example 1-1, with the coating solution sufficient to achieve 2.5 or 3.5 micrograms of paclitaxel / square millimeter of balloon surface. The balloons were then dried, folded, sheathed, and packaged in Tyvek bags and sterilized with ethylene oxide in preparation for benchtop testing.
[0371] Example I-24. Benchtop drug release test.
[0372] A benchtop drug release device was developed consisting of a 10 inch long by 2 inch diameter cylindrical container placed in a temperature controlled water bath. The cylindrical container was filled with 0.9% saline and maintained at 37°C in preparation for testing. An 8 Fr (i.e., where 3 Fr is 1 mm) by 13 cm long guide sheath was inserted into the top of the cylindrical container and used as a conduit for passing balloon catheter samples into the cylindrical container. The samples formed in Example 1-22 were passed individually into the cylindrical container where they were soaked for 1 minute and then inflated to 10 atmospheres for 1 minute before being removed. The remaining drug on the balloon was analyzed to determine how much drug was released. The amount of drug released during this test ranged from 37% to 97%.
[0373] Part II.
[0374] Example II-1. Benchtop test with pig urethra.
[0375] The purpose of this study was to evaluate whether a necked balloon design could prevent movement of an anatomical model during inflation.
[0376] Intact male porcine bladders and urethras were obtained from a local research institution. The balloon catheter consisted of 20 mm diameter x 80 mm length 7233 Balloon construction. Two balloon neck portions are made in the balloon using UHMWPE sutures. The sutures are tied at the desired locations of the balloon to prevent balloon expansion, thereby creating a neck. The neck is positioned symmetrically along the length of the balloon, dividing the 80mm length into three approximately 20mm body portions. The dimensions of the neck portion are 10mm long and approximately 8mm in diameter. The neck portion length is measured from one larger body portion to the adjacent larger body portion. The balloon is attached to a 10Fr catheter shaft, and pleats / folds are formed and placed in a sheath to facilitate insertion.
[0377] The intact porcine urethra and bladder were placed in a 37°C water bath to simulate body temperature. A balloon catheter was inserted through the urethra and the distal edge of the balloon was positioned at the bladder neck. The balloon was inflated until urethral dehiscence was visually observed or the maximum rated burst pressure (RBP) of 6 atm was reached. Upon confirmation of urethral dehiscence, the balloon was deflated immediately. The inflation speed varied from sample to sample, with 0.5 atm / min, 1.0 atm / min, and 2.0 atm / min used. The total inflation time was between 3 and 10 minutes, depending on the inflation speed.
[0378] The necking in this study was able to prevent the balloon from moving during inflation. The stretch ratio of the inflated balloon diameter to the standard prostatic urethra diameter was approximately 3.0-3.5. In addition, this study showed that the inflation rate played a role in balloon movement. By inflating the balloon more slowly and allowing tissue stress to relax and yield, balloon movement toward the bladder was further minimized. Rates of 0.5 atm / min and 1.0 atm / min resulted in less balloon movement during inflation.
[0379] Part III. Testing of drug-coated balloons in urethral strictures in human subjects.
[0380] The following examples include embodiments of using medical devices having drug coatings within the scope of the present invention.While the following examples are believed to embody the present invention, the examples should not be construed as limiting the present invention.
[0381] Materials. In clinical studies, human subjects with stenotic disease were treated with drug-coated balloon catheters at a dose density of 3.5 μg paclitaxel / mm2. The drug-coated balloon catheters had nominal diameters of 6, 8, 10, 12, and 14 mm and lengths of 30 and 50 mm at a nominal pressure of 6 atm. The paclitaxel (PTX) dosing for each balloon size can be found in Table 6.
[0382] Table 6. Paclitaxel (PTX) dosing per balloon size.
[0383] Diameter(mm) 30mm Length 50mm Length 6 1979 μg PTX 3299 μg PTX 8 2639 μg PTX 4398 μg PTX 10 3299 μg PTX 5498 μg PTX 12 3958 μg PTX 6597 μg PTX 14 4618 μg PTX 7697 μg PTX
[0384] The Drug Coated Balloon Catheter has a dual lumen shaft design, plus a single inflatable balloon. One lumen is sized to accommodate a 0.038" guidewire lumen. The other lumen is the inflation port lumen and allows the balloon to be inflated with a mixture of saline and contrast fluid. The Drug Coated Balloon Catheter has a manifold with two Luer connections, one connection is compatible with an inflation syringe, and the other connection allows the guidewire to protrude from the manifold so that the balloon catheter can slide freely over the guidewire. The 6 and 8 mm Drug Coated Balloon Catheters have a rated burst pressure of 12 atmospheres. The 10, 12, and 14 mm Drug Coated Balloon Catheters have a rated burst pressure of 10 atmospheres. The balloon is made of polyamide.
[0385] Urine flow rate (Q max Uroflowmetry is done by urinating into a special urinal, toilet or disposable device with a built-in measuring device. Parameter Q max It is the maximum flow rate measured during the uroflowmetry test. This method is used before treatment (baseline) and at the 1, 3, 6, and 12 month follow-up visits to demonstrate longevity of treatment.
[0386] International Prostate Symptom Score (IPSS). The IPSS is based on responses to eight questions—seven about disease symptoms and one about the patient's quality of life: 1) Incomplete urination; How often do you feel like you have not emptied your bladder? 2) Frequency; How often do you have to urinate less than every two hours? 3) Intermittency; How often do you find yourself stopping while urinating and starting again multiple times? 4) Urgency; How often do you find it difficult to put off urination? 5) Weak stream; How often do you have a weak stream? 6) Straining; How often do you strain to start urinating? 7) Nocturia; How many times during the night do you typically get up to urinate? 8) Quality of life due to urinary symptoms; How would you feel if you had to live with your current urinary condition for the rest of your life? The IPSS was developed for BPH, but it can be applied to other bladder outlet obstructive diseases, such as strictures, to determine whether obstructive symptoms improve after medical treatment. For the symptom questions, the patient is asked to select the rating that best represents their condition. The scale ranges from 0 to 5, with 5 representing the most severe symptomatic disease. The seven symptom scores were summed to give a total maximum score of 35. Quality of life responses were scored on a scale of 0 to 6. According to these scoring systems, scores can be classified as follows: if the score is 7 or less, the symptoms are mild; if the score is 8 to 19, the symptoms are moderate; and if the score is 20 to 35, the symptoms are severe. This questionnaire was administered before treatment (baseline) and at the 1, 3, 6, and 12 month follow-up visits to document longevity of treatment.
[0387] Example III-1. Treatment of human clinical cases with a pre-dilated balloon and then an 8 mm nominal diameter drug-coated balloon catheter Subject A
[0388] Subject A had a 1.5 cm long by 2.5 mm diameter stenosis in the anterior urethra. Specifically, the bulbar portion of the anterior urethra. This was determined by performing a retrograde urethrogram. The human clinical subject had a baseline Q of 4.0 mL / sec. max(maximum urinary flow rate) and a baseline IPSS score of 25. First, a cystoscope is inserted into the urethra. Then a guide wire is inserted into the working channel of the cystoscope. Next, a pre-expansion balloon with a nominal diameter of 7 mm and a length of 20 mm is inserted into the urethra onto the guide wire and positioned so that the balloon passes through the stenosis. The pre-expansion balloon is inflated to 14 atmospheres with a syringe with a pressure gauge on it. The syringe contains a mixture of saline and contrast agent. Fluoroscopic images are collected to ensure that the balloon is evenly inflated. Once confirmed, the balloon is deflated and removed from the urethra. Next, a drug-coated balloon with a nominal diameter of 8 mm and a length of 30 mm is inserted into the urethra onto the guide wire. The drug-coated balloon is positioned so that the balloon body completely covers the pre-expansion stenosis area. The drug-coate...
Claims
1. A composition for treating gastrointestinal tract stricture or biliary stricture, the treatment comprising: providing a pre-soaked balloon catheter in a gastrointestinal tract stricture or a biliary stricture, the balloon catheter comprising a balloon and a coating, the coating comprising the composition covering the outer surface of the balloon, the composition comprising a hydrophobic therapeutic agent and one or more water-soluble additives; inflating the balloon such that the coating contacts the wall of the stenosis and the therapeutic agent is delivered to the wall of the stenosis; deflation of the balloon after the inflation period; as well as The balloon catheter is removed from the stenosis.
2. The composition of claim 1, wherein the treatment comprises soaking the balloon catheter in vitro with a soaking solution comprising water or saline.
3. The composition of claim 1, wherein the hydrophobic therapeutic agent comprises paclitaxel, an analog of paclitaxel, docetaxel, an analog of docetaxel, taxol, an analog of taxol, rapamycin, an analog of rapamycin, sirolimus, an analog of sirolimus, everolimus, an analog of everolimus, tacrolimus, an analog of tacrolimus, a mammalian target of rapamycin (mTOR) inhibitor, an analog of an mTOR inhibitor, or a combination thereof.
4. The composition of claim 1, wherein the water-soluble additive is selected from the group consisting of: N-acetylglucosamine, N-octyl-D-glucamide, N-nonanoyl-N-methylglucosamine, N-octanoyl-N-methylglutamine, C6-ceramide, dihydro-C6-ceramide, cerebrosides, sphingomyelins, galactocerebrosides, lactocerebrosides, N-acetyl-D-sphingosine, N-hexanoyl-D-sphingosine, N-octanoyl-D-sphingosine, N-lauroyl-D-sphingosine, N-palmitoyl-D-sphingosine, N-oleoyl-D-sphingosine, PEG caprylic / capric diglyceride, PEG 8 caprylic / capric glyceride, PEG caprylate, PEG 8 caprylate, PEG caprate, PEG caproate, glyceryl monocaprylate, glyceryl monocaprate, glyceryl monohexanoate Esters, monolaurin, monocaprin, monocaprylin, monomyristic glyceryl, monopalmitolein, monoolein, sarcosine, creatinine, agmatine, citrulline, guanidine, sucralose, aspartame, hypoxanthine, theobromine, theophylline, adenine, uracil, uridine, guanine, thymine, thymidine, xanthine, xanthine nucleoside, xanthine nucleoside monophosphate, caffeine, allantoin, (2-hydroxyethyl) urea, N,N'-bis(hydroxymethyl) urea, pentaerythritol ethoxylate, pentaerythritol propoxylate, pentaerythritol propoxylate / ethoxylate, glycerol ethoxylate, glycerol propoxylate, ethoxylated trimethylolpropane, pentaerythritol, dipentaerythritol, crown ethers, 18-crown-6, 15-crown-5, 12-crown-4, and combinations thereof.
5. The composition of claim 1, wherein the water-soluble additive is selected from the group consisting of: pentaerythritol ethoxylate, pentaerythritol propoxylate, and combinations thereof.
6. The composition of claim 1, wherein the stricture is a gastrointestinal stricture.
7. The composition of claim 1, wherein the stricture is a biliary stricture.
8. The composition of claim 1, wherein the stricture is a gastric stricture.
9. The composition of claim 1, wherein the stricture is an esophageal stricture or an achalasia stricture.
10. The composition of claim 1, wherein the stricture is a small intestinal stricture.
11. The composition of claim 1, wherein the stricture is duodenal stricture, jejunal stricture, or ileal stricture.
12. The composition of claim 1, wherein the stricture is a colonic stricture or a rectal stricture.
13. The composition of claim 1, wherein the stricture is a stricture of the large intestine.
14. The composition of claim 1, wherein the treatment further comprises observing with a scope the inflation of the balloon, the contact of the coating with the wall of the stenosis, the delivery of the therapeutic agent to the wall of the stenosis, the deflation of the balloon, the therapeutic agent on the wall of the stenosis after the deflation, or a combination thereof, wherein the scope comprises an endoscope, an enteroscope, a colonoscope, a sigmoidoscope, a proctoscope, anoscope, or a combination thereof, wherein the scope and the balloon catheter are side-by-side when the balloon catheter is in the stenosis, or the balloon catheter is in the scope when the balloon catheter is in the stenosis.
15. The composition of claim 14, wherein said treating comprises visualizing with said speculum a therapeutic agent on a wall of said stenosis after said contracting.
Citation Information
Cited By
Drug-coated balloon catheters for body lumens
US12280226B2
